Targeted Gene-Hormone Therapy of Colorectal Cancer with Guanylin Expressing Nano-system: In Silico and In Vitro Study

Targeted Gene-Hormone Therapy of Colorectal Cancer with Guanylin Expressing Nano-system: In Silico and In Vitro Study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Targeted Gene-Hormone Therapy of Colorectal Cancer with Guanylin Expressing Nano-system: In Silico and In Vitro Study Pouria Samadi, Fatemeh Rahbarizadeh, Fatemeh Nouri, Meysam Soleimani, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4508842/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background: Addressing colorectal cancer (CRC) poses a significant challenge, demanding the precise delivery of therapeutic agents to eliminate cancer cells while minimizing the impact on healthy cells. The strategic selection of therapeutic targets, the utilization of nanocarriers with optimal efficacy and low toxicity, and the development of gene constructs with targeted expression in cancer cells are crucial aspects of this pursuit. Materials and Methods: This study employed a systems biology approach to comprehensively investigate the guanylin hormone-encoding gene ( GUCA2A ). Exploration encompassed expression patterns across tissues and single cells, clinical endpoints, methylation profiles, mutations, and immune and functional analyses. Subsequently, GUCA2A was identified as a potential target for gain of function studies, leading to its amplification and cloning into gene constructs featuring both a robust CMV promoter and a cancer-specific MUC1 promoter. The succinylated PEI-9, characterized by low toxicity and high gene transfer efficiency, was then fabricated and characterized on HCT-116 cancer cells and normal Vero cell lines. Results: systems biology studies revealed guanylin ’s aberrant expression patterns, methylation variations, and mutational changes as well as its remarkable association with immune engagement and poor survival outcomes in CRC. Moreover, SPEI-9 was introduced as a highly efficient and safe nanocarrier for gene delivery purposes. Additionally, in vitro studies revealed that both guanylin-expressing gene constructs exhibited the potential to inhibit cell growth and proliferation, inducing apoptosis, suppressing cell migration, and curtailing colony formation. Notably, these effects were more robust but non-specific in cancer cells treated with constructs containing the CMV general promoter, while, induction via the MUC1 promoter was more specific. Conclusion: A genetic construct featuring the strong universal CMV and specific MUC1 promoter, expressing the guanylin peptide hormone, demonstrated highly effective and specific anticancer effects when transfected with nanocarriers characterized by high efficiency and low cytotoxicity. This nano-system holds promising implications for targeted CRC therapy. colorectal cancer guanylin guanylyl cyclase c gene therapy gene delivery Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Introduction In the past decades, with increasing concerns regarding the side effects and low effectiveness of conventional treatments, researchers sought to develop new approaches to fight cancer more effectively [ 1 ]. Hence, with the rapid surge in the utilization of (multi-)omics technology and computational modeling in biological systems over the past decade, in silico analyses have played a pivotal role in the identification of novel therapeutic targets and potential drug candidates for human diseases, specifically cancers [ 2 – 5 ]. The most prevalent occurrence in colorectal cancer (CRC), ~ 70–80%, involves the inactivation of the tumor suppressor gene adenomatous polyposis coli ( APC ). This often co-occurs with the activation of oncogenic KRAS (40–50%), and the presence of mutations in other tumor suppressor genes, such as PTEN or TP53 , or oncogenes like PIK3CA , is also frequently observed [ 6 ]. Previous research has shown that GUCA2A (encoding endogenous peptide hormone guanylin), experiences loss after APC inactivation in mouse models featuring conditional biallelic Apc deletion (Apc CKO/CKO ) and Apc loss of heterozygosity (Apc min/+ ) [ 7 ]. Given that guanylin is a peptide stimulant for GUCY2C , encoding a member of the family of transmembrane receptor guanylyl cyclases, it fosters cGMP accumulation, which in turn, facilitates electrolyte and fluid secretion within the large intestine as well as many other important roles summarized in Fig. 1A [ 8 , 9 ]. Beyond this, GUCY2C regulates essential homeostatic processes that are often dysregulated during tumorigenesis, including cellular functions like metabolism, proliferation, and differentiation programs [ 10 , 11 ]. Silencing GUCY2C is a universal characteristic of colorectal tumorigenesis which contributes to the promotion of crypt hyperplasia, acceleration of the cell cycle, induction of DNA damage, and higher susceptibility to tumor development [ 12 , 13 ]. The majority of tumor subtypes maintain the presence of cell-surface GUCY2C expression as they progress through different stages of the disease [ 14 , 15 ]. However, transformation universally orphans the receptor due to the depletion of endogenous hormones [ 15 , 16 ]. These observations suggest reactivating endogenous hormone generation via gene therapy approaches, which may be a novel therapeutic strategy for CRC [ 17 ]. Gene therapy involves treating a genetic disease by introducing specific genetic material that alters cell function into a patient. The crucial aspect of gene therapy lies in the effective delivery of genes to the targeted tissues or cells, a process facilitated by specialized carriers known as vectors. An avenue that holds promise for elevating cancer gene therapy to a potent strategy is the implementation of precision-targeted gene expression facilitated by tissue-specific or tumor-specific promoters [ 18 ]. The conventional promoters like hTERT, Survivin, uPAR, COX-2, and more recently, MUC1 , exhibit notably higher expression levels in a spectrum of cancer types (specifically gastrointestinal (GI) cancers), compared to normal tissues [ 19 ]. Due to its specificity, the MUC1 promoter, which demonstrates expression over 90% within CRC cells, presents itself as a potent substitute for the conventional promoters employed in the context of gene therapy for CRC [ 20 , 21 ]. Further, the utilization of specific enhancers tailored to tumor-specific physiological conditions, notably hypoxia, through the incorporation of the hypoxia-sensitive element (HRE) upstream of the MUC1 promoter serves to augment gene expression within cancer cells, particularly under hypoxic conditions [ 22 ]. Polyethylenimine (PEI) and similar polycations have emerged as promising nonviral gene carriers, leveraging their capacity to establish stable complexes via electrostatic interactions with nucleic acids. This polyplex formation not only fortifies plasmid-based gene delivery but also shields against enzyme-mediated digestion, thereby facilitating enhanced intracellular delivery [ 23 ]. While PEI has demonstrated efficacy as a gene carrier, its application at higher doses has raised concerns due to its inherent toxicity. This toxicity primarily stems from the potent positive charge of PEI, fostering intense interactions with cell surfaces that can result in cellular damage. Recognizing this challenge, there is a growing interest in exploring modifications to the polymeric backbone of PEI aimed at mitigating its positive charge and, consequently, diminishing its toxicity. These modifications hold promise in enhancing the safety profile of PEI, ensuring its utility as a gene carrier while minimizing the potential adverse effects associated with its application at elevated concentrations [ 24 ]. Succinylated PEI refer to PEI molecules that have undergone a chemical modification involving the addition of succinyl groups. The modification involves attaching succinyl (a dicarboxylic acid) moieties to the polymeric backbone of PEI. The succinylation of PEI serves several purposes. One notable effect is the reduction of the overall positive charge of the PEI molecule. PEI is known for its strong positive charge, which can lead to interactions with cell surfaces and potential cytotoxicity. By succinylating PEI, the charge density decreases, making the modified PEI less positively charged. Succinylated PEIs are often explored in the field of gene delivery. The modification aims to maintain the desirable properties of PEI as a gene carrier, such as its ability to form stable complexes with nucleic acids, while mitigating its potential toxicity. The resulting succinylated PEIs may exhibit improved biocompatibility, reduced cytotoxicity, and enhanced efficiency in delivering genetic material to target cells, making them attractive candidates for gene therapy applications [ 25 ]. SPEI-9 as a succinylated derivative of PEI with low succinylation degree (about 9% based on polymer weight), lower charge density, much lower cytotoxicity reduction, and higher gene transfer efficiency compared to unmodified PEI is an optimal and potential gene delivery vector for gene therapy agents [ 26 , 27 ]. In this study, we first analyze the transcriptomics data of CRC as well as pan-cancer with the gene expression data from human tissues, tumors, and single-cell types. Secondly, we devised a gene therapy construct aimed at reinstating endogenous guanylin hormone expression, with MUC1 serving as the tumor-specific promoter and CMV as the universal promoter for precise CRC therapy. Thirdly, we synthesized and characterized SPEI-9 as a robust carrier to facilitate the delivery of these gene therapy constructs. We finally conducted down-stream investigations to evaluate the anti-tumor effects of this innovative and potent gene therapy-based nanosystem in both cancer and normal cell lines. A schematic diagram of the mechanisms underlying the treatment with the developed guanylin expressing nano-system is displayed in Fig. 1B . Materials and methods Exploration of GUCA2A gene expression patterns We utilized the resources of Tabula Muris ( https://tabula-muris.ds.czbiohub.org ) and single cell ( https://singlecell.broadinstitute.org ) databases to gain insights into the broad spectrum of GUCA2A and MUC1 gene expression levels across diverse tissues in the human body, as well as within distinct epithelial cells of CRC and their adjacent normal counterparts. Additionally, we conducted a differential analysis to investigate alterations in GUCA2A gene expression across microarray and The Cancer Genome Atlas (TCGA) datasets. These expression data, derived from the extensive Cancer Cell Line Encyclopedia (CCLE) project (GSE36133) (n = 55 CRC cell lines), and a clinically homogenous dataset of CRC tumor and normal tissues, TCGA COAD-READ (normal = 51 cases, CRC = 644 cases), which were analyzed using LIMMA and edgeR packages in R [ 28 , 29 ]. Assessing GUCA2A expression as a prognostic indicator in CRC To assess the prognostic significance of GUCA2A expression on patient outcomes, we conducted univariate Cox regression analyses. Our investigation involved different CRC datasets from multiple microarray studies and TCGA. This comprehensive approach allowed us to make predictions concerning different clinical endpoints including Cancer-Specific Survival (CSS), Disease-Free Interval (DFI), Disease-Free Survival (DFS), Disease-Free Metastasis Survival (DFMS), Disease-Specific Survival (DSS), Overall Survival (OS), Progression-Free Interval (PFI), Progression-Free Survival (PFS), and Relapse-Free Survival (RFS). across diverse CRC datasets. Additionally, we conducted a Kaplan-Meier survival analysis to explore the association between GUCA2A expression levels and OS. The log-rank test was utilized to assess the prognostic significance of GUCA2A in the TCGA COAD-READ dataset. These analyses were performed using the R packages survival, survminer, and ggplot2 [ 30 – 32 ]. Relationship between GUCA2A expression and immunity We also investigate the potential link between the association of GUCA2A expression and the tumor microenvironment (TME) in pan-cancer. To achieve this, we assessed various parameters, including stromal score, ESTIMATE score, immune score, tumor purity, and immune-related pathways. Multiple algorithms, such as XCELL, QUANTISEQ, CIBERSORT-ABS, EPIC, and TIMER, were employed for this analysis. To visualize the results, we utilized the ggplot2 R package. The generated heat maps provided insights into the relationships between GUCA2A expression, the above metrics, and immune infiltrating cells across different cancers. Mutation and methylation profile analysis To comprehensively investigate the mutational landscape of GUCA2A across various cancer types, we utilized the capabilities of the cBioPortal tool ( http://www.cbioportal.org/ ). Focusing our efforts on the "TCGA Pan-Cancer Atlas Studies" cohort, we conducted an extensive investigation. This analysis encompassed the assessment of specific mutation sites, genetic alteration frequencies, and mutation types influencing GUCA2A . Furthermore, we utilized methylation data obtained from the SMART App ( http://www.bioinfo-zs.com/smartapp ) to investigate the relationship between GUCA2A expression and methylation patterns within the TCGA COAD-READ dataset. Box plot visualizations were generated using the ggplot2 package in R. GSVA Analyses We employed the R package "GSVA" to conduct Gene Set Variation Analysis (GSVA) [ 33 ], aiming to identify pathways most closely associated with GUCA2A expression. Pathways that were consistently enriched through GSVA analysis were regarded as potential pathways linked to GUCA2A expression. Amplification of GUCA2A coding sequence The primer for the amplification of the GUCA2A coding sequence (CDS) was designed using the primer3plus online tool, and then it was analyzed with the primer blast, Multiple Primer Analyzer, and IDT OligoAnalyzer Tool to check the optimality of various parameters. The Kozak sequence was placed at the beginning of the Forward (F) primer to initiate translation. Also, the cut site of BamHI enzyme was placed at the 5’ end of the primer before the Kozak sequence and the XbaI enzyme cut site was placed at the 5’ end of the Reverse (R) primer (Table. 1) . Following the successful PCR amplification of the GUCA2A CDS from CRC normal tissue-derived cDNA, the resulting fragment was subjected to purification using the AccuPrep® PCR/Gel Purification Kit (Bioneer, Korea) following the manufacturer's protocol. Subsequently, enzymatic digestion utilizing BamHI and XbaI restriction enzymes was employed to process the digested fragment, facilitating the removal of undesired cleavage sites through additional gel extraction steps. Construction of the guanylin expressing vectors In this investigation, the mammalian expression vector, pCDNA 3.1/Hygro(+) (Invitrogen) was selected as the basic genetic construct. Specifically, the MUC1 gene promoter and cassettes containing the hypoxia response element (HRE), were amplified and cloned into the pcDNA3.1/Hygro (+) basic vector to replace the CMV promoter, yielding the HRE-pMUC1-Insert construct, which was generously provided by Dr. Rahbarizadeh's lab. The HRE-pMUC1-mRNA, alongside the default pCMV-mRNA vector, were both prepared with BamHI / XbaI flanking cutting sites for subsequent subcloning procedures. To propagate these vectors, GM2163 bacteria (Dam − Dcm − ), a derivative of E. coli strain K12, were employed, as the XbaI cut site is hindered by dam methylation. Following bacterial transformation, the vectors were extracted using The GeneJET Plasmid Miniprep kit. Following enzymatic digestion with BamHI and XbaI, a further gel extraction step was performed to prepare vectors for downstream procedures. The digested vectors and GUCA2A CDS fragment were subsequently ligated together. After successful transformation, colony selection was carried out via colony PCR, followed by validation through Sanger sequencing. The resulting vectors, named HRE-pMUC1-GUCA2A and pCMV-GUCA2A, were then prepared for subsequent cell culture analyses. Synthesis and structural characterization of SPEI-9 PEI (0.5 grams) was dissolved in 8.5 mL of water and 1.5 mL of a NaCl solution (3 M). The pH of the solution was then adjusted to 5 using 1 M HCl. Precise quantities of succinic anhydride (0.1 M, for 9% modification) were dissolved in dimethyl sulfoxide (DMSO) and carefully added dropwise to the PEI solution. The reaction was conducted at room temperature for a duration of 3 h. To purify the crude products, a dialysis process was performed using a 10,000–12,000 molecular weight cutoff membrane. Initially, dialysis was carried out against a 0.25 M NaCl solution to eliminate any unreacted succinate. Subsequently, the solution was dialyzed twice against water at a temperature of 4°C to remove residual salt. Following the dialysis process, the aqueous solution was subjected to lyophilization. A schematic diagram of the reaction of succinic anhydride and basic PEI to make SPEI-9 is displayed in Fig. 4E . For the downstream tests (except structural analysis), we prepared the polymers in different concentrations with HBG buffer (20 mM HEPES in 5% glucose solution, pH 7.2) to obtain different C/P ratios. The degree of modification was assessed using 1H nuclear magnetic resonance (NMR) spectroscopy (Varian INOVA 500MHz, Palo Alto, USA) in deuterium oxide (D2O). The presence of carboxylic acid changes on the surface of SPEI-9 was also confirmed using Fourier Transform Infrared (FT-IR) (Agilent-USA-Cary 680). The spectra were analyzed using Origin software (version 9.85). The buffering capacity of PEI and SPEI-9 nanocarriers PEI-based nanocarriers exhibit robust pH resistance within a broad range (pH 2 to 10). This resistance eventually leads to an increase in the osmotic pressure, its bursting, and the release of the polyplex into the cytosol due to the proton sponge effect. To assess the buffering capacity of both PEI and SPEI-9, a 2 mg/mL solution of the nanocarriers was initially dissolved in deionized water, and its pH was measured. Subsequently, the solution's pH was adjusted to 12 using 1N NaOH and then titrated incrementally with 5 µl of 1N HCl until the pH dropped below 2.5. Throughout this process, a pH curve was generated based on the added acid. The experiment included deionized water as a negative control and PEI as a positive control. Preparation and loading efficiency of PEI and SPEI-9 polyplexes PEI/DNA and SPEI-9/DNA polyplexes were prepared by adding 50 µl of the polymer solution in different concentrations to 50 µl of the gene construct with the same concentration (at a concentration of 40 µg/ml in HBG buffer). After gently pipetting the mixture (10–20 times), it was allowed to incubate for 20–30 min at room temperature to form stable complexes. To assess the binding affinity of PEI and SPEI-9 polymers with genetic constructs, a gel retardation assay was employed. Polyplexes were prepared at various C/P ratios ranging from 0.25 to 8. Gel electrophoresis was subsequently conducted, and the results were analyzed using a Gel-Doc device. DNase degradation assay To assess the protective ability of PEI and SPEI-9 against enzymatic degradation of loaded DNA by serum nucleases, a DNase protection test was conducted. Polyplexes were prepared at various C/P ratios (ranging from 0.25 to 8) and exposed to 1 µl of DNase I enzyme (1 U/µl) in PBS or DNase/Mg2 + reaction buffer for 30 min at 37°C. Then, 4 µl of 50 mM EDTA was added to deactivate the enzyme by removing the Mg2 + ions present in the enzyme buffer. All microtubes were then incubated for 10 min at 65°C to inactivate the enzyme. Subsequently, 10 µl of 1 mg/ml heparin was added to facilitate the separation of the DNA from the nanocarrier. The microtubes were further incubated for 2 h at room temperature. Finally, the samples were subjected to electrophoresis in a 1% agarose gel. Measurements of the size and zeta potential of the polyplexes The average hydrodynamic particle size and surface charge density of polyplexes were measured by Dynamic Light Scattering and Laser Doppler Velocimetry by Malvern Nano Zetasizer (Malvern, UK) and results were reported as mean ± SEM. Hemolysis test of polyplexes The hemolysis assay was conducted using human blood to assess the blood compatibility of the synthesized polymers. Arterial blood was collected, and red blood cells (RBC) were isolated through centrifugation (3000 rpm for 10 min) and washing with PBS. Washed RBCs were then exposed to polyplexes (using 100 µl of washed RBC) with various C/P ratios, with deionized water and PBS serving as positive and negative controls, respectively. The samples were incubated at 37°C for 2 h, followed by centrifugation (13,000 rpm for 10 min), and the absorbance of the supernatant (A) was measured at 540 nm. The percentage of hemolysis was calculated as follows. \(Hemolysis \left(\text{%}\right)=\frac{\text{A} \text{s}\text{a}\text{m}\text{p}\text{l}\text{e} - \text{A} \text{n}\text{e}\text{g}\text{a}\text{t}\text{i}\text{v}\text{e}}{\text{A} \text{p}\text{o}\text{s}\text{i}\text{t}\text{i}\text{v}\text{e} - \text{A} \text{n}\text{e}\text{g}\text{a}\text{t}\text{i}\text{v}\text{e}}\) × 100 Protein Interaction To evaluate nonspecific protein binding interactions, 0.5 mL of bovine serum albumin (BSA) standard solution (2 mg/ml) was mixed with 0.5 ml of each polyplex solution (using 1 mg/ml of polymers). These mixtures were incubated at 37°C for 1 h, followed by centrifugation to collect supernatant samples. The protein concentrations in these samples were quantified using a BCA assay with a BSA calibration curve. The parameter A, representing protein interaction, was defined as: $$A=1- \frac{\text{C}\text{s}\text{V}\text{s}}{\text{C}\text{i}\text{V}\text{i}}$$ Here, Ci represents the initial BSA concentration (2 mg/ml), Cs is the BSA concentration in the supernatant determined by the BCA assay, Vi is the initial volume of the BSA solution (0.5 ml), and Vs is the total volume of the BSA solution after the adsorption measurement (1 ml). The interaction value A quantifies the extent to which protein has been removed from the initial solution through interaction with the polymer. It ranges from 0 (indicating no removal of protein) to 1 (representing complete removal of protein). Evaluation of the gene-hormone therapy nano-system in vitro After designing, constructing, and validating the therapeutic vectors, pCMV-GUCA2A and HRE-ERE-pMUC-GUCA2A, as well as SPEI-9 (C/P 4) as a potent gene delivery nano-system, we evaluate the therapeutic nano-system through different in vitro assays on two cell lines of HCT-116 as CRC cell line and the Vero, as a normal African green monkey kidney cell line. Cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) medium (Bioidea, Iran) supplemented with 10% fetal bovine serum (FBS, Gibco, USA), 1% Penicillin/Streptomycin (Gibco, USA) and were maintained in an incubator at 37°C and 5% CO 2 . Cell culture and transfection of the nano-system On the first day, the total number of 1 × 10 5 HCT-116 and Vero cells were seeded in separate wells of 12-well plates. The following day, for cell transfection, a mixture of 50 µL PEI and SPEI-9 nanocarriers with a pEGFP-N1 gene construct (40 ng/µl stock) encoding enhanced green fluorescent protein (EGFP) was created. This mixture, along with 50 µL culture medium lacking FBS, was vortexed for 10 s. The combined media, a total of 200 µL, were thoroughly mixed and pipetted multiple times before being incubated for 30 min at room temperature to form respective polyplexes. Once polyplexes were established, a dropwise addition of complete medium to each well, containing 100 µL culture medium, took place, and the plates were placed in the incubator. After 6–8 h, following the transfection of nanocarriers carrying genetic constructs into the cells, the supernatant medium was replaced with 1 ml of complete culture medium containing FBS. The plates were incubated at 24 h, 48 h, and 72 h. The efficiency of transfection was evaluated using a fluorescent microscope, determining the optimal time for subsequent treatments. Assessment of mRNA expression levels for guanylin and downstream genes Following transfection of 3 × 10 5 HCT-116 and Vero cells with different groups (pCMV-GUCA2A, HRE-pMUC1-GUCA2A, pEGFP-N1, and control) using SPEI-9 in a 6-well plate, we examined alterations in the expression of the GUCA2A gene and its downstream targets, specifically β-catenin ( CTNNB1 ) and p21 ( CDKN1A ), in addition to genes associated with apoptosis ( BAX and BCL-2 ) and cell migration ( VIM and CDH2 ) pathways. To do this, RNA was extracted from the transfection cells 72 h upon transfection utilizing the RNX-Plus kit (CinnaGen, Iran). Subsequently, the extracted RNA was reverse transcribed into complementary DNA (cDNA) using the RevertAid First Strand cDNA Synthesis kit (Thermo Fisher Scientific, USA). The primers used in quantitative reverse transcription PCR (RT-qPCR) of the GUCA2A gene along with the primers used to evaluate the downstream pathways are given in Table 1 . For each group, RT-qPCR was conducted in duplicate using SYBR Green and a LightCycler 96 RT-qPCR detection system (Roche, USA) according to the manufacturer’s instructions. Further, changes in gene expression between tumor and adjacent healthy tissues were also evaluated utilizing CRC tissue samples (10 samples) along with their respective adjacent non-cancerous tissues (10 samples) from Iranian patients who visited the Poursina Hakim Research Institute in Esfahan, Iran, during 2021 to 2022. The RNA extraction to RT-qPCR step was performed as mentioned above. The study protocol was granted ethical approval by the Ethical Committee of the Hamadan University of Medical Science (ethical code: IR.UMSHA.REC.1399.562). Evaluation of guanylin expression changes following hypoxia treatment After transfection with HRE-pMUC1-GUCA2A using SPEI-9, the HCT-116 cells were subjected to hypoxic conditions. This was achieved by filling the culture medium up to the top of the well and subsequently sealing it with parafilm. Following a 16 h incubation period post-transfection, alterations in GUCA2A gene expression were assessed through RT-qPCR analysis. Annexin V-PI flow cytometry To assess apoptosis/necrosis induced by the gene therapy nano-system, the following procedure was followed on two CRC and normal cell lines: a total number of 3 × 10 5 cells were initially cultured in individual 6-well plates and transfected the following day. After a 72 h incubation period, the cells were harvested using a combination of trypsinization and mechanical scraping (specifically for Vero cells due to their strong cell adhesion), and then centrifuged at 1500 g for 5 min. Following this, the cells were subjected to a PBS wash. To the cell pellet dissolved in binding buffer, a mixture containing 10 µl of propidium iodide (PI) dye and 5 µl of Annexin-V dye was added. The samples were then incubated in the dark at room temperature (25°C) for 10 min. The analysis of the cells was carried out using an Attune NxT Flow Cytometer (Thermo Fisher Scientific, USA) and then FlowJo software. Cell toxicity experiments Cell proliferation assays were conducted to assess the impact of PEI and SPEI-9 nanocarriers with different C/P ratios, along with various gene therapy groups, on both HCT-116 and Vero cells seeded in a 96-well plate with a confluency of 1 × 10 4 cells. Initially, cells were cultured in 96-well plates until they reached the desired confluence (70–80%). Subsequently, the cytotoxicity of PEI nanocarriers (at C/P ratios of 0.25 and 1) and SPEI-9 (at different C/P ratios of 0.25, 1, 4, and 8) was evaluated after a 72 h exposure (no removal of medium post-transfection), using the control pEGFP-N1 vector. Additionally, the cytotoxic effects of the gene therapy nano-systems were also investigated following 72 h transfection. To perform this evaluation, 10 µL of MTT solution (5 mg/ml in PBS) was added to each well-containing cell and incubated for an additional 4 h at 37°C. Following this incubation, the culture medium was carefully removed, and 150 µL of DMSO was added to each well to dissolve the purple formazan crystals. The absorbance was then measured at 490 nm using a microplate reader (Epoch BioTek, USA). In vitro scratch assay In this research, we employed the scratch test (wound-healing assay) to evaluate the effect of gene therapy nano-system on the migration and metastatic ability of HCT-116 and Vero cells seeded in a 12-well plate with a confluency of 1 × 10 5 cells. The procedure involved transfecting cells with various constructs and creating artificial scratches to assess cell viability. Microscopic imaging was conducted at specific time points (0, 24, and 48 h) to monitor the cells' capability to close the gap created by the scratch. Subsequently, we analyzed the gap area using Image J software to quantify and compare cell migration concerning the control group. Colony formation assays Two different cell lines were seeded into 6-well plates (with 500 cells/well for the HCT-116 cell line and 1000 cells/well for the Vero cell line). The transfection procedure involving gene constructs was initiated, and the plates were incubated for a minimum of 8 days until visible colonies were formed. Once adequate colony growth was achieved, the plates were subjected to staining with a crystal violet solution to stain the colonies (with at least 50 cells). Subsequently, the number of colonies was quantified and analyzed using Image J software. Statistical analysis All data are expressed as the mean with SD and the results are representatives of at least three independent experiments. Inferential statistical analyses were performed with an unpaired t-test, Wilcoxon signed-rank test, and one-way analysis of variance (ANOVA) (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). SPSS 18.0 or GraphPad Prism 9 was used for analysis. Results Expression analysis reveals intestine-specific expression of GUCA2A We investigated the tissue distribution of GUCA2A expression utilizing the Tabula Muris and single-cell databases, repositories enriched with valuable single-cell RNA-seq data. The results unveiled an interesting pattern of GUCA2A expression primarily within the large intestinal tissue (Fig. 2A, 2B) . Notably, within the large intestine, GUCA2A displayed marked variation in expression across distinct cell types. Notably, the highest expression was observed in enterocytes, BEST4 + epithelial cells, and goblet cells (Fig. 2C, 2D) , which play pivotal roles in processes such as water and ion absorption, nutrient uptake, and vitamin absorption. Conversely, the expression of the GUCA2A gene within CRC tumor tissue cells was found to be notably low and, in many cells, entirely lost (Fig. 2C, 2F) . Moreover, MUC1 expression showed elevation in goblet cells, immature goblet cells, and intestinal stem cells within normal cell populations as normally mucin is primarily localized to the apical cell membranes in these cell types. In contrast, MUC1 expression exhibited a more widespread and significant distribution across various tumor cells (Fig. 2D, 2C) . Additionally, the expression analysis of GUCA2A using TCGA COAD-READ datasets displayed significant down regulation in CRC tissues compared with normal tissues (Fig. 2G) . Further investigation for the GUCA2A (Fig. 2H) and MUC1 (Fig. 2I) were also performed in 55 CRC cell lines, which revealed their distributed expression levels across all CRC cell lines, with a particular emphasis on HCT-116, which aligns with the focus of our study. GUCA2A expression level correlates with poor prognosis in CRC We employed a univariate Cox regression model to evaluate the association between GUCA2A expression and various clinical endpoints, in different CRC datasets. Remarkably, reduced GUCA2A expression was significantly linked to adverse outcomes across multiple clinical endpoints in CRC (Fig. 3A) . In this regard, GUCA2A expression significantly correlated with worse DFI, DFS, DSS, OS, PFI, PFS, and RFS, which makes it a key gene for prognosis of CRC. The HR values demonstrate that decreased GUCA2A expression is generally associated with a higher risk of unfavorable events such as disease recurrence, progression, and mortality across various clinical endpoints in CRC, except for RFS, where increased GUCA2A expression is linked to a reduced risk of disease relapse (Fig. 3A) . Moreover, the survival curve analysis emphasized that decreased GUCA2A expression was also associated with significantly shorter OS time (Fig. 3B) . Collectively, these discoveries underscore the potential of GUCA2A as an innovative and valuable prognostic biomarker in CRC. Immune cell infiltration analysis of GUCA2A in CRC To investigate the connection between GUCA2A expression and immune cell infiltration, we performed correlation analyses using data from different algorithms. The results unveiled significant positive correlations between GUCA2A expression and the infiltration of various immune cell types, including neutrophils, B cell plasma, activated myeloid dendritic cells, M1- and M2-like macrophages, CD4 + T cells, and CD8 + T cells (Fig. 3C) . Conversely, GUCA2A expression exhibited negative correlations with M0-like macrophages, cancer-associated fibroblasts, NK cells, myeloid-derived suppressor cells, mast cells, and CD4 + T cells (Fig. 3C) . While the correlation values ranged from ± 0.1 to ± 0.5 and were not exceptionally high, these findings suggest that GUCA2A may play a role in promoting T cell infiltration, which could contribute to its protective effects in CRC. Nonetheless, further clinical investigations are warranted to explore deeper into this finding. DNA methylation and alterations of GUCA2A in pan-cancer To investigate the relationship between GUCA2A gene mutations and tumor development, we conducted a pan-cancer analysis using the cBioPortal platform, with a specific focus on CRC. The primary alteration type predominantly indicated "mRNA low" in the majority of samples across various cancer types, with a lesser frequency of "mRNA high" alterations (Fig. 3D, 3F) . Notably, "mRNA low" alterations were observed in over 60% of CRC samples (Fig. 3D) . Moreover, the somatic mutation frequency analysis of GUCA2A revealed missense mutations in several cancer types, including Breast Prostate Adenocarcinoma, Invasive Ductal Carcinoma, Acute Myeloid Leukemia, Hepatocellular Carcinoma, Renal Clear Cell Carcinoma, Uterine Endometrioid Carcinoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, and notably in CRC (Fig. 3E) . Furthermore, the analysis of GUCA2A gene methylation data unveiled a significant decrease in the promoter methylation level of GUCA2A in CRC (Fig. 3G) . These findings enhance our knowledge of the genetic mechanisms underlying tumor progression and offer further research and potential therapeutic exploration of GUCA2A . Identification of key cancer-related pathways linked to GUCA2A To assess the potential impact of GUCA2A expression on cellular pathways, we conducted a GSVA involving 50 HALLMARK pathways. The relationship between GUCA2A expression levels and GSVA scores in CRC is illustrated in Fig. 3H . Our biological enrichment analysis revealed distinctive patterns, exhibiting upregulation in pathways associated with pancreas beta cells, bile acid metabolism, and KRAS signaling with elevated GUCA2A expression. Conversely, as GUCA2A expression increased, pathways related to mitotic spindle dynamics, protein secretion processes, G2M checkpoint regulation, and interferon alpha responses were downregulated (Fig. 3H) . These findings provide insights into how GUCA2A expression may influence various pathways in CRC, shedding light on potential mechanisms and functional associations. Construction of guanylin expressing constructs Following the amplification and isolation of the CDS region of the GUCA2A gene (Additional file 1. Figure S1 A, S2A) , the obtained fragment and the plasmid constructs (HRE-pMUC1 and pCMV) underwent digestion using BamHI and XbaI enzymes. Subsequently, they were purified from the gel and linked together through a ligation process. These resulting plasmids were then introduced into competent bacteria via transformation. Afterward, bacterial colonies were cultured on plates, and the colonies were verified using colony PCR to amplify a 117 bp product (Additional file 1. Figure S1 B, S2B) . A single colony was selected for the extraction of plasmids. Finally, the validation of both the HRE-pMUC1-GUCA2A and pCMV-GUCA2A plasmids was performed through Sanger sequencing (Additional file 1. Figure S1 C) . the schematic illustration of the resulting guanylin expressing constructs is shown in Additional file 1. Figure S1 D . Structural confirmation of SPEI-9 nanocarrier The FT-IR analysis conducted on basic PEI and SPEI-9 revealed distinct peaks corresponding to the functional groups present in the polymer. These peaks were cross-referenced with the FT-IR spectra library for validation. Notably, the spectrum exhibited a prominent peak at approximately 1760 cm − 1 , which is associated with the stretching vibration of the carbonyl group (C = O) found in succinyl (Fig. 4A) . This peak serves as an indicator of the binding of the succinyl group to the PEI structure. NMR spectroscopy was employed to perform a structural analysis of SPEI-9. Through this analysis, distinctive peaks associated with various proton environments within the polymer were identified. Notably, the observation of peaks in chemical shifts ranging from 2.5 to 3.5 ppm signified the presence of the PEI backbone (Fig. 4B) . Additionally, the emergence of new peaks with chemical shifts in the range of 2.3 to 2.5 ppm provided confirmation of the succinyl group's presence. Consequently, the chemical environment of carbon atoms in the SPEI-9 sample served as confirmation of the successful modification of the polymer. Measuring buffering capacity of SPEI-9 nanocarrier The buffer capacity of PEI and SPEI-9 was also evaluated in this study. In this regard, compared to the negative control (deionized water), both SPEI-9 and PEI showed significant buffer capacity (Fig. 4C) . The pH of the solutions remained relatively stable even with the addition of high amounts of acid, indicating their resilience to pH changes. However, since the degree of 9% succinylation was used, SPEI-9 showed relatively lower buffering capacity compared to PEI at concentrations above 80 µl of HCl (Fig. 4C) . Therefore, the modification of PEI with 9% succinic anhydride largely preserved the suitable buffering properties of the basic nanocarrier, which can be useful for various applications such as drug delivery and gene therapy, where maintaining a specific pH range is very important. Measuring the gel retardation by SPEI-9 nanocarrier The DNA loading capacity of both PEI and SPEI-9 was assessed through a gel retardation assay, utilizing various C/P ratios ranging from 0.25 to 8. The results of the gel retardation assay revealed that at lower C/P ratios, specifically 0.25 and 1, SPEI-9 polyplexes exhibited limited DNA loading, as evidenced by their increased mobility during gel electrophoresis (Additional file 1. Figure S2C) . In contrast, at C/P ratios of 4 and 8, SPEI-9 nanocarriers demonstrated complete plasmid encapsulation, signifying an optimal loading capacity conducive to efficient plasmid delivery (Fig. 4D) . Conversely, the PEI-based nanocarrier displayed full DNA loading at three distinct C/P ratios: 1, 4, and 8 (Fig. 4D) . Consequently, the findings from agarose gel electrophoresis underscored the suitability of SPEI-9 nanocarriers at a C/P ratio of 4 and PEI at a C/P ratio of 1 as optimal ratio for gene delivery applications. DNase protection analysis of SPEI-9 The experiment involved treating SPEI-9 polyplexes at C/P ratios of 0.25, 4, and 8, along with a control gene construct group, with and without DNase. This simulated the presence of nucleases that could potentially break down genetic material. The results revealed that polyplexes formed at a C/P ratio of 0.25, as well as the plasmid structure, were significantly degraded after DNase treatment, as evidenced by the absence of plasmid bands in agarose gel electrophoresis (Fig. 4E) (Additional file 1. Figure S2D) . This indicated the vulnerability of genetic material when complexed with SPEI-9 at this specific C/P ratio. In contrast, polyplexes formed with SPEI-9 at C/P ratios of 4 and 8 displayed robust resistance against DNase degradation (Fig. 4E) . The bands corresponding to the gene constructs remained well-defined and intact after DNase treatment, underscoring the effective protection provided by SPEI-9 against enzymatic digestion. Measuring the size and surface charge of SPEI-9 nanocarrier The size and surface charge (zeta potential) of PEI and SPEI-9 nanocarriers were determined to evaluate their physicochemical properties, which can affect their stability and interaction with genetic materials. In this regard, the results showed that the polyplexes formed with SPEI-9 had an average size of 149.6 nm with an optimum PDI, which indicates that the polyplexes are relatively homogeneous in size and have good stability (Fig. 4F) . In contrast, polyplexes formed with PEI had a larger average size of 205 nm, indicating a broader size distribution compared to SPEI-9 polyplexes (Fig. 4F) . Zeta potential measurements also showed that SPEI-9 polyplexes have a positive surface charge, with an average surface charge of + 11.2 mV (Fig. 4G) . This positive charge is attributed to the presence of succinyl and amine groups in the PEI column, which can interact with the negatively charged genetic material. Positive zeta potential indicates good electrostatic stability and effective complexation potential with nucleic acids. In contrast, unmodified PEI polyplexes showed positive zeta potential with an average value of + 17.7 mV (Fig. 4G) . This higher positive charge is due to the lack of coverage of amine groups by succinyl. With this positive zeta potential, PEI polyplexes showed good stability and the ability to form complexes with genetic materials. Measuring the effect of SPEI-9 nanocarrier on hemolysis rate The hemolytic activity of PEI and SPEI-9 polyplexes was evaluated to assess their potential cytotoxic effects on RBCs. The hemolysis assay included the incubation of polyplexes with RBCs and the measurement of hemoglobin release, which acts as an indicator of cell membrane damage and hemolysis. The results showed that the rate of hemolysis increases with increasing C/P ratio for SPEI-9 polyplexes (Fig. 4H) . At the C/P ratio of 0.25, the amount of hemolysis was relatively low. However, with the increase of C/P ratio to 1, 4, and 8, the degree of hemolysis also increased gradually (Fig. 4H) . This shows that higher concentrations of SPEI-9 polyplexes may have more potential to induce hemolysis. In comparison, PEI polyplexes at a C/P ratio of 1 had slightly similar hemolysis rates to SPEI-9 polyplexes at a C/P ratio of 4. This suggests that PEI polyplexes may also have some hemolytic activity. Although to a lesser extent compared to the SPEI-9 polyplex, the C/P ratio was higher than 8 (Fig. 4H) . These results highlight the importance of carefully selecting the C/P ratio and optimizing the formulation of polyplexes to minimize potential cytotoxic effects, especially in the context of functional in vivo gene delivery purposes. Interaction assay of SPEI-9 nanocarrier with BSA protein The interaction of PEI and SPEI-9 polyplexes with BSA was evaluated to assess their protein interaction capabilities. The BSA interaction test included the incubation of polyplexes with BSA and measuring the removal or retention of protein in the supernatant of the interaction reaction using spectrometry. In this regard, the results showed that the SPEI-9 polyplex with a C/P ratio of 4, which was selected based on previous tests for downstream studies, had a lower interaction (with an average of 0.48) with BSA compared to PEI polyplexes of C/P ratio 1 with an average of 0.61 (p = 0.017) (Fig. 4I) . The reduction of protein interaction observed with SPEI-9 polyplex indicates that modification of succinylation of PEI may change its surface characteristics and reduce its ability to interact with serum proteins such as BSA. This can be useful in gene delivery applications, as reduced protein interactions can improve stability in circulation to help transfer with higher efficiency. Cytotoxicity assay of SPEI-9 nanocarrier Cytotoxicity assessment of PEI and SPEI-9 was performed in two cell lines, HCT-116 and Vero. In this regard, PEI in C/P ratio 1 showed the highest cytotoxicity in both cell lines, which indicates its destructive effect on cell viability (p = 0 < 0.0001) (Fig. 4J, 4K) . This can be attributed to the high cationic charge density of PEI, which leads to electrostatic interactions with negatively charged cell membranes. These interactions can eventually cause irreparable damage to the cell membrane and lead to cell lysis or necrosis. In contrast, the cytotoxicity of SPEI-9 in both cell lines at different C/P ratios was relatively lower compared to PEI 1 (p = 0.0102, 0.0004, 0 < 0.0001) (Fig. 4J, 4K) . Reducing the charge density of succinylated polymers may help reduce the deleterious effects on cell viability. HCT-116 cells had the lowest toxicity in the presence of SPEI-9 at all C/P ratios, which indicates higher resistance compared to Vero cells. Furthermore, the cytotoxicity of SPEI-9 increased with increasing C/P ratio, indicating a concentration-dependent effect. Even at the highest C/P ratio (8:1), the cytotoxicity of SPEI-9 was almost equal compared to PEI at a C/P ratio of 1:1 (Fig. 4J) . Cytotoxicity was observed in Vero cells treated with PEI and SPEI-9 more severely. In this context, it was observed that the cytotoxicity of Vero cells was notably lower when treated with SPEI-9 at a C/P ratio of 0.25:1 in comparison to other ratios. However, as the C/P ratio increased, there was a significant elevation in cytotoxicity among Vero cells (p = 0.017, p < 0.0001) (Fig. 4K) . These findings underscore the significance of polymer modification, such as succinylation, in mitigating the cytotoxic effects associated with PEI. The reduced cytotoxicity observed with SPEI-9 implies its potential as a safer alternative for gene transfer applications, particularly in the context of cancer cells like HCT-116. Transfection efficiency assay by SPEI-9 nanocarrier Analysis of the images acquired via fluorescence microscopy revealed that both SPEI-9 (C/P 4) and PEI (C/P 1) nanocarriers exhibited remarkable efficacy in delivering the pEGFP-N1 plasmid construct, which contains the EGFP protein as a transfection marker. The results indicated that the optimal transfection time for plasmid treatment was 72 h, a widely accepted standard in plasmid transfection protocols. Notably, the transfection rate achieved by the SPEI-9 nanocarrier surpassed that of PEI in both the cancer cell lines HCT-116 (Fig. 5A, 5B, 5E, p = 0.0229) and the normal Vero cell line (Fig. 5C, 5D, 5E, p = 0.0373) . Consequently, the SPEI-9 nanocarrier, administered for 72 h, was selected for subsequent assessments in cell culture studies. Cell culture study design After conducting different studies involving PEI and SPEI-9 nanocarriers at varying C/P ratios, we have determined that SPEI-9, due to its significantly lower toxicity and superior transfection efficiency during the 72 h treatment, is the optimal choice for subsequent cell culture studies. Furthermore, considering its effective loading at a C/P ratio of 4, along with its reduced toxicity compared to a C/P ratio of 8, we have selected this C/P ratio for the treatment groups in conjunction with various constructs, including pCMV-GUCA2A loaded SPEI-9, HRE-pMUC1-GUCA2A loaded SPEI-9, pEGFP-N1 loaded SPEI-9, and a control group. Evaluation of gene expression changes At first, the GUCA2A expression level in 10 CRC tissues and 10 adjacent healthy tissues was investigated using RT-qPCR. The results of this study showed a notable decreased and differential expression of GUCA2A in tumor tissue compared to the adjacent healthy tissue among different patients (Fig. 5F) . Additionally, RT-qPCR for GUCA2A , p21, β-catenin, BAX , BCL-2 , Cadherin-2, Vimentin, and GAPDH (as reference gene) was performed to evaluate the mRNA expression changes upon treatment with different gene therapeutics. In both cell lines, SPEI-9 loaded with pCMV-GUCA2A showed remarkable over-expression of guanylin hormone (≈ 15-fold increase in logFC, p = 0 < 0.0001) (Fig. 5G) . While, SPEI-9 nanocarrier loaded with pMUC1-GUCA2A, shown a lower level of increased expression than pCMV-GUCA2A in HCT-116 (≈ 5-fold increase in logFC, p = 0 < 0.0001) and much lower level of increased expression in Vero cells (not significant), indicating moderate but specific expression of guanylin in cancer cells lines (Fig. 5G) . This result is consistent with the tumor-specific nature of the MUC1 gene promoter, which directs the expression of guanylin specifically in tumor cells and minimizes its expression in normal cells. In addition to measuring expression changes by the gene constructs, the effects of inducing gene expression by HRE cassette were also evaluated. We chose the treatment time with and without the effects of hypoxia for 16 h, which showed a significant increase in this period compared to the untreated group (≈ 3.5-fold increase in fold change, p = 0.0004) (Fig. 5H) . In this regard, the pCMV-GUCA2A group showed a significant decrease of ≈ 6-fold (p = 0.0005) and ≈ 1.5-fold (p = 0.0023) decrease in β-catenin mRNA levels in HCT-116 and Vero cells, respectively (Fig. 5I) . Regarding the pMUC1-GUCA2A construct, it showed a significant decrease of ≈ 2-fold (p = 0.002) and ≈ 1-fold (p = 0.113) in both HCT-116 and Vero cell lines, but with less intensity (Fig. 5I) . Concerning p21, a significant increase in the expression of the pCMV-GUCA2A gene construct (p = 0.001) compared to pMUC1-GUCA2A (p = 0.0019) was observed for the HCT-116 cell line (Fig. 5J) . However, in Vero cell line, both gene constructs showed ≈ a 1-fold decrease in p21 mRNA level, that this result can be based on the fact that in this cell line the expression of p21 is naturally reduced [ 34 ] (Fig. 5K) . The effect of guanylin over expression on the levels of two key mediators of apoptosis, BAX and BCL-2 as promoter and inhibitor of apoptosis were also investigated, respectively. In this regard, both gene constructs of pCMV-GUCA2A and pMUC1-GUCA2A showed a significant increase in the expression of the apoptosis-promoting gene, BAX, for the HCT-116 cell line (p = 0.0040 and p = 0.0173) (Fig. 5K) . These changes in the pCMV-GUCA2A group were more intense (≈ 2-fold), which is caused by the significant difference in guanylin expression. On the other hand, in the Vero cell line, this difference in expression was observed with less severity for both pCMV-GUCA2A (p = 0.0199) and pMUC1-GUCA2A (p = 0.0493) treatment groups (Fig. 5K) . Moreover, BCL-2 levels have shown a significant decrease in both gene constructs in HCT-116 (p = 0 < 0.0001) and Vero (p = 0 < 0.001) cell lines (Fig. 5L) . However, these changes were more intense for pCMV-GUCA2A compared to pMUC1-GUCA2A, with tumor-specific promoters (Fig. 5L) . These differential results were also repeated in the expression of two key genes involved in the epithelial-mesenchymal transition (EMT) pathway, including Vimentin and N-cadherin, due to the strong but non-specific CMV promoter and the moderate but tumor-specific promoter MUC1 . Regarding Vimentin, the results showed a significant decrease in expression in the HCT-116 cell line for both treatments (p = 0 < 0.0001) (Fig. 5M) . For the Vero cell line, the pCMV-GUCA2A group showed a lower expression decrease (p = 0.0156) (Fig. 5M) . On the other hand, in the case of pMUC1-GUCA2A treatment, this gene showed a very small increase (p = 0.0142). Additionally, for N-cadherin in both HCT-116 and Vero cell lines, both treatment groups showed a significant decrease in expression (p = 0 < 0.001), while for the Vero cell line, the changes in the mRNA level were less intense than HCT-116 cancer cell line (Fig. 5N) . Finally, heat maps were also generated based on the expression of GUCA2A and its 6 downstream genes for both cancer and normal cell lines to better show the expression distribution between these two cell lines (Fig. 5O, 5P) . Evaluation of apoptosis induction upon guanylin expressing nano-system To assess the anti-tumor effects of the gene therapeutics, we measured the percentage of induced apoptosis using the Annexin-PI kit and analyzed the results in three categories: necrosis, apoptosis, and total cell death. In this context, we observed minimal necrosis in HCT-116 cancer cells as a result of the genetic constructs (Fig. 6A, 6B) . However, in normal Vero cells, necrosis reached levels of up to 25% (Fig. 6A, 6B) . This relatively higher necrosis percentage in Vero cells can be attributed to their strong adhesion to the culture plate. Additionally, mechanical scraping with a cell scraper contributed to the induction of necrosis. Furthermore, both gene constructs exhibited significant induction of apoptosis in HCT-116 cancer cells (p = 0.0001), with approximately 35% for pCMV-GUCA2A and approximately 30% for pMUC1-GUCA2A (Fig. 6A, 6C) . In Vero cells, the induction of apoptosis was relatively lower, approximately 25% for pCMV-GUCA2A (p = 0.0001), and even less in the pMUC1-GUCA2A group, approximately 11% (p = 0.0120) (Fig. 6A, 6C) . Finally, the overall assessment of cell death, which included both early and late apoptosis as well as necrosis, revealed similar patterns to apoptosis and necrosis (Fig. 6D) . Evaluation of cytotoxicity upon guanylin gain of function Following the evaluation of guanylin expression through RT-qPCR, we proceeded to assess the impact of different gene constructs delivered via SPEI-9 on cell viability and potential cytotoxicity. In the case of HCT-116 cells, it was evident that cell viability significantly decreased in both the pCMV-GUCA2A (p = 0.0001) and pMUC1-GUCA2A (p = 0.0030) groups when compared to the control and SPEI-9 groups (Fig. 6E) . Conversely, the cytotoxicity induced by the gene therapeutics markedly increased in both groups when applied to HCT-116 cell lines. In normal Vero cells, the cytotoxicity induced by pCMV-GUCA2A was higher in comparison to pMUC1-GUCA2A (p = 0.0001) (Fig. 6F) . The subsequent increase in cytotoxicity observed with pMUC1-GUCA2A was relatively lower than that associated with pCMV-GUCA2A (p = 0.0019), aligning with expectations (Fig. 6F) . Evaluation of cell migration ability To investigate the inhibitory effect of gene constructs on cell migration, a scratch or wound-healing assay was performed. The results of this test showed that pCMV-GUCA2A had stronger anti-migration effects compared to the pMUC1-GUCA2A vector. In this regard, after 24 and 48 h after treatment in HCT-116 cancer cells, the scratch assay created in the group treated with guanylin expression constructs, cell migration at a much lower speed than the nanocarrier group containing gene constructs control and group without treatment were performed (Fig. 7A, 7C) . Interestingly, these effects in Vero cells were accompanied by a significant decrease in the inhibition of cell migration by treatment with the pMUC1-GUCA2A gene construct, which results from the low expression of guanylin (Fig. 7B, 7D) . It is noteworthy to mention that in part A, 24 h and 48 h are separately seeded, treated, and colored, and the control group shown corresponds to the 24 h group. Evaluation of the guanylin expressing nano-system on colony formation In this test, the effect of different treatments through genetic constructs on the process of colony formation from a seeded cell to a colony of cells (about 50 cells) was evaluated. The obtained results, like the previous results, indicated stronger inhibitory effects of pCMV-GUCA2A treatment compared to the structure containing the specific promoter in the HCT-116 cancer cell line. In this regard, both gene constructs in the HCT-116 cell line showed a significant decrease in the number of colonies (p = 0 < 0.0001) (Fig. 7E, 7G) . Also, in the group of normal Vero cells, far less inhibitory effects of the structure containing the MUC1 promoter (p = 0.0001) than CMV (p = 0 < 0.0001) were observed, which is consistent with the previous findings (Fig. 7F, 7G) . Discussion The application of gene therapy as a potential treatment for cancer has urged the development of various polymeric nanocarriers. The aim is to enhance non-viral vectors as safe and efficient agents for gene transfer. Among these, the PEI nanocarrier, recognized as a benchmark for polymeric vectors, demonstrates notable gene transfer efficiency in serum-free and in vitro conditions. Nevertheless, challenges arise under serum-supplemented conditions that mimic the in vivo environment. Specifically, PEI/DNA polyplexes tend to aggregate with serum proteins, leading to a reduction in overall transfection efficiency [ 23 , 35 ]. The approaches employed to enhance transfection efficiency and improve the physicochemical characteristics of PEI nanocarriers encompass the conjugation of PEI with diverse polymers, the incorporation of distinct chemical moieties, and the integration of targeting components. For instance, the coupling of polyethylene glycol (PEG) or a stealth polymer, along with more complex chemical groups, establishes a charge protection layer within PEI/DNA polyplexes. This layer serves to mitigate the excess positive charge of the polycation, preventing nonspecific binding to other proteins [ 36 ]. Nevertheless, while these chemical modifications can alleviate polymer toxicity and mitigate interactions with nonspecific proteins, they may concurrently diminish the efficacy of DNA transfer into the cell by reducing its buffering capacity. Hence, the modifications contribute to enhanced gene transfer efficiency, reduced cytotoxicity, improved stability, and tunable properties were explored to make modified PEI a promising candidate for advancing gene therapy applications [ 37 , 38 ]. One approach involves attaching anionic components to PEI to reduce the cationic charge density of polyplexes, thereby mitigating cytotoxicity. The utilization of succinic anhydride as a surface modification agent for this polymer can alter its surface characteristics. Following the surface modification of PEI with succinic anhydride, carboxylic groups are introduced to the polymer surface. These carboxylic groups induce various alterations, encompassing changes in contact angle, hydrophobic properties, dispersibility, and the capacity to modify and enhance the electrical charge of the polymer [ 26 ]. The modification degree of Succinylated PEI (SPEI) can be adjusted by varying the quantity of succinic anhydride employed during the modification process, which ranges from 9 to 55% of modified amines. This variability can result in distinct levels of modification, impacting the properties of the resulting SPEI polymer. Notably, SPEI-9, denoting SPEI with a low degree of succinylation (approximately 9% by polymer weight), usually yields lower charge density. Despite a relatively modest reduction in toxicity, it demonstrates higher gene transfer efficiency compared to unmodified PEI. Due to its efficient DNA condensation and protective attributes against degradation, SPEI-9 emerges as a promising and optimal gene delivery vector [ 26 , 35 ]. In this regard, in a study conducted by Warriner et al., it was demonstrated that modifying the PEI polymer with varying degrees of succinyl groups diminishes the strength of electrostatic interactions between the plasmid and the polymer. Conversely, as the degree of succinylation increases, nonspecific interactions between the polymer and serum proteins decrease, allowing more polymer to be utilized for efficient DNA loading [ 35 ]. Additionally, the resultant SPEI-9 polyplex exhibited a size of approximately 150 nm, falling within the optimum range for endocytosis without receptor mediation [ 39 ]. It has been observed that the increase in the size of SPEI-based nanocarriers, corresponding to an escalation in the degree of succinylation (ranging from 9, the lowest, to 55, the highest), is primarily attributed to the reduction of electrostatic interactions produced by the polyplex with lower density, resulting in a larger nanocarrier. Moreover, the ζ potential of the polyplexes remained positive, albeit experiencing a slight decrease attributable to succinylation [ 35 ]. However, the significance of size in polymer design for gene delivery is often underestimated. Studies reveal that PEI-pDNA polyplexes exceeding 100 nm demonstrate enhanced transfection efficiency compared to smaller counterparts [ 40 – 42 ]. Several explanations have been suggested to rationalize this observation. Firstly, smaller particles indeed exhibit greater solution stability compared to larger ones, which may lead to higher interactions as they sediment onto cell surfaces. Similarly, centrifuging smaller particles onto cells can achieve a similar effect. Another explanation lies in the role of size in endocytic cycle. For polymers reliant on buffering the endosome and escaping via the proton-sponge phenomenon, larger complexes resulting from higher polymer weight possess increased buffering capacity. This is evident from the limited benefits observed in transfections with lysosomotropic agents for large complexes, while significant efficiency increases are noted for smaller ones. Additionally, vector size can influence the route of internalization [ 43 , 44 ]. Clathrin-coated vesicles measure approximately 200 nm in diameter, necessitating adherence to this constraint for particles entering via this route. Larger particles, on the other hand, opt for clathrin-independent pathways, thereby avoiding harsh acidification and trafficking to lysosomes. Cationic polyplexes have a tendency to aggregate with circulatory components like serum proteins and erythrocytes, resulting in clearance or toxicity [ 45 ]. However, smaller and more neutrally charged polyplexes evade this issue by minimizing electrostatic and non-specific binding interactions. Conversely, large polyplexes face reduced cytosolic mobility and rely on active transportation by microtubular and microfibril networks. thus, achieving an optimal polyplex size entails balancing favorable endocytic trafficking and cellular interactions while optimizing cytotoxicity and cytosolic mobility [ 46 ]. It is also possible that the end groups of carboxyl succinate may induce a hydration layer, protecting the nanocarrier against serum proteins. However, similar to PEG derivatives, an elevation in the degree of succinylation (45 or 55 degrees) may lead to diminished interactions, stemming either from electrostatic repulsion or physical shielding through hydrated branches. This, in turn, could enhance the polymer's potential to cause damage to the cell membrane, ultimately associated with a decrease in effective gene transfer [ 35 , 47 ]. Therefore, considering that SPEI with lower degrees of succinylation offers both lower cytotoxicity and more effective gene transfer, and, in contrast, higher degrees of succinylation lead to increased interactions with serum proteins, the current study opted for the minimum degree of succinylation, 9%, on branched PEI. This choice was made to reduce cytotoxic effects and enhance the efficiency of gene transfer. Given that prior investigations on PEI succinylation primarily employed 2 kDa linear PEI, this study stands out by conducting comprehensive structural and functional analyses on the SPEI-9 nanocarrier based on 25 kDa nanocarrier, yielding novel and promising outcomes. The results obtained from structural confirmation, utilizing FT-IR and H-NMR for the SPEI-9 nanocarrier, align with the findings presented in studies conducted by Zaaeri et al. [ 48 ] and Warriner et al.[ 35 ]. Furthermore, concerning the efficient loading of genetic material and the protective capability of the SPEI-9 nanocarrier against degradation by the DNase enzyme, the findings align with the broader outcomes of the study conducted by Nouri et al. Specifically, their study focused on a succinic anhydride group-conjugated nanocarrier (PEI-SUC-PEI) with determined structural and functional characteristics. Nouri et al. demonstrated that this nanocarrier exhibited superior buffering resistance compared to both PEI-SUC and the base PEI. Interestingly, the loading efficiency and resistance to genetic structure degradation by DNase were nearly identical between PEI-SUC-PEI and PEI-SUC. Notably, the study's results indicated that the PEI-SUC-PEI nanocarrier, benefiting from the presence of two PEI groups, facilitated more effective gene transfer at higher C/P ratios compared to other groups [ 41 ]. In addition, Zintchenko et al. conducted a foundational study in 2008 where the PEI nanocarrier underwent modification with various functional groups, including ethyl acrylate (PEI-EA), acetyl (PEI-AC), succinyl (PEI-SUC), and propionic acid (PEI-PROP). These modifications were applied with varying degrees to assess siRNA transfer efficiency and cytotoxicity in HuH-7 hepatoma cells. The results regarding cell viability demonstrated a proportional increase in cytotoxicity with the escalation of modification degree for all four PEI groups. Notably, the cytotoxicity of PEI-SUC and PEI-PROP nanocarriers was significantly lower than the others. Furthermore, to evaluate the efficacy of siRNA transfer, polymers from each group were examined at different C/P ratios (ranging from 0.5 to 8). Interestingly, among all the polymers tested, PEI-PROP-18 (C/P ratio 8), PEI-EA-31 (C/P ratios 6 and 8), and PEI-SUC-9 (C/P ratios 4, 6, and 8) exhibited the most potent silencing effects of siRNA. Among these, PEI-SUC-9 demonstrated the highest efficiency, highlighting its remarkable capability for effective gene transfer. Considering the cumulative evidence, the nanocarrier based on succinylated PEI with the lowest modification degree, 9%, emerges as the optimal choice for gene transfer due to its minimal cytotoxicity and maximal gene transfer efficiency [ 26 ]. Guanylyl cyclase C (GC-C) is a transmembrane receptor prominently expressed apically in intestinal crypts and villus cells [ 9 ]. The GC-C signaling pathway has emerged as a promising therapeutic target for widespread gastrointestinal disorders, including irritable bowel syndrome with constipation, chronic idiopathic constipation, and inflammatory bowel disease [ 9 , 49 ]. Specifically, GC-C activation is facilitated by intracellular hormonal ligands, uroguanylin and guanylin predominantly expressed in the small intestine and large intestine, respectively. These hormones activate GC-C, setting off a cascade of downstream signaling pathways. These pathways play a pivotal role in regulating fluid and electrolyte homeostasis, maintaining the integrity of the intestinal epithelium, and influencing tumorigenesis [ 50 ]. Inactivating mutations in APC are linked to 80% of CRC tumors [ 51 ] and are also prevalent in other gastrointestinal cancers like gastric cancer [ 52 ]. In this subtype of CRCs, the loss of function in both APC alleles is a crucial step in tumor initiation. The inability of APC to regulate the stability of β-catenin protein results in uncontrolled β-catenin nuclear signaling, leading to the activation of oncogenic genes [ 51 ]. Although the APC/β-catenin signaling pathway is an appealing target for gastrointestinal cancers, achieving therapeutic effects with drug interventions targeting these molecules proves to be challenging [ 50 ]. Remarkably, the connection between the GC-C signaling pathway and CRC was initially revealed through population studies, highlighting an inverse relationship between CRC prevalence and enterotoxigenic Escherichia coli (ETEC) infections [ 53 ]. ETEC infections involve heat-stable enterotoxins that produce STs, ultimately activating the GC-C signaling pathway and causing diarrhea [ 50 ]. Additionally, the GC-C signaling pathway is implicated in CRC through the depletion of intracellular ligands, guanylin and uroguanylin. In a study encompassing around 300 tumors and their corresponding adjacent normal tissues, guanylin mRNA exhibited a loss of expression in over 85% of tumors compared to the corresponding normal epithelium [ 16 ]. Notably, recent observations in mice suggest that the loss of guanylin is a direct downstream consequence of mutant APC/β-catenin signaling [ 15 ]. Furthermore, the loss of APC heterozygosity (loss of two alleles) is pivotal for the loss of guanylin hormone expression [ 7 ]. Consequently, these findings highlight that the GUCY2C signaling pathway, mediated by guanylin and uroguanylin hormones, may be directly associated with APC/β-catenin mutant signaling in CRC tumorigenesis. Thus, investigating the gain of function of these two hormones holds promise for advancing CRC treatment, representing the primary objective of this study. Furthermore, based on our prior study involving an integrative transcriptome analysis, we identified the peptide hormone guanylin as the primary therapeutic target for the gain of function studies [ 54 ]. Subsequently, guanylin was amplified and cloned into gene constructs containing CMV and MUC1 promoters. Conversely, considering the synthesis and characterization of the SPEI-9 nanocarrier as an efficient and safe gene delivery agent for gene constructs, diverse cell culture studies were conducted to assess the anti-tumor effects of this therapeutic system. Initially, to validate the transfection efficiency, the SPEI-9 nanocarrier, with a C/P ratio of 4 and loaded with pCMV-GUCA2A and pMUC1-GUCA2A gene constructs, was applied to HCT-116 cancer cells and normal Vero cells. The optimal transfection period of 72 h was chosen to induce maximal peptide hormone expression within the cells. The results of the transfection process, as indicated by GUCA2A mRNA expression levels, revealed that the pCMV-GUCA2A gene construct exhibited significantly higher expression with lower specificity compared to the construct containing the MUC1-specific promoter. It can be inferred that the efficacy of the MUC1 promoter is contingent on its tissue-specific expression in the relevant cancer. For instance, in a study by Farokhimanesh et al., the PEI nanocarrier loaded with a gene construct containing the MUC1 promoter and encoding the pro-apoptotic gene truncated BID (tBid) demonstrated specific and elevated expression in breast cancer in contrast to the construct with the CMV promoter. Their findings suggested that this heightened and specific expression could potentially induce apoptosis in breast cancer cells (MCF7, T47D, and SKBR3) with minimal impact on normal AGO skin fibroblast cells. Moreover, the induction of expression through the specific MUC1 promoter in the CRC cell line HT-29 exhibited a notable increase, albeit less obvious than in breast cancer cell lines. Considering that the expression of MUC1 in this cell line differs from HCT-116, it holds more potential for inducing expression [ 22 ]. However, according to diverse investigations, HCT-116 cells are identified as non-differentiated and highly aggressive, with a p53 mutation occurring in the advanced stages of cancer and this cell line exhibited a low expression profile for MUC1. In contrast, HT-29 cells are recognized as more differentiated and less aggressive cell lines with mutations in APC observed in the early stages of cancer. Additionally, HT-29 cells can differentiate into enterocytes and MUC1-expressing cells [ 55 , 56 ]. Conversely, given the markedly reduced or absent expression of the guanylin hormone in the progression of CRC and the proved enhanced therapeutic effects in advanced disease stages, the HCT-116 cell line was selected as a tumor model. As a counterpart, the Vero cell line, characterized by very low MUC1 expression, was chosen as a normal model [ 57 ]. In addition to assessing the specific induction effects of the MUC1 promoter, we explored the impact of this stimulus using the HRE upstream of the promoter. Recognizing that prolonged exposure to hypoxia can inhibit apoptosis through therapeutic interventions, a treatment duration of 16 h was chosen based on literature findings. This short period yielded favorable results in terms of expression, as evaluated by RT-qPCR. However, it's important to note that this aspect remained focused on the measurement of expression levels, with the primary emphasis of the study directed towards investigating the therapeutic effects of the promoters, GUCA2A gene, and the SPEI-9 nanocarrier [ 22 , 58 , 59 ]. In alignment with the signaling pathways associated with the guanylin hormone, this study focused on the expression of β-catenin and p21 genes as direct components engaged in the downstream pathway. In this regard, in the study by Rajabi et al., they explored the inhibitory effect of the doxorubicin-loaded zymosan nanoparticles on the Wnt/β-catenin pathway. The research revealed that zymosan nanoparticles were effective in suppressing the expression of key genes associated with the Wnt/β-catenin pathway and the treatment groups upregulated caspase-8 expression while modulating the Bax/Bcl-2 ratio, promoting apoptosis [ 60 ]. Gonzalez-Valdivieso et al. and Fatemi et al. investigated not only the PI3K/Akt pathway but also delved into the Wnt/β-catenin signaling pathway to examine their respective inhibitory effects on CRC cell lines [ 61 , 62 ]. Additionally, to explore the impact on apoptosis induction and the inhibition of cell migration pathways, measurements were conducted on BAX/BCL-2 , Cadherin 2, and Vimentin genes. The results demonstrated that elevating guanylin expression, facilitated by both gene constructs, led to suppressed apoptosis induction and diminished expression of genes associated with cell migration pathways. In accordance with our results, Chen et al. conducted a study revealing that the long noncoding RNA SRRM2-AS exerts inhibitory effects on angiogenesis in nasopharyngeal carcinoma by activating the MYLK-mediated cGMP-PKG signaling pathway. Their research demonstrated that silencing SRRM2-AS led to increased levels of MYLK, cGMP, PKG, Bax, and Caspase 3, while decreasing levels of VEGF, PCNA, Ki-67, and Bcl-2. Consequently, SRRM2-AS silencing suppressed cell proliferation, colony formation, and angiogenesis, disrupted the cell cycle, and heightened cell apoptosis in nasopharyngeal carcinoma [ 63 ]. Replication of these effects by activation of the cGMP-PKG signaling pathway has also been followed by several other studies in the field[ 64 – 66 ]. Notably, in the group treated with the gene construct featuring the specific MUC1 promoter, there was a quantitative increase in tumor suppressor genes and a decrease in oncogene expression, as observed in the normal Vero cell group. These outcomes signify a specific expression pattern. In this context, Basu et al.'s study yielded interesting findings. In Gucy2c +/+ model mice, where the guanylate cyclase C pathway was activated, treatment with bacterial heat-resistant enterotoxin (ST) led to potent antitumor effects. This activation positively regulated the expression of p21 and p38 MAPK genes, culminating in a significant reduction in formed colonies. Notably, these effects were absent in the Gucy2c −/− mouse model, underscoring the critical role of the combined GC-C/cGMP signaling pathway in colorectal carcinogenesis [ 67 ]. Considering the dual regulation (up- and down-regulation) of genes involved in diverse carcinogenic pathways upon increased guanylin hormone function, its potential therapeutic effects were systematically assessed through various assays. Notably, tests focusing on cytotoxicity and apoptosis induction revealed a significant augmentation in both parameters in HCT-116 cancer cells in groups containing both CMV and MUC1 promoters, correlating with elevated guanylin hormone function. However, distinctive patterns were observed between the two promoters. The induction of guanylin hormone by the CMV promoter exhibited stronger inhibitory effects on cytotoxicity and apoptosis induction, indicating robust but less specific impacts. Conversely, the induction by the MUC1 promoter demonstrated slightly weaker effects but showcased greater specificity. In the Vero cell line, induction of the hormone from the CMV promoter displayed obvious inhibitory effects, an aspect that remains relatively unexplored in the current body of research. Existing studies in this domain have predominantly centered on activating the GC-C pathway through bacterial ST. For instance, Li et al.'s 2017 study elucidated the effects of GC-C paracrine pathway activation via oral administration of bacterial ST in a mouse model of radiation-induced gastrointestinal syndrome and different cancer cells. The outcomes highlighted the significant induction of apoptosis in CRC cells (HCT-116) upon GC-C activation by ST. Interestingly, these antitumor effects were contingent on the p53 pathway, as evidenced by their absence in the HCT-116 cell line with an altered phenotype of p53 int−/− (with biallelic loss of p53). Moreover, in mouse models of gastrointestinal syndrome, oral administration of bacterial ST manifested substantial reductions in disease symptoms and mortality rates, underscoring its potential therapeutic efficacy [ 68 ]. Based on the findings of this study, the modified SPEI nanocarrier demonstrates superior gene transfer efficacy and safety compared to the conventional PEI carrier. This characteristic holds immense significance, particularly in animal research. However, certain challenges hindered our ability to conduct practical tests. Notably, the considerable difference between human and mouse guanylin hormone sequences (approximately 68% similarity) posed a significant hurdle. In this case, the use of nude mice models for experimentation was not applicable due to the lack of experimental and well-established facility for this purpose. Moreover, the PEI-based nanocarriers exhibits a remarkable ability to target cancerous tissues in vivo , primarily leveraging the Enhanced Permeability and Retention (EPR) effect. Future investigations are poised to enhance the carrier's efficacy by incorporating targeting moieties into the PEI structure. This approach holds promise for maximizing therapeutic outcomes, either individually or synergistically, particularly when combined with genetic vectors containing tumor-specific promoters. These prospective studies are primed to boost advancements in targeted gene therapy and cancer treatment [ 23 ]. Conclusion In our thorough examination of pan-cancer, we discovered exciting insights into the expression patterns of the guanylin hormone across various parts of the colon and rectum. Our findings suggest that guanylin may exert a significant influence on the development of colorectal cancer, participating in intricate pathways of interaction. Moreover, the hormone experiences numerous mutations and widespread depletion in cancer cases, leading to a marked decline in patient survival rates. This aberration also correlates with dysfunctional interactions with the immune system, heightened cell proliferation, inhibition of apoptosis, etc. The comprehensive findings highlight the pivotal role of the GC-C signaling pathway in leading the digestive system, encompassing both the small and large intestines. Disruption of this pathway, whether through alterations in the receptor itself or via exogenous ligands like guanylin and uroguanylin, can precipitate lethal effects on healthy digestive system. It's noteworthy that the bulk of existing research has predominantly focused on activating this pathway using chemical stimuli such as bacterial ST and analogous pharmaceutical agents. In contrast, the present study introduces a novel approach, evaluating the potential antitumor effects arising from the targeted induction of the guanylin hormone via safe and efficient transfection of pMUC1-GUCA2A vector with SPEI-9 as a potent nanocarrier. Both specifically and universally expression of guanylin hormone, the outcomes of this study can be characterized as promising. Declarations Funding Declaration This work is supported by a grant from Hamadan University of Medical Sciences, Hamadan, Iran (No. 9907295351). Availability of supporting data All the data employed in this study are comprehensively presented within the article, and availability upon reasonable request from the corresponding author is ensured. The relevant datasets can also be accessed through direct web links: TCGA - https://www.cancer.gov/; GTEx - https://commonfund.nih.gov/GTEx/; GDC-https://gdc.cancer.gov/; cBioPortal-https://www.cbioportal.org/; DAVID-https://david.ncifcrf.gov/; TIMER2.0- http://timer.cistrome.org/; Smartapp-www.bioinfo-zs.com/smartapp/; TISDB- http://cis.hku.hk/TISIDB/index.php. Further inquiries are available from the corresponding author upon reasonable request. Ethical Approval and Consent to participate All procedures were performed in accordance with the Declaration of Helsinki and approved by the ethics committee of the Hamadan university of medical sciences (IR.UMSHA.REC.1399.562). Informed consent was obtained from all subjects and or their legal guardians. Patient samples were collected from the Poursina Hakim Research Institute (Esfahan, Iran). Competing interests The authors declare that there are no conflicts of interest. Consent for publication Not applicable. Authors' information Affiliations Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran PS, AJ & RN Department of Pharmaceutical Biotechnology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran MS & FN Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran FR Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran AJ Authors' contributions PS designed the research, performed the experiments, analyzed the bioinformatics data, and prepared the original draft and revised the manuscript during rounds of revision. MS, FN, and RN supervised the synthesis of the nanocarrier, edited and revised the manuscript, and evaluated the final data. FR prepared the HRE-pMUC1 plasmid and edited and revised the manuscript. AJ conceptualized the project, revised the manuscript, and provided final suggestions. All authors read and approved the final manuscript. * Correspondence : Correspondence to Akram Jalali, Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. Email: [email protected] References Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, Kitui SK, Manyazewal T: New approaches and procedures for cancer treatment: Current perspectives. SAGE open medicine 2021, 9: 20503121211034366. Katsila T, Spyroulias GA, Patrinos GP, Matsoukas M-T: Computational approaches in target identification and drug discovery. Computational and structural biotechnology journal 2016, 14: 177-184. Wang Y, Wang Z, Xu J, Li J, Li S, Zhang M, Yang D: Systematic identification of non-coding pharmacogenomic landscape in cancer. Nature communications 2018, 9: 3192. Zhang Y, Chen F, Chandrashekar DS, Varambally S, Creighton CJ: Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways. Nature Communications 2022, 13: 2669. Chen F, Chandrashekar DS, Varambally S, Creighton CJ: Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nature communications 2019, 10: 5679. Vande Voorde J, Steven RT, Najumudeen AK, Ford CA, Dexter A, Gonzalez-Fernandez A, Nikula CJ, Xiang Y, Ford L, Maneta Stavrakaki S: Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target. Nature Metabolism 2023 : 1-16. Pattison AM, Barton JR, Entezari AA, Zalewski A, Rappaport JA, Snook AE, Waldman SA: Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity. Cancer Biol Ther 2020, 21: 799-805. Waldman SA, Camilleri M: Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut 2018, 67: 1543-1552. Kuhn M: Molecular physiology of membrane guanylyl cyclase receptors. Physiol Rev 2016, 96: 751-804. Pitari GM, Di Guglielmo M, Park J, Schulz S, Waldman SA: Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proceedings of the National Academy of Sciences 2001, 98: 7846-7851. Lin JE, Li P, Snook AE, Schulz S, Dasgupta A, Hyslop TM, Gibbons AV, Marszlowicz G, Pitari GM, Waldman SA: The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. Gastroenterology 2010, 138: 241-254. Wang R, Kwon I-K, Thangaraju M, Singh N, Liu K, Jay P, Hofmann F, Ganapathy V, Browning DD: Type 2 cGMP-dependent protein kinase regulates proliferation and differentiation in the colonic mucosa. American Journal of Physiology-Gastrointestinal and Liver Physiology 2012, 303: G209-G219. Piroozkhah M, Aghajani A, Jalali P, Shahmoradi A, Piroozkhah M, Tadlili Y, Salehi Z: Guanylate cyclase-C Signaling Axis as a theragnostic target in colorectal cancer: a systematic review of literature. Front Oncol 2023, 13 . Bashir B, Merlino DJ, Rappaport JA, Gnass E, Palazzo JP, Feng Y, Fearon ER, Snook AE, Waldman SA: Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia. Hum Pathol 2019, 87: 103-114. Blomain ES, Rappaport JA, Pattison AM, Bashir B, Caparosa E, Stem J, Snook AE, Waldman SA: APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis. Cancer Biol Ther 2020, 21: 441-451. Wilson C, Lin JE, Li P, Snook AE, Gong J, Sato T, Liu C, Girondo MA, Rui H, Hyslop T: The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2014, 23: 2328-2337. Rappaport JA, Waldman SA: The guanylate cyclase C—cGMP signaling axis opposes intestinal epithelial injury and neoplasia. Front Oncol 2018, 8: 299. Kumar A, Das SK, Emdad L, Fisher PB: Applications of tissue-specific and cancer-selective gene promoters for cancer diagnosis and therapy. Adv Cancer Res 2023, 160: 253-315. Montaño-Samaniego M, Bravo-Estupiñan DM, Méndez-Guerrero O, Alarcón-Hernández E, Ibáñez-Hernández M: Strategies for targeting gene therapy in cancer cells with tumor-specific promoters. Front Oncol 2020, 10: 605380. Pourjafar M, Samadi P, Saidijam M: MUC1 antibody-based therapeutics: The promise of cancer immunotherapy. Immunotherapy 2020, 12: 1269-1286. Guo M, You C, Dou J: Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates. Biomed Pharmacother 2018, 107: 1318-1325. Farokhimanesh S, Rahbarizadeh F, Rasaee MJ, Kamali A, Mashkani B: Hybrid promoters directed tBid gene expression to breast cancer cells by transcriptional targeting. Biotechnol Prog 2010, 26: 505-511. Casper J, Schenk SH, Parhizkar E, Detampel P, Dehshahri A, Huwyler J: Polyethylenimine (PEI) in gene therapy: Current status and clinical applications. Journal of Controlled Release 2023, 362: 667-691. Linsha Mali A, Priya S, Rekha M: Hydrophobic and hydrophilic modifications of polyethylenimine towards gene delivery applications. J Appl Polym Sci 2021, 138: 51323. Kobayashi Y, Nirasawa K, Negishi Y, Asayama S: Noncorrelative relation between in vitro and in vivo for plasmid DNA transfection by succinylated polyethylenimine muscular injection. J Biomater Sci Polym Ed 2021, 32: 405-416. Zintchenko A, Philipp A, Dehshahri A, Wagner E: Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity. Bioconjugate chemistry 2008, 19: 1448-1455. He S, Liu S: Zwitterionic materials for nucleic acid delivery and therapeutic applications. Journal of Controlled Release 2024, 365: 919-935. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015, 43: e47-e47. Robinson MD, McCarthy DJ, Smyth GK: edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010, 26: 139-140. Kassambara A, Kosinski M, Biecek P, Fabian S: Package ‘survminer’. Drawing Survival Curves using ‘ggplot2’(R package version 03 1) 2017, 3 . Therneau TM, Lumley T: Package ‘survival’. R Top Doc 2015, 128: 28-33. Wickham H, Chang W, Wickham MH: Package ‘ggplot2’. Create elegant data visualisations using the grammar of graphics Version 2016, 2: 1-189. Hänzelmann S, Castelo R, Guinney J: GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 2013, 14: 1-15. Yang L, Wang C, Shu J, Feng H, He Y, Chen J, Shu J: Porcine epidemic diarrhea virus induces vero cell apoptosis via the p53-PUMA signaling pathway. Viruses 2021, 13: 1218. Warriner LW, Duke III JR, Pack DW, DeRouchey JE: Succinylated polyethylenimine derivatives greatly enhance polyplex serum stability and gene delivery in vitro. Biomacromolecules 2018, 19: 4348-4357. Yang S, Wang Z, Ping Y, Miao Y, Xiao Y, Qu L, Zhang L, Hu Y, Wang J: PEG/PEI-functionalized single-walled carbon nanotubes as delivery carriers for doxorubicin: synthesis, characterization, and in vitro evaluation. Beilstein Journal of Nanotechnology 2020, 11: 1728-1741. Han X-M, Zheng K-W, Wang R-L, Yue S-F, Chen J, Zhao Z-W, Song F, Su Y, Ma Q: Functionalization and optimization-strategy of graphene oxide-based nanomaterials for gene and drug delivery. American Journal of Translational Research 2020, 12: 1515. Liu L, Yang Z, Liu C, Wang M, Chen X: Preparation of PEI‐modified nanoparticles by dopamine self‐polymerization for efficient DNA delivery. Biotechnology and Applied Biochemistry 2023, 70: 824-834. Sheikhsaran F, Sadeghpour H, Khalvati B, Entezar-Almahdi E, Dehshahri A: Tetraiodothyroacetic acid-conjugated polyethylenimine for integrin receptor mediated delivery of the plasmid encoding IL-12 gene. Colloids Surf B Biointerfaces 2017, 150: 426-436. Cao M, Gao Y, Qiu N, Shen Y, Shen P: Folic acid directly modified low molecular weight of polyethyleneimine for targeted pDNA delivery. J Drug Deliv Sci Technol 2020, 56: 101522. Nouri F, Sadeghpour H, Heidari R, Dehshahri A: Preparation, characterization, and transfection efficiency of low molecular weight polyethylenimine-based nanoparticles for delivery of the plasmid encoding CD200 gene. International journal of nanomedicine 2017 : 5557-5569. Cheraghi R, Alipour M, Nazari M, Hosseinkhani S: Optimization of conditions for gene delivery system based on PEI. Nanomedicine Journal 2017, 4 . Von Gersdorff K, Sanders NN, Vandenbroucke R, De Smedt SC, Wagner E, Ogris M: The internalization route resulting in successful gene expression depends on both cell line and polyethylenimine polyplex type. Mol Ther 2006, 14: 745-753. Ogris M, Steinlein P, Kursa M, Mechtler K, Kircheis R, Wagner E: The size of DNA/transferrin-PEI complexes is an important factor for gene expression in cultured cells. Gene Ther 1998, 5: 1425-1433. Rajendran AP, Morales LC, Meenakshi Sundaram DN, Kucharski C, Uludağ H: Tuning the Potency of Farnesol-Modified Polyethylenimine with Polyanionic Trans-Booster to Enhance DNA Delivery. ACS Biomaterials Science & Engineering 2024. Winkeljann B, Keul DC, Merkel OM: Engineering poly-and micelleplexes for nucleic acid delivery–A reflection on their endosomal escape. Journal of Controlled Release 2023, 353: 518-534. Stefani S, Sharma SK, Haag R, Servin P: Core-shell nanocarriers based on PEGylated hydrophobic hyperbranched polyesters. European Polymer Journal 2016, 80: 158-168. Zaaeri F, Khoobi M, Rouini M, Akbari Javar H: pH-responsive polymer in a core–shell magnetic structure as an efficient carrier for delivery of doxorubicin to tumor cells. International Journal of Polymeric Materials and Polymeric Biomaterials 2018, 67: 967-977. Shailubhai K, Palejwala V, Arjunan KP, Saykhedkar S, Nefsky B, Foss JA, Comiskey S, Jacob GS, Plevy SE: Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. World J Gastrointest Pharmacol Ther 2015, 6: 213. Entezari AA, Snook AE, Waldman SA: Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential. Expert Opin Ther Targets 2021, 25: 335-346. Zhang L, Shay JW: Multiple roles of APC and its therapeutic implications in colorectal cancer. JNCI: Journal of the National Cancer Institute 2017, 109: djw332. Clément G, Bosman FT, Fontolliet C, Benhattar J: Monoallelic methylation of the APC promoter is altered in normal gastric mucosa associated with neoplastic lesions. Cancer Res 2004, 64: 6867-6873. Pitari G, Zingman L, Hodgson D, Alekseev A, Kazerounian S, Bienengraeber M, Hajnoczky G, Terzic A, Waldman S: Bacterial enterotoxins are associated with resistance to colon cancer. Proceedings of the National Academy of Sciences 2003, 100: 2695-2699. Samadi P, Soleimani M, Nouri F, Rahbarizadeh F, Najafi R, Jalali A: An integrative transcriptome analysis reveals potential predictive, prognostic biomarkers and therapeutic targets in colorectal cancer. BMC Cancer 2022, 22: 1-22. Szaryńska M, Olejniczak A, Kobiela J, Łaski D, Śledziński Z, Kmieć Z: Cancer stem cells as targets for DC-based immunotherapy of colorectal cancer. Sci Rep 2018, 8: 12042. Yeung TM, Gandhi SC, Wilding JL, Muschel R, Bodmer WF: Cancer stem cells from colorectal cancer-derived cell lines. Proceedings of the National Academy of Sciences 2010, 107: 3722-3727. Zhang Y, Guo S, Huang H, Mao G, Ji X, He Z: Silicon nanodot-based aptasensor for fluorescence turn-on detection of mucin 1 and targeted cancer cell imaging. Anal Chim Acta 2018, 1035: 154-160. Minassian LM, Cotechini T, Huitema E, Graham CH: Hypoxia-induced resistance to chemotherapy in cancer. Hypoxia and Cancer Metastasis 2019 : 123-139. Peters MC, Maas RG, van Adrichem I, Doevendans PA, Mercola M, Šarić T, Buikema JW, van Mil A, Chamuleau SA, Sluijter JP: Metabolic maturation increases susceptibility to hypoxia-induced damage in human iPSC-derived cardiomyocytes. Stem Cells Translational Medicine 2022, 11: 1040-1051. Rajabi A, Nejati M, Homayoonfal M, Arj A, Razavi ZS, Ostadian A, Mohammadzadeh B, Vosough M, Karimi M, Rahimian N: Doxorubicin-loaded zymosan nanoparticles: Synergistic cytotoxicity and modulation of apoptosis and Wnt/β-catenin signaling pathway in C26 colorectal cancer cells. Int J Biol Macromol 2024, 260: 128949. Fatemi M, Meshkini A, Matin MM: A dual catalytic functionalized hollow mesoporous silica-based nanocarrier coated with bacteria-derived exopolysaccharides for targeted delivery of irinotecan to colorectal cancer cells. Int J Biol Macromol 2024 : 129179. Gonzalez-Valdivieso J, Vallejo R, Rodriguez-Rojo S, Santos M, Schneider J, Arias FJ, Girotti A: CD44-targeted nanoparticles for co-delivery of docetaxel and an Akt inhibitor against colorectal cancer. Biomaterials Advances 2023, 154: 213595. Chen S, Lv L, Zhan Z, Wang X, You Z, Luo X, You H: Silencing of long noncoding RNA SRRM2‐AS exerts suppressive effects on angiogenesis in nasopharyngeal carcinoma via activating MYLK‐mediated cGMP‐PKG signaling pathway. J Cell Physiol 2020, 235: 7757-7768. Zhao C-B, Chen W-B, Wang W-Z, Gong F-X, Fan C-Q, Li Y, Lan T, Wang W-J, Yuan M-Z: Nitro-oleic acid ameliorates erectile dysfunction in a streptozotocin-induced rat model of diabetes by inhibiting oxidative stress and apoptosis and activating the NO/cGMP pathway. Asian Journal of Andrology 2024, 26: 57-66. Xu D, Liu A, Liu Q, Zhang H, Tian M, Bian Y, Zhang X, Ying M, Shen H: Cucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis. Biochem Pharmacol 2023, 217: 115810. Deng X, Wu Q, Li D, Liu Y: Erianin Exerts Antineoplastic Effects on Esophageal Squamous Cell Carcinoma Cells by Activating the cGMP-PKG Signaling Pathway. Nutrition and Cancer 2023 : 1-12. Basu N, Saha S, Khan I, Ramachandra SG, Visweswariah SS: Intestinal cell proliferation and senescence are regulated by receptor guanylyl cyclase C and p21. J Biol Chem 2014, 289: 581-593. Li P, Wuthrick E, Rappaport JA, Kraft C, Lin JE, Marszalowicz G, Snook AE, Zhan T, Hyslop TM, Waldman SA: GUCY2C signaling opposes the acute radiation-induced GI syndrome. Cancer Res 2017, 77: 5095-5106. Table Table 1. Characteristics of primers and oligomers used in amplification and RT-qPCR. Additional Declarations No competing interests reported. Supplementary Files SupplementaryMaterial.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4508842","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":322038682,"identity":"f4a1e237-d0f2-4a46-8feb-109fbd8f0a94","order_by":0,"name":"Pouria Samadi","email":"","orcid":"","institution":"Hamadan University of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Pouria","middleName":"","lastName":"Samadi","suffix":""},{"id":322038683,"identity":"11921c8c-00b5-438d-8b9c-e0c02ba50ef2","order_by":1,"name":"Fatemeh Rahbarizadeh","email":"","orcid":"","institution":"Tarbiat Modares University","correspondingAuthor":false,"prefix":"","firstName":"Fatemeh","middleName":"","lastName":"Rahbarizadeh","suffix":""},{"id":322038684,"identity":"5e88cbf3-7980-4de2-adb5-287f80e9cd14","order_by":2,"name":"Fatemeh Nouri","email":"","orcid":"","institution":"Hamadan University of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Fatemeh","middleName":"","lastName":"Nouri","suffix":""},{"id":322038685,"identity":"7d2d212c-8a5e-465d-9c70-6f322424dc16","order_by":3,"name":"Meysam Soleimani","email":"","orcid":"","institution":"Hamadan University of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Meysam","middleName":"","lastName":"Soleimani","suffix":""},{"id":322038686,"identity":"0590be75-cfee-4022-b824-2ae063684744","order_by":4,"name":"Rezvan Najafi","email":"","orcid":"","institution":"Hamadan University of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Rezvan","middleName":"","lastName":"Najafi","suffix":""},{"id":322038687,"identity":"7d88f2f7-60cd-45e8-ac6f-a5e06afc2f88","order_by":5,"name":"Akram Jalali","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABDElEQVRIiWNgGAWjYDACHjDJxsDHwNxw+EeFDZDD2HiAKC1sDIwNhxnOpIG0NBCjhQGshZmx7TCYg1cLf8/Zh59uMPDJs7EfbDxc2Hbebm37YaAtNTbRuLRInG03ls5hYDNs40lsODzj3O3kbWcSgVqOpeU24NJzno0BpIWxjQGokqfsdrLZASAD6C+cWuTPszH/Bmqxb+N/CNTCdi7Z7PxD/FoMzraxgWxJbJMAOoyn7YCd2Q0CthieOcZmnWPAltwm8bDh4IwzyQlmN4C2JODxi9yZNObbORXHbPv5kw9/+FBhZ292Pv3hgw81Nri9D3HeMTgzEawyAa9yMKiBs+wJKx4Fo2AUjIKRBgD3W2P/VI1+GAAAAABJRU5ErkJggg==","orcid":"","institution":"Hamadan University of Medical Sciences","correspondingAuthor":true,"prefix":"","firstName":"Akram","middleName":"","lastName":"Jalali","suffix":""}],"badges":[],"createdAt":"2024-05-31 12:10:54","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4508842/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4508842/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":59659736,"identity":"84481378-6598-428b-90a3-4fae108b6b60","added_by":"auto","created_at":"2024-07-04 11:35:54","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":3202471,"visible":true,"origin":"","legend":"\u003cp\u003eSignaling Mechanisms in the Intestine are Mediated by the activation of Guanylate Cyclase C (GC-C) by the Guanylin peptide hormone. \u003cstrong\u003eA)\u003c/strong\u003e In normal conditions the cascade begins with the secretion of guanylin hormone via enteroendocrine cells into the intestinal lumen in response to various stimuli, including luminal contents and physiological signals. The ligand binding involves endogenous ligands guanylin and uroguanylin, as well as bacterial heat-stable toxins (STs), activating GC-C. This activation induces a conformational change in GC-C, leading to the synthesis of cGMP from GTP. Subsequently, cGMP serves as a second messenger, activating cGMP-dependent protein kinase II (PKG-II). The pathway regulates various physiological processes, including ion transport (such as Ca2+, Na+, H+, Cl-, HCO3-, etc.), smooth muscle relaxation, neurotransmitter release modulation, and the maintenance of intestinal barrier function. Additionally, it plays a crucial role in fluid homeostasis, cell proliferation, and differentiation. The anti-inflammatory and immunomodulatory effects of GC-C signaling, its involvement in CRC tumorigenesis, and its influence on gut hormone secretion are highlighted. Furthermore, GC-C signaling may contribute to the modulation of gut microbiota composition and activity. The positive and negative regulations are displayed in green and red circles. \u003cstrong\u003eB)\u003c/strong\u003e A schematic representation illustrating the functioning mechanism of the guanylin-expressing nano-system. Initially, the nano-system, loaded with SPEI-9 and pMUC1-GUCA2A, enters the cell through endocytosis. Utilizing its proton sponge ability, it escapes from the endosome, undergoing an endosomal burst to release into the cytosol. The guanylin-expressing construct translocates into the nucleus, facilitating the translation of guanylin, which is subsequently secreted into the cell culture media. Ligand-mediated activation of GC-C initiates an increase in intracellular cGMP levels. This, in turn, triggers the activation of PKGII and p38 MAPK, leading to the phosphorylation of the Sp1 transcription factor. Sp1, in its activated state, upregulates the expression of p21, inducing cytostasis. The PKGII-mediated signaling pathway also counteracts pro-survival, pro-proliferative, pro-migratory, and anti-apoptotic phenotypes associated with the β-catenin/TCF and PTEN/Akt pathways.\u003c/p\u003e","description":"","filename":"Fig1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4508842/v1/be91ca09be6fa569f3eb1d77.jpg"},{"id":59660796,"identity":"ef0834d9-348c-4322-9f26-eccc7a2f67b1","added_by":"auto","created_at":"2024-07-04 11:51:54","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":5581166,"visible":true,"origin":"","legend":"\u003cp\u003eAssessment of GUCA2A gene expression across diverse sources. \u003cstrong\u003eA, B)\u003c/strong\u003e evaluation of single-cell sequencing data from various tissues highlights the predominant expression of GUCA2A in normal large intestine tissues. \u003cstrong\u003eC, D, F)\u003c/strong\u003e Single-cell sequencing data of various epithelial cells underscores substantial GUCA2A expression in enterocytes, BEST4\u003csup\u003e+\u003c/sup\u003e epithelial cells, stem/TA-like cells, and goblet cells under normal conditions, contrasting with a significant reduction in GUCA2A expression in CRC cells. \u003cstrong\u003eE)\u003c/strong\u003e Expression of MUC1 is notably extensive in goblet cells as mucin-producing cells, and stem/TA-like cells, and is distributed significantly across different CRC cells. \u003cstrong\u003eG, H) \u003c/strong\u003eGUCA2A expression levels are also depicted across CRC/normal tissues and 55 CRC cancer cell lines. \u003cstrong\u003eI)\u003c/strong\u003e Expression levels of MUC1 across 55 CRC cell lines.\u003c/p\u003e","description":"","filename":"Fig2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4508842/v1/fd2649ada09485c431189078.jpg"},{"id":59660302,"identity":"ad35869f-ad6b-488e-b74f-3dd64719b163","added_by":"auto","created_at":"2024-07-04 11:43:54","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":4941850,"visible":true,"origin":"","legend":"\u003cp\u003eIntegrative systems biology analysis of GUCA2A. \u003cstrong\u003eA)\u003c/strong\u003e Depiction of univariate Cox regression analysis for GUCA2A across various clinical endpoints in a forest plot. \u003cstrong\u003eB)\u003c/strong\u003e Kaplan-Meier plot illustrating the correlation between GUCA2A expression and overall survival. \u003cstrong\u003eC)\u003c/strong\u003e Illustration of the correlation between GUCA2A expression and infiltration of diverse immune cells using different algorithms. \u003cstrong\u003eD)\u003c/strong\u003e Mutational profile of GUCA2A observed across different cancer types. \u003cstrong\u003eE)\u003c/strong\u003e Identification of hot spot mutation sites in the TCGA cohort. \u003cstrong\u003eF)\u003c/strong\u003e Comprehensive view of all genetic alterations in GUCA2A. \u003cstrong\u003eG)\u003c/strong\u003e Aggregated methylation values (beta-value) across all samples in the TCGA COAD-READ project. \u003cstrong\u003eH)\u003c/strong\u003e Gene Set Variation Analysis (GSVA) depicting the functional implications of GUCA2A.\u003c/p\u003e","description":"","filename":"Fig3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4508842/v1/957879046f6bcd257b0d2365.jpg"},{"id":59659735,"identity":"ef83511b-fbd6-4109-9b74-c7771b74267d","added_by":"auto","created_at":"2024-07-04 11:35:54","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":3026141,"visible":true,"origin":"","legend":"\u003cp\u003eStructural and functional characterization of the SPEI-9 nanocarrier. \u003cstrong\u003eA)\u003c/strong\u003e Validation of successful conjugation of succinic anhydride to the PEI base nanocarrier through FT-IR. \u003cstrong\u003eB)\u003c/strong\u003e Confirmation of the conjugation using NMR. \u003cstrong\u003eC)\u003c/strong\u003eComparison of the buffering capacity between synthesized SPEI-9 and PEI. \u003cstrong\u003eD)\u003c/strong\u003e Evaluation of the loading efficiency of synthesized SPEI-9 and PEI. \u003cstrong\u003eE)\u003c/strong\u003e Assessment of vector protection against degradation by DNase I loaded in SPEI-9. \u003cstrong\u003eF)\u003c/strong\u003e Size and \u003cstrong\u003eG)\u003c/strong\u003e zeta potential analysis of the synthesized SPEI-9 and PEI. \u003cstrong\u003eH)\u003c/strong\u003e Hemolytic activity comparison between synthesized SPEI-9 and PEI. \u003cstrong\u003eI)\u003c/strong\u003e Examination of protein interaction ability for synthesized SPEI-9 and PEI. Assessment of cell cytotoxicity in \u003cstrong\u003eJ)\u003c/strong\u003e CRC HCT-116 and \u003cstrong\u003eK)\u003c/strong\u003e normal Vero cell lines for synthesized SPEI-9 and PEI.\u003c/p\u003e","description":"","filename":"Fig4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4508842/v1/af842dc9241c08d282fd9495.jpg"},{"id":59659738,"identity":"7be5c240-b4e0-4db7-983a-15e4ebeaa70e","added_by":"auto","created_at":"2024-07-04 11:35:55","extension":"jpg","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":1632277,"visible":true,"origin":"","legend":"\u003cp\u003eEvaluation of nanocarrier transfection efficiency and RT-qPCR measurements. Cellular uptake of the EGFP-producing vector in \u003cstrong\u003eA, B)\u003c/strong\u003e the HCT-116 cell line and \u003cstrong\u003eC, D) \u003c/strong\u003ethe Vero cell line using synthesized SPEI-9 and PEI, respectively, \u003cstrong\u003eE)\u003c/strong\u003ealong with their quantified chart. \u003cstrong\u003eF)\u003c/strong\u003e Analysis of GUCA2A differential expression in 10 CRC and adjacent normal tissues. \u003cstrong\u003eG)\u003c/strong\u003e Measurement of mRNA expression levels for GUCA2A after treatment with guanylin-expressing nano-systems. \u003cstrong\u003eH)\u003c/strong\u003e Assessment of mRNA expression levels in hypoxic conditions. Evaluation of mRNA expression levels for \u003cstrong\u003eI)\u003c/strong\u003e β-catenin (CTNNB1), \u003cstrong\u003eJ)\u003c/strong\u003ep21 (CDKN1A), \u003cstrong\u003eK)\u003c/strong\u003e BAX, \u003cstrong\u003eL)\u003c/strong\u003e BCL-2, \u003cstrong\u003eM)\u003c/strong\u003e Vimentin (VIM), \u003cstrong\u003eN)\u003c/strong\u003eN-cadherin (CDH2) after treatment with guanylin-expressing nano-systems. Heatmaps illustrating overall changes in downstream genes after treatment with guanylin-expressing nano-systems for GUCA2A in \u003cstrong\u003eO)\u003c/strong\u003e HCT-116 cell line and \u003cstrong\u003eP)\u003c/strong\u003eVero cell line.\u003c/p\u003e","description":"","filename":"Fig5.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4508842/v1/dc3ef22ad9b27c7e771a86ab.jpg"},{"id":59660305,"identity":"4a2e7701-ad55-4ab3-ba70-873b2fa01499","added_by":"auto","created_at":"2024-07-04 11:43:55","extension":"jpg","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":540585,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003eIn vitro\u003c/em\u003eassessment of apoptosis and cell cytotoxicity induced by the guanylin-expressing nano-system. \u003cstrong\u003eA)\u003c/strong\u003e Dot plot showing Annexin V/PI-stained cells treated with the pCMV-GUCA2A and HRE-pMUC1-GUCA2A vectors in HCT-116 and Vero cells. \u003cstrong\u003eB)\u003c/strong\u003e Quantification of apoptosis, \u003cstrong\u003eC)\u003c/strong\u003enecrosis, and \u003cstrong\u003eD)\u003c/strong\u003e overall cell death percentage in HCT-116 and Vero cells following treatment with the pCMV-GUCA2A and HRE-pMUC1-GUCA2A vectors. Cell cytotoxicity of pCMV-GUCA2A and HRE-pMUC1-GUCA2A vectors in HCT-116 and Vero cells revealed by \u003cstrong\u003eE)\u003c/strong\u003e live cells and \u003cstrong\u003eF)\u003c/strong\u003e dead cells.\u003c/p\u003e","description":"","filename":"Fig6.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4508842/v1/e546406821990716d39515ce.jpg"},{"id":59660304,"identity":"a13cbcb4-ecec-4f9a-9b3c-bc0a2941c3cc","added_by":"auto","created_at":"2024-07-04 11:43:55","extension":"jpg","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":2200447,"visible":true,"origin":"","legend":"\u003cp\u003eAssessment of the impact of the guanylin-expressing nano-system on cellular migration and colony-forming ability. The potential of pCMV-GUCA2A and HRE-pMUC1-GUCA2A vectors to inhibit the migration ability of \u003cstrong\u003eA, C)\u003c/strong\u003e HCT-116 and \u003cstrong\u003eB, D)\u003c/strong\u003eVero cells. The influence of pCMV-GUCA2A and HRE-pMUC1-GUCA2A vectors on the colony formation capability of \u003cstrong\u003eE, G)\u003c/strong\u003e HCT-116 and \u003cstrong\u003eF, G)\u003c/strong\u003e Vero cells.\u003c/p\u003e","description":"","filename":"Fig7.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4508842/v1/1dbba96ccb1915d9781cd25d.jpg"},{"id":60588354,"identity":"4ca93792-90e5-4506-bece-9f4ac2f795f6","added_by":"auto","created_at":"2024-07-18 14:00:37","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":24467451,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4508842/v1/2b7806a5-3c1b-4ce2-9fa9-6264c41ccacb.pdf"},{"id":59659739,"identity":"0c08901e-f3ec-4cfe-9a18-fe361c67808c","added_by":"auto","created_at":"2024-07-04 11:35:55","extension":"docx","order_by":9,"title":"","display":"","copyAsset":false,"role":"supplement","size":840641,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryMaterial.docx","url":"https://assets-eu.researchsquare.com/files/rs-4508842/v1/30afb8838cee787065620150.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"Targeted Gene-Hormone Therapy of Colorectal Cancer with Guanylin Expressing Nano-system: In Silico and In Vitro Study","fulltext":[{"header":"Introduction","content":"\u003cp\u003eIn the past decades, with increasing concerns regarding the side effects and low effectiveness of conventional treatments, researchers sought to develop new approaches to fight cancer more effectively [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Hence, with the rapid surge in the utilization of (multi-)omics technology and computational modeling in biological systems over the past decade, in silico analyses have played a pivotal role in the identification of novel therapeutic targets and potential drug candidates for human diseases, specifically cancers [\u003cspan additionalcitationids=\"CR3 CR4\" citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe most prevalent occurrence in colorectal cancer (CRC), ~\u0026thinsp;70\u0026ndash;80%, involves the inactivation of the tumor suppressor gene adenomatous polyposis coli (\u003cem\u003eAPC\u003c/em\u003e). This often co-occurs with the activation of oncogenic \u003cem\u003eKRAS\u003c/em\u003e (40\u0026ndash;50%), and the presence of mutations in other tumor suppressor genes, such as \u003cem\u003ePTEN\u003c/em\u003e or \u003cem\u003eTP53\u003c/em\u003e, or oncogenes like \u003cem\u003ePIK3CA\u003c/em\u003e, is also frequently observed [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e \u003cp\u003ePrevious research has shown that \u003cem\u003eGUCA2A\u003c/em\u003e (encoding endogenous peptide hormone guanylin), experiences loss after \u003cem\u003eAPC\u003c/em\u003e inactivation in mouse models featuring conditional biallelic Apc deletion (Apc\u003csup\u003eCKO/CKO\u003c/sup\u003e) and Apc loss of heterozygosity (Apc\u003csup\u003emin/+\u003c/sup\u003e) [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. Given that guanylin is a peptide stimulant for \u003cem\u003eGUCY2C\u003c/em\u003e, encoding a member of the family of transmembrane receptor guanylyl cyclases, it fosters cGMP accumulation, which in turn, facilitates electrolyte and fluid secretion within the large intestine as well as many other important roles summarized in \u003cb\u003eFig.\u0026nbsp;1A\u003c/b\u003e [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. Beyond this, \u003cem\u003eGUCY2C\u003c/em\u003e regulates essential homeostatic processes that are often dysregulated during tumorigenesis, including cellular functions like metabolism, proliferation, and differentiation programs [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Silencing \u003cem\u003eGUCY2C\u003c/em\u003e is a universal characteristic of colorectal tumorigenesis which contributes to the promotion of crypt hyperplasia, acceleration of the cell cycle, induction of DNA damage, and higher susceptibility to tumor development [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. The majority of tumor subtypes maintain the presence of cell-surface \u003cem\u003eGUCY2C\u003c/em\u003e expression as they progress through different stages of the disease [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. However, transformation universally orphans the receptor due to the depletion of endogenous hormones [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. These observations suggest reactivating endogenous hormone generation via gene therapy approaches, which may be a novel therapeutic strategy for CRC [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eGene therapy involves treating a genetic disease by introducing specific genetic material that alters cell function into a patient. The crucial aspect of gene therapy lies in the effective delivery of genes to the targeted tissues or cells, a process facilitated by specialized carriers known as vectors. An avenue that holds promise for elevating cancer gene therapy to a potent strategy is the implementation of precision-targeted gene expression facilitated by tissue-specific or tumor-specific promoters [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. The conventional promoters like hTERT, Survivin, uPAR, COX-2, and more recently, \u003cem\u003eMUC1\u003c/em\u003e, exhibit notably higher expression levels in a spectrum of cancer types (specifically gastrointestinal (GI) cancers), compared to normal tissues [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. Due to its specificity, the \u003cem\u003eMUC1\u003c/em\u003e promoter, which demonstrates expression over 90% within CRC cells, presents itself as a potent substitute for the conventional promoters employed in the context of gene therapy for CRC [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. Further, the utilization of specific enhancers tailored to tumor-specific physiological conditions, notably hypoxia, through the incorporation of the hypoxia-sensitive element (HRE) upstream of the \u003cem\u003eMUC1\u003c/em\u003e promoter serves to augment gene expression within cancer cells, particularly under hypoxic conditions [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e].\u003c/p\u003e \u003cp\u003ePolyethylenimine (PEI) and similar polycations have emerged as promising nonviral gene carriers, leveraging their capacity to establish stable complexes via electrostatic interactions with nucleic acids. This polyplex formation not only fortifies plasmid-based gene delivery but also shields against enzyme-mediated digestion, thereby facilitating enhanced intracellular delivery [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. While PEI has demonstrated efficacy as a gene carrier, its application at higher doses has raised concerns due to its inherent toxicity. This toxicity primarily stems from the potent positive charge of PEI, fostering intense interactions with cell surfaces that can result in cellular damage. Recognizing this challenge, there is a growing interest in exploring modifications to the polymeric backbone of PEI aimed at mitigating its positive charge and, consequently, diminishing its toxicity. These modifications hold promise in enhancing the safety profile of PEI, ensuring its utility as a gene carrier while minimizing the potential adverse effects associated with its application at elevated concentrations [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eSuccinylated PEI refer to PEI molecules that have undergone a chemical modification involving the addition of succinyl groups. The modification involves attaching succinyl (a dicarboxylic acid) moieties to the polymeric backbone of PEI. The succinylation of PEI serves several purposes. One notable effect is the reduction of the overall positive charge of the PEI molecule. PEI is known for its strong positive charge, which can lead to interactions with cell surfaces and potential cytotoxicity. By succinylating PEI, the charge density decreases, making the modified PEI less positively charged. Succinylated PEIs are often explored in the field of gene delivery. The modification aims to maintain the desirable properties of PEI as a gene carrier, such as its ability to form stable complexes with nucleic acids, while mitigating its potential toxicity. The resulting succinylated PEIs may exhibit improved biocompatibility, reduced cytotoxicity, and enhanced efficiency in delivering genetic material to target cells, making them attractive candidates for gene therapy applications [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. SPEI-9 as a succinylated derivative of PEI with low succinylation degree (about 9% based on polymer weight), lower charge density, much lower cytotoxicity reduction, and higher gene transfer efficiency compared to unmodified PEI is an optimal and potential gene delivery vector for gene therapy agents [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn this study, we first analyze the transcriptomics data of CRC as well as pan-cancer with the gene expression data from human tissues, tumors, and single-cell types. Secondly, we devised a gene therapy construct aimed at reinstating endogenous guanylin hormone expression, with \u003cem\u003eMUC1\u003c/em\u003e serving as the tumor-specific promoter and CMV as the universal promoter for precise CRC therapy. Thirdly, we synthesized and characterized SPEI-9 as a robust carrier to facilitate the delivery of these gene therapy constructs. We finally conducted down-stream investigations to evaluate the anti-tumor effects of this innovative and potent gene therapy-based nanosystem in both cancer and normal cell lines. A schematic diagram of the mechanisms underlying the treatment with the developed guanylin expressing nano-system is displayed in \u003cb\u003eFig.\u0026nbsp;1B\u003c/b\u003e.\u003c/p\u003e"},{"header":"Materials and methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eExploration of GUCA2A gene expression patterns\u003c/h2\u003e \u003cp\u003eWe utilized the resources of Tabula Muris (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://tabula-muris.ds.czbiohub.org\u003c/span\u003e\u003cspan address=\"https://tabula-muris.ds.czbiohub.org\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e) and single cell (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://singlecell.broadinstitute.org\u003c/span\u003e\u003cspan address=\"https://singlecell.broadinstitute.org\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e) databases to gain insights into the broad spectrum of \u003cem\u003eGUCA2A\u003c/em\u003e and \u003cem\u003eMUC1\u003c/em\u003e gene expression levels across diverse tissues in the human body, as well as within distinct epithelial cells of CRC and their adjacent normal counterparts. Additionally, we conducted a differential analysis to investigate alterations in \u003cem\u003eGUCA2A\u003c/em\u003e gene expression across microarray and The Cancer Genome Atlas (TCGA) datasets. These expression data, derived from the extensive Cancer Cell Line Encyclopedia (CCLE) project (GSE36133) (n\u0026thinsp;=\u0026thinsp;55 CRC cell lines), and a clinically homogenous dataset of CRC tumor and normal tissues, TCGA COAD-READ (normal\u0026thinsp;=\u0026thinsp;51 cases, CRC\u0026thinsp;=\u0026thinsp;644 cases), which were analyzed using LIMMA and edgeR packages in R [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e, \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eAssessing GUCA2A expression as a prognostic indicator in CRC\u003c/h2\u003e \u003cp\u003eTo assess the prognostic significance of \u003cem\u003eGUCA2A\u003c/em\u003e expression on patient outcomes, we conducted univariate Cox regression analyses. Our investigation involved different CRC datasets from multiple microarray studies and TCGA. This comprehensive approach allowed us to make predictions concerning different clinical endpoints including Cancer-Specific Survival (CSS), Disease-Free Interval (DFI), Disease-Free Survival (DFS), Disease-Free Metastasis Survival (DFMS), Disease-Specific Survival (DSS), Overall Survival (OS), Progression-Free Interval (PFI), Progression-Free Survival (PFS), and Relapse-Free Survival (RFS). across diverse CRC datasets. Additionally, we conducted a Kaplan-Meier survival analysis to explore the association between \u003cem\u003eGUCA2A\u003c/em\u003e expression levels and OS. The log-rank test was utilized to assess the prognostic significance of GUCA2A in the TCGA COAD-READ dataset. These analyses were performed using the R packages survival, survminer, and ggplot2 [\u003cspan additionalcitationids=\"CR31\" citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eRelationship between GUCA2A expression and immunity\u003c/h2\u003e \u003cp\u003eWe also investigate the potential link between the association of \u003cem\u003eGUCA2A\u003c/em\u003e expression and the tumor microenvironment (TME) in pan-cancer. To achieve this, we assessed various parameters, including stromal score, ESTIMATE score, immune score, tumor purity, and immune-related pathways. Multiple algorithms, such as XCELL, QUANTISEQ, CIBERSORT-ABS, EPIC, and TIMER, were employed for this analysis. To visualize the results, we utilized the ggplot2 R package. The generated heat maps provided insights into the relationships between GUCA2A expression, the above metrics, and immune infiltrating cells across different cancers.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eMutation and methylation profile analysis\u003c/h2\u003e \u003cp\u003eTo comprehensively investigate the mutational landscape of \u003cem\u003eGUCA2A\u003c/em\u003e across various cancer types, we utilized the capabilities of the cBioPortal tool (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.cbioportal.org/\u003c/span\u003e\u003cspan address=\"http://www.cbioportal.org/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e). Focusing our efforts on the \"TCGA Pan-Cancer Atlas Studies\" cohort, we conducted an extensive investigation. This analysis encompassed the assessment of specific mutation sites, genetic alteration frequencies, and mutation types influencing \u003cem\u003eGUCA2A\u003c/em\u003e. Furthermore, we utilized methylation data obtained from the SMART App (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.bioinfo-zs.com/smartapp\u003c/span\u003e\u003cspan address=\"http://www.bioinfo-zs.com/smartapp\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e) to investigate the relationship between \u003cem\u003eGUCA2A\u003c/em\u003e expression and methylation patterns within the TCGA COAD-READ dataset. Box plot visualizations were generated using the ggplot2 package in R.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eGSVA Analyses\u003c/h2\u003e \u003cp\u003eWe employed the R package \"GSVA\" to conduct Gene Set Variation Analysis (GSVA) [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e], aiming to identify pathways most closely associated with \u003cem\u003eGUCA2A\u003c/em\u003e expression. Pathways that were consistently enriched through GSVA analysis were regarded as potential pathways linked to \u003cem\u003eGUCA2A\u003c/em\u003e expression.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eAmplification of GUCA2A coding sequence\u003c/h2\u003e \u003cp\u003eThe primer for the amplification of the \u003cem\u003eGUCA2A\u003c/em\u003e coding sequence (CDS) was designed using the primer3plus online tool, and then it was analyzed with the primer blast, Multiple Primer Analyzer, and IDT OligoAnalyzer Tool to check the optimality of various parameters. The Kozak sequence was placed at the beginning of the Forward (F) primer to initiate translation. Also, the cut site of \u003cem\u003eBamHI\u003c/em\u003e enzyme was placed at the 5\u0026rsquo; end of the primer before the Kozak sequence and the \u003cem\u003eXbaI\u003c/em\u003e enzyme cut site was placed at the 5\u0026rsquo; end of the Reverse (R) primer \u003cb\u003e(Table. 1)\u003c/b\u003e. Following the successful PCR amplification of the \u003cem\u003eGUCA2A\u003c/em\u003e CDS from CRC normal tissue-derived cDNA, the resulting fragment was subjected to purification using the AccuPrep\u0026reg; PCR/Gel Purification Kit (Bioneer, Korea) following the manufacturer's protocol. Subsequently, enzymatic digestion utilizing \u003cem\u003eBamHI\u003c/em\u003e and \u003cem\u003eXbaI\u003c/em\u003e restriction enzymes was employed to process the digested fragment, facilitating the removal of undesired cleavage sites through additional gel extraction steps.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003eConstruction of the guanylin expressing vectors\u003c/h2\u003e \u003cp\u003eIn this investigation, the mammalian expression vector, pCDNA 3.1/Hygro(+) (Invitrogen) was selected as the basic genetic construct. Specifically, the MUC1 gene promoter and cassettes containing the hypoxia response element (HRE), were amplified and cloned into the pcDNA3.1/Hygro (+) basic vector to replace the CMV promoter, yielding the HRE-pMUC1-Insert construct, which was generously provided by Dr. Rahbarizadeh's lab. The HRE-pMUC1-mRNA, alongside the default pCMV-mRNA vector, were both prepared with \u003cem\u003eBamHI\u003c/em\u003e/\u003cem\u003eXbaI\u003c/em\u003e flanking cutting sites for subsequent subcloning procedures. To propagate these vectors, GM2163 bacteria (Dam\u003csup\u003e\u0026minus;\u003c/sup\u003e Dcm\u003csup\u003e\u0026minus;\u003c/sup\u003e), a derivative of E. coli strain K12, were employed, as the \u003cem\u003eXbaI\u003c/em\u003e cut site is hindered by dam methylation. Following bacterial transformation, the vectors were extracted using The GeneJET Plasmid Miniprep kit. Following enzymatic digestion with \u003cem\u003eBamHI\u003c/em\u003e and XbaI, a further gel extraction step was performed to prepare vectors for downstream procedures. The digested vectors and \u003cem\u003eGUCA2A\u003c/em\u003e CDS fragment were subsequently ligated together. After successful transformation, colony selection was carried out via colony PCR, followed by validation through Sanger sequencing. The resulting vectors, named HRE-pMUC1-GUCA2A and pCMV-GUCA2A, were then prepared for subsequent cell culture analyses.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eSynthesis and structural characterization of SPEI-9\u003c/h2\u003e \u003cp\u003ePEI (0.5 grams) was dissolved in 8.5 mL of water and 1.5 mL of a NaCl solution (3 M). The pH of the solution was then adjusted to 5 using 1 M HCl. Precise quantities of succinic anhydride (0.1 M, for 9% modification) were dissolved in dimethyl sulfoxide (DMSO) and carefully added dropwise to the PEI solution. The reaction was conducted at room temperature for a duration of 3 h. To purify the crude products, a dialysis process was performed using a 10,000\u0026ndash;12,000 molecular weight cutoff membrane. Initially, dialysis was carried out against a 0.25 M NaCl solution to eliminate any unreacted succinate. Subsequently, the solution was dialyzed twice against water at a temperature of 4\u0026deg;C to remove residual salt. Following the dialysis process, the aqueous solution was subjected to lyophilization. A schematic diagram of the reaction of succinic anhydride and basic PEI to make SPEI-9 is displayed in \u003cb\u003eFig.\u0026nbsp;4E\u003c/b\u003e. For the downstream tests (except structural analysis), we prepared the polymers in different concentrations with HBG buffer (20 mM HEPES in 5% glucose solution, pH 7.2) to obtain different C/P ratios.\u003c/p\u003e \u003cp\u003eThe degree of modification was assessed using 1H nuclear magnetic resonance (NMR) spectroscopy (Varian INOVA 500MHz, Palo Alto, USA) in deuterium oxide (D2O). The presence of carboxylic acid changes on the surface of SPEI-9 was also confirmed using Fourier Transform Infrared (FT-IR) (Agilent-USA-Cary 680). The spectra were analyzed using Origin software (version 9.85).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eThe buffering capacity of PEI and SPEI-9 nanocarriers\u003c/h2\u003e \u003cp\u003ePEI-based nanocarriers exhibit robust pH resistance within a broad range (pH 2 to 10). This resistance eventually leads to an increase in the osmotic pressure, its bursting, and the release of the polyplex into the cytosol due to the proton sponge effect. To assess the buffering capacity of both PEI and SPEI-9, a 2 mg/mL solution of the nanocarriers was initially dissolved in deionized water, and its pH was measured. Subsequently, the solution's pH was adjusted to 12 using 1N NaOH and then titrated incrementally with 5 \u0026micro;l of 1N HCl until the pH dropped below 2.5. Throughout this process, a pH curve was generated based on the added acid. The experiment included deionized water as a negative control and PEI as a positive control.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003ePreparation and loading efficiency of PEI and SPEI-9 polyplexes\u003c/h2\u003e \u003cp\u003ePEI/DNA and SPEI-9/DNA polyplexes were prepared by adding 50 \u0026micro;l of the polymer solution in different concentrations to 50 \u0026micro;l of the gene construct with the same concentration (at a concentration of 40 \u0026micro;g/ml in HBG buffer). After gently pipetting the mixture (10\u0026ndash;20 times), it was allowed to incubate for 20\u0026ndash;30 min at room temperature to form stable complexes. To assess the binding affinity of PEI and SPEI-9 polymers with genetic constructs, a gel retardation assay was employed. Polyplexes were prepared at various C/P ratios ranging from 0.25 to 8. Gel electrophoresis was subsequently conducted, and the results were analyzed using a Gel-Doc device.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eDNase degradation assay\u003c/h2\u003e \u003cp\u003eTo assess the protective ability of PEI and SPEI-9 against enzymatic degradation of loaded DNA by serum nucleases, a DNase protection test was conducted. Polyplexes were prepared at various C/P ratios (ranging from 0.25 to 8) and exposed to 1 \u0026micro;l of DNase I enzyme (1 U/\u0026micro;l) in PBS or DNase/Mg2\u0026thinsp;+\u0026thinsp;reaction buffer for 30 min at 37\u0026deg;C. Then, 4 \u0026micro;l of 50 mM EDTA was added to deactivate the enzyme by removing the Mg2\u0026thinsp;+\u0026thinsp;ions present in the enzyme buffer. All microtubes were then incubated for 10 min at 65\u0026deg;C to inactivate the enzyme. Subsequently, 10 \u0026micro;l of 1 mg/ml heparin was added to facilitate the separation of the DNA from the nanocarrier. The microtubes were further incubated for 2 h at room temperature. Finally, the samples were subjected to electrophoresis in a 1% agarose gel.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003eMeasurements of the size and zeta potential of the polyplexes\u003c/h2\u003e \u003cp\u003eThe average hydrodynamic particle size and surface charge density of polyplexes were measured by Dynamic Light Scattering and Laser Doppler Velocimetry by Malvern Nano Zetasizer (Malvern, UK) and results were reported as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SEM.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eHemolysis test of polyplexes\u003c/h2\u003e \u003cp\u003eThe hemolysis assay was conducted using human blood to assess the blood compatibility of the synthesized polymers. Arterial blood was collected, and red blood cells (RBC) were isolated through centrifugation (3000 rpm for 10 min) and washing with PBS. Washed RBCs were then exposed to polyplexes (using 100 \u0026micro;l of washed RBC) with various C/P ratios, with deionized water and PBS serving as positive and negative controls, respectively. The samples were incubated at 37\u0026deg;C for 2 h, followed by centrifugation (13,000 rpm for 10 min), and the absorbance of the supernatant (A) was measured at 540 nm. The percentage of hemolysis was calculated as follows.\u003c/p\u003e \u003cp\u003e \u003cspan class=\"InlineEquation\"\u003e \u003cspan class=\"mathinline\"\u003e\\(Hemolysis \\left(\\text{%}\\right)=\\frac{\\text{A} \\text{s}\\text{a}\\text{m}\\text{p}\\text{l}\\text{e} - \\text{A} \\text{n}\\text{e}\\text{g}\\text{a}\\text{t}\\text{i}\\text{v}\\text{e}}{\\text{A} \\text{p}\\text{o}\\text{s}\\text{i}\\text{t}\\text{i}\\text{v}\\text{e} - \\text{A} \\text{n}\\text{e}\\text{g}\\text{a}\\text{t}\\text{i}\\text{v}\\text{e}}\\)\u003c/span\u003e \u003c/span\u003e\u0026times; 100\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003eProtein Interaction\u003c/h2\u003e \u003cp\u003eTo evaluate nonspecific protein binding interactions, 0.5 mL of bovine serum albumin (BSA) standard solution (2 mg/ml) was mixed with 0.5 ml of each polyplex solution (using 1 mg/ml of polymers). These mixtures were incubated at 37\u0026deg;C for 1 h, followed by centrifugation to collect supernatant samples. The protein concentrations in these samples were quantified using a BCA assay with a BSA calibration curve. The parameter A, representing protein interaction, was defined as:\u003cdiv id=\"Equa\" class=\"Equation\"\u003e\u003cdiv format=\"TEX\" class=\"mathdisplay\" id=\"FileID_Equa\" name=\"EquationSource\"\u003e\n$$A=1- \\frac{\\text{C}\\text{s}\\text{V}\\text{s}}{\\text{C}\\text{i}\\text{V}\\text{i}}$$\u003c/div\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003eHere, Ci represents the initial BSA concentration (2 mg/ml), Cs is the BSA concentration in the supernatant determined by the BCA assay, Vi is the initial volume of the BSA solution (0.5 ml), and Vs is the total volume of the BSA solution after the adsorption measurement (1 ml). The interaction value A quantifies the extent to which protein has been removed from the initial solution through interaction with the polymer. It ranges from 0 (indicating no removal of protein) to 1 (representing complete removal of protein).\u003c/p\u003e \u003cp\u003e \u003cb\u003eEvaluation of the gene-hormone therapy nano-system\u003c/b\u003e \u003cb\u003ein vitro\u003c/b\u003e\u003c/p\u003e \u003cp\u003eAfter designing, constructing, and validating the therapeutic vectors, pCMV-GUCA2A and HRE-ERE-pMUC-GUCA2A, as well as SPEI-9 (C/P 4) as a potent gene delivery nano-system, we evaluate the therapeutic nano-system through different \u003cem\u003ein vitro\u003c/em\u003e assays on two cell lines of HCT-116 as CRC cell line and the Vero, as a normal African green monkey kidney cell line. Cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) medium (Bioidea, Iran) supplemented with 10% fetal bovine serum (FBS, Gibco, USA), 1% Penicillin/Streptomycin (Gibco, USA) and were maintained in an incubator at 37\u0026deg;C and 5% CO\u003csub\u003e2\u003c/sub\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003eCell culture and transfection of the nano-system\u003c/h2\u003e \u003cp\u003eOn the first day, the total number of 1 \u0026times; 10\u003csup\u003e5\u003c/sup\u003e HCT-116 and Vero cells were seeded in separate wells of 12-well plates. The following day, for cell transfection, a mixture of 50 \u0026micro;L PEI and SPEI-9 nanocarriers with a pEGFP-N1 gene construct (40 ng/\u0026micro;l stock) encoding enhanced green fluorescent protein (EGFP) was created. This mixture, along with 50 \u0026micro;L culture medium lacking FBS, was vortexed for 10 s. The combined media, a total of 200 \u0026micro;L, were thoroughly mixed and pipetted multiple times before being incubated for 30 min at room temperature to form respective polyplexes. Once polyplexes were established, a dropwise addition of complete medium to each well, containing 100 \u0026micro;L culture medium, took place, and the plates were placed in the incubator. After 6\u0026ndash;8 h, following the transfection of nanocarriers carrying genetic constructs into the cells, the supernatant medium was replaced with 1 ml of complete culture medium containing FBS. The plates were incubated at 24 h, 48 h, and 72 h. The efficiency of transfection was evaluated using a fluorescent microscope, determining the optimal time for subsequent treatments.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003eAssessment of mRNA expression levels for guanylin and downstream genes\u003c/h2\u003e \u003cp\u003eFollowing transfection of 3 \u0026times; 10\u003csup\u003e5\u003c/sup\u003e HCT-116 and Vero cells with different groups (pCMV-GUCA2A, HRE-pMUC1-GUCA2A, pEGFP-N1, and control) using SPEI-9 in a 6-well plate, we examined alterations in the expression of the \u003cem\u003eGUCA2A\u003c/em\u003e gene and its downstream targets, specifically β-catenin (\u003cem\u003eCTNNB1\u003c/em\u003e) and p21 (\u003cem\u003eCDKN1A\u003c/em\u003e), in addition to genes associated with apoptosis (\u003cem\u003eBAX\u003c/em\u003e and \u003cem\u003eBCL-2\u003c/em\u003e) and cell migration (\u003cem\u003eVIM\u003c/em\u003e and \u003cem\u003eCDH2\u003c/em\u003e) pathways. To do this, RNA was extracted from the transfection cells 72 h upon transfection utilizing the RNX-Plus kit (CinnaGen, Iran). Subsequently, the extracted RNA was reverse transcribed into complementary DNA (cDNA) using the RevertAid First Strand cDNA Synthesis kit (Thermo Fisher Scientific, USA). The primers used in quantitative reverse transcription PCR (RT-qPCR) of the \u003cem\u003eGUCA2A\u003c/em\u003e gene along with the primers used to evaluate the downstream pathways are given in \u003cb\u003eTable\u0026nbsp;1\u003c/b\u003e. For each group, RT-qPCR was conducted in duplicate using SYBR Green and a LightCycler 96 RT-qPCR detection system (Roche, USA) according to the manufacturer\u0026rsquo;s instructions. Further, changes in gene expression between tumor and adjacent healthy tissues were also evaluated utilizing CRC tissue samples (10 samples) along with their respective adjacent non-cancerous tissues (10 samples) from Iranian patients who visited the Poursina Hakim Research Institute in Esfahan, Iran, during 2021 to 2022. The RNA extraction to RT-qPCR step was performed as mentioned above. The study protocol was granted ethical approval by the Ethical Committee of the Hamadan University of Medical Science (ethical code: IR.UMSHA.REC.1399.562).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003eEvaluation of guanylin expression changes following hypoxia treatment\u003c/h2\u003e \u003cp\u003eAfter transfection with HRE-pMUC1-GUCA2A using SPEI-9, the HCT-116 cells were subjected to hypoxic conditions. This was achieved by filling the culture medium up to the top of the well and subsequently sealing it with parafilm. Following a 16 h incubation period post-transfection, alterations in \u003cem\u003eGUCA2A\u003c/em\u003e gene expression were assessed through RT-qPCR analysis.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec20\" class=\"Section2\"\u003e \u003ch2\u003eAnnexin V-PI flow cytometry\u003c/h2\u003e \u003cp\u003eTo assess apoptosis/necrosis induced by the gene therapy nano-system, the following procedure was followed on two CRC and normal cell lines: a total number of 3 \u0026times; 10\u003csup\u003e5\u003c/sup\u003e cells were initially cultured in individual 6-well plates and transfected the following day. After a 72 h incubation period, the cells were harvested using a combination of trypsinization and mechanical scraping (specifically for Vero cells due to their strong cell adhesion), and then centrifuged at 1500 g for 5 min. Following this, the cells were subjected to a PBS wash. To the cell pellet dissolved in binding buffer, a mixture containing 10 \u0026micro;l of propidium iodide (PI) dye and 5 \u0026micro;l of Annexin-V dye was added. The samples were then incubated in the dark at room temperature (25\u0026deg;C) for 10 min. The analysis of the cells was carried out using an Attune NxT Flow Cytometer (Thermo Fisher Scientific, USA) and then FlowJo software.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec21\" class=\"Section2\"\u003e \u003ch2\u003eCell toxicity experiments\u003c/h2\u003e \u003cp\u003eCell proliferation assays were conducted to assess the impact of PEI and SPEI-9 nanocarriers with different C/P ratios, along with various gene therapy groups, on both HCT-116 and Vero cells seeded in a 96-well plate with a confluency of 1 \u0026times; 10\u003csup\u003e4\u003c/sup\u003e cells. Initially, cells were cultured in 96-well plates until they reached the desired confluence (70\u0026ndash;80%). Subsequently, the cytotoxicity of PEI nanocarriers (at C/P ratios of 0.25 and 1) and SPEI-9 (at different C/P ratios of 0.25, 1, 4, and 8) was evaluated after a 72 h exposure (no removal of medium post-transfection), using the control pEGFP-N1 vector. Additionally, the cytotoxic effects of the gene therapy nano-systems were also investigated following 72 h transfection. To perform this evaluation, 10 \u0026micro;L of MTT solution (5 mg/ml in PBS) was added to each well-containing cell and incubated for an additional 4 h at 37\u0026deg;C. Following this incubation, the culture medium was carefully removed, and 150 \u0026micro;L of DMSO was added to each well to dissolve the purple formazan crystals. The absorbance was then measured at 490 nm using a microplate reader (Epoch BioTek, USA).\u003c/p\u003e \u003cp\u003e \u003cb\u003eIn vitro\u003c/b\u003e \u003cb\u003escratch assay\u003c/b\u003e\u003c/p\u003e \u003cp\u003eIn this research, we employed the scratch test (wound-healing assay) to evaluate the effect of gene therapy nano-system on the migration and metastatic ability of HCT-116 and Vero cells seeded in a 12-well plate with a confluency of 1 \u0026times; 10\u003csup\u003e5\u003c/sup\u003e cells. The procedure involved transfecting cells with various constructs and creating artificial scratches to assess cell viability. Microscopic imaging was conducted at specific time points (0, 24, and 48 h) to monitor the cells' capability to close the gap created by the scratch. Subsequently, we analyzed the gap area using Image J software to quantify and compare cell migration concerning the control group.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec22\" class=\"Section2\"\u003e \u003ch2\u003eColony formation assays\u003c/h2\u003e \u003cp\u003eTwo different cell lines were seeded into 6-well plates (with 500 cells/well for the HCT-116 cell line and 1000 cells/well for the Vero cell line). The transfection procedure involving gene constructs was initiated, and the plates were incubated for a minimum of 8 days until visible colonies were formed. Once adequate colony growth was achieved, the plates were subjected to staining with a crystal violet solution to stain the colonies (with at least 50 cells). Subsequently, the number of colonies was quantified and analyzed using Image J software.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec23\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eAll data are expressed as the mean with SD and the results are representatives of at least three independent experiments. Inferential statistical analyses were performed with an unpaired t-test, Wilcoxon signed-rank test, and one-way analysis of variance (ANOVA) (*P\u0026thinsp;\u0026lt;\u0026thinsp;0.05; **P\u0026thinsp;\u0026lt;\u0026thinsp;0.01; ***P\u0026thinsp;\u0026lt;\u0026thinsp;0.001; ****P\u0026thinsp;\u0026lt;\u0026thinsp;0.0001). SPSS 18.0 or GraphPad Prism 9 was used for analysis.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cp\u003e \u003cb\u003eExpression analysis reveals intestine-specific expression of\u003c/b\u003e \u003cb\u003eGUCA2A\u003c/b\u003e\u003c/p\u003e \u003cp\u003eWe investigated the tissue distribution of \u003cem\u003eGUCA2A\u003c/em\u003e expression utilizing the Tabula Muris and single-cell databases, repositories enriched with valuable single-cell RNA-seq data. The results unveiled an interesting pattern of \u003cem\u003eGUCA2A\u003c/em\u003e expression primarily within the large intestinal tissue \u003cb\u003e(Fig.\u0026nbsp;2A, 2B)\u003c/b\u003e. Notably, within the large intestine, \u003cem\u003eGUCA2A\u003c/em\u003e displayed marked variation in expression across distinct cell types. Notably, the highest expression was observed in enterocytes, BEST4\u0026thinsp;+\u0026thinsp;epithelial cells, and goblet cells \u003cb\u003e(Fig.\u0026nbsp;2C, 2D)\u003c/b\u003e, which play pivotal roles in processes such as water and ion absorption, nutrient uptake, and vitamin absorption. Conversely, the expression of the \u003cem\u003eGUCA2A\u003c/em\u003e gene within CRC tumor tissue cells was found to be notably low and, in many cells, entirely lost \u003cb\u003e(Fig.\u0026nbsp;2C, 2F)\u003c/b\u003e. Moreover, \u003cem\u003eMUC1\u003c/em\u003e expression showed elevation in goblet cells, immature goblet cells, and intestinal stem cells within normal cell populations as normally mucin is primarily localized to the apical cell membranes in these cell types. In contrast, \u003cem\u003eMUC1\u003c/em\u003e expression exhibited a more widespread and significant distribution across various tumor cells \u003cb\u003e(Fig.\u0026nbsp;2D, 2C)\u003c/b\u003e. Additionally, the expression analysis of \u003cem\u003eGUCA2A\u003c/em\u003e using TCGA COAD-READ datasets displayed significant down regulation in CRC tissues compared with normal tissues \u003cb\u003e(Fig.\u0026nbsp;2G)\u003c/b\u003e. Further investigation for the \u003cem\u003eGUCA2A\u003c/em\u003e \u003cb\u003e(Fig.\u0026nbsp;2H)\u003c/b\u003e and \u003cem\u003eMUC1\u003c/em\u003e \u003cb\u003e(Fig.\u0026nbsp;2I)\u003c/b\u003e were also performed in 55 CRC cell lines, which revealed their distributed expression levels across all CRC cell lines, with a particular emphasis on HCT-116, which aligns with the focus of our study.\u003c/p\u003e \u003cp\u003e \u003cb\u003eGUCA2A\u003c/b\u003e \u003cb\u003eexpression level correlates with poor prognosis in CRC\u003c/b\u003e\u003c/p\u003e \u003cp\u003eWe employed a univariate Cox regression model to evaluate the association between \u003cem\u003eGUCA2A\u003c/em\u003e expression and various clinical endpoints, in different CRC datasets. Remarkably, reduced \u003cem\u003eGUCA2A\u003c/em\u003e expression was significantly linked to adverse outcomes across multiple clinical endpoints in CRC \u003cb\u003e(Fig.\u0026nbsp;3A)\u003c/b\u003e. In this regard, \u003cem\u003eGUCA2A\u003c/em\u003e expression significantly correlated with worse DFI, DFS, DSS, OS, PFI, PFS, and RFS, which makes it a key gene for prognosis of CRC. The HR values demonstrate that decreased \u003cem\u003eGUCA2A\u003c/em\u003e expression is generally associated with a higher risk of unfavorable events such as disease recurrence, progression, and mortality across various clinical endpoints in CRC, except for RFS, where increased \u003cem\u003eGUCA2A\u003c/em\u003e expression is linked to a reduced risk of disease relapse \u003cb\u003e(Fig.\u0026nbsp;3A)\u003c/b\u003e. Moreover, the survival curve analysis emphasized that decreased \u003cem\u003eGUCA2A\u003c/em\u003e expression was also associated with significantly shorter OS time \u003cb\u003e(Fig.\u0026nbsp;3B)\u003c/b\u003e. Collectively, these discoveries underscore the potential of \u003cem\u003eGUCA2A\u003c/em\u003e as an innovative and valuable prognostic biomarker in CRC.\u003c/p\u003e \u003cp\u003e \u003cb\u003eImmune cell infiltration analysis of\u003c/b\u003e \u003cb\u003eGUCA2A\u003c/b\u003e \u003cb\u003ein CRC\u003c/b\u003e\u003c/p\u003e \u003cp\u003eTo investigate the connection between \u003cem\u003eGUCA2A\u003c/em\u003e expression and immune cell infiltration, we performed correlation analyses using data from different algorithms. The results unveiled significant positive correlations between \u003cem\u003eGUCA2A\u003c/em\u003e expression and the infiltration of various immune cell types, including neutrophils, B cell plasma, activated myeloid dendritic cells, M1- and M2-like macrophages, CD4\u0026thinsp;+\u0026thinsp;T cells, and CD8\u0026thinsp;+\u0026thinsp;T cells \u003cb\u003e(Fig.\u0026nbsp;3C)\u003c/b\u003e. Conversely, \u003cem\u003eGUCA2A\u003c/em\u003e expression exhibited negative correlations with M0-like macrophages, cancer-associated fibroblasts, NK cells, myeloid-derived suppressor cells, mast cells, and CD4\u0026thinsp;+\u0026thinsp;T cells \u003cb\u003e(Fig.\u0026nbsp;3C)\u003c/b\u003e. While the correlation values ranged from \u0026plusmn;\u0026thinsp;0.1 to \u0026plusmn;\u0026thinsp;0.5 and were not exceptionally high, these findings suggest that \u003cem\u003eGUCA2A\u003c/em\u003e may play a role in promoting T cell infiltration, which could contribute to its protective effects in CRC. Nonetheless, further clinical investigations are warranted to explore deeper into this finding.\u003c/p\u003e \u003cp\u003e \u003cb\u003eDNA methylation and alterations of\u003c/b\u003e \u003cb\u003eGUCA2A\u003c/b\u003e \u003cb\u003ein pan-cancer\u003c/b\u003e\u003c/p\u003e \u003cp\u003eTo investigate the relationship between \u003cem\u003eGUCA2A\u003c/em\u003e gene mutations and tumor development, we conducted a pan-cancer analysis using the cBioPortal platform, with a specific focus on CRC. The primary alteration type predominantly indicated \"mRNA low\" in the majority of samples across various cancer types, with a lesser frequency of \"mRNA high\" alterations \u003cb\u003e(Fig.\u0026nbsp;3D, 3F)\u003c/b\u003e. Notably, \"mRNA low\" alterations were observed in over 60% of CRC samples \u003cb\u003e(Fig.\u0026nbsp;3D)\u003c/b\u003e. Moreover, the somatic mutation frequency analysis of \u003cem\u003eGUCA2A\u003c/em\u003e revealed missense mutations in several cancer types, including Breast Prostate Adenocarcinoma, Invasive Ductal Carcinoma, Acute Myeloid Leukemia, Hepatocellular Carcinoma, Renal Clear Cell Carcinoma, Uterine Endometrioid Carcinoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, and notably in CRC \u003cb\u003e(Fig.\u0026nbsp;3E)\u003c/b\u003e. Furthermore, the analysis of \u003cem\u003eGUCA2A\u003c/em\u003e gene methylation data unveiled a significant decrease in the promoter methylation level of \u003cem\u003eGUCA2A\u003c/em\u003e in CRC \u003cb\u003e(Fig.\u0026nbsp;3G)\u003c/b\u003e. These findings enhance our knowledge of the genetic mechanisms underlying tumor progression and offer further research and potential therapeutic exploration of \u003cem\u003eGUCA2A\u003c/em\u003e.\u003c/p\u003e \u003cp\u003e \u003cb\u003eIdentification of key cancer-related pathways linked to\u003c/b\u003e \u003cb\u003eGUCA2A\u003c/b\u003e\u003c/p\u003e \u003cp\u003eTo assess the potential impact of \u003cem\u003eGUCA2A\u003c/em\u003e expression on cellular pathways, we conducted a GSVA involving 50 HALLMARK pathways. The relationship between \u003cem\u003eGUCA2A\u003c/em\u003e expression levels and GSVA scores in CRC is illustrated in \u003cb\u003eFig.\u0026nbsp;3H\u003c/b\u003e. Our biological enrichment analysis revealed distinctive patterns, exhibiting upregulation in pathways associated with pancreas beta cells, bile acid metabolism, and KRAS signaling with elevated \u003cem\u003eGUCA2A\u003c/em\u003e expression. Conversely, as \u003cem\u003eGUCA2A\u003c/em\u003e expression increased, pathways related to mitotic spindle dynamics, protein secretion processes, G2M checkpoint regulation, and interferon alpha responses were downregulated \u003cb\u003e(Fig.\u0026nbsp;3H)\u003c/b\u003e. These findings provide insights into how \u003cem\u003eGUCA2A\u003c/em\u003e expression may influence various pathways in CRC, shedding light on potential mechanisms and functional associations.\u003c/p\u003e \u003cdiv id=\"Sec25\" class=\"Section2\"\u003e \u003ch2\u003eConstruction of guanylin expressing constructs\u003c/h2\u003e \u003cp\u003eFollowing the amplification and isolation of the CDS region of the \u003cem\u003eGUCA2A\u003c/em\u003e gene \u003cb\u003e(Additional file 1. Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eA, S2A)\u003c/b\u003e, the obtained fragment and the plasmid constructs (HRE-pMUC1 and pCMV) underwent digestion using \u003cem\u003eBamHI\u003c/em\u003e and \u003cem\u003eXbaI\u003c/em\u003e enzymes. Subsequently, they were purified from the gel and linked together through a ligation process. These resulting plasmids were then introduced into competent bacteria via transformation. Afterward, bacterial colonies were cultured on plates, and the colonies were verified using colony PCR to amplify a 117 bp product \u003cb\u003e(Additional file 1. Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eB, S2B)\u003c/b\u003e. A single colony was selected for the extraction of plasmids. Finally, the validation of both the HRE-pMUC1-GUCA2A and pCMV-GUCA2A plasmids was performed through Sanger sequencing \u003cb\u003e(Additional file 1. Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eC)\u003c/b\u003e. the schematic illustration of the resulting guanylin expressing constructs is shown in \u003cb\u003eAdditional file 1. Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eD\u003c/b\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec26\" class=\"Section2\"\u003e \u003ch2\u003eStructural confirmation of SPEI-9 nanocarrier\u003c/h2\u003e \u003cp\u003eThe FT-IR analysis conducted on basic PEI and SPEI-9 revealed distinct peaks corresponding to the functional groups present in the polymer. These peaks were cross-referenced with the FT-IR spectra library for validation. Notably, the spectrum exhibited a prominent peak at approximately 1760 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e, which is associated with the stretching vibration of the carbonyl group (C\u0026thinsp;=\u0026thinsp;O) found in succinyl \u003cb\u003e(Fig.\u0026nbsp;4A)\u003c/b\u003e. This peak serves as an indicator of the binding of the succinyl group to the PEI structure. NMR spectroscopy was employed to perform a structural analysis of SPEI-9. Through this analysis, distinctive peaks associated with various proton environments within the polymer were identified. Notably, the observation of peaks in chemical shifts ranging from 2.5 to 3.5 ppm signified the presence of the PEI backbone \u003cb\u003e(Fig.\u0026nbsp;4B)\u003c/b\u003e. Additionally, the emergence of new peaks with chemical shifts in the range of 2.3 to 2.5 ppm provided confirmation of the succinyl group's presence. Consequently, the chemical environment of carbon atoms in the SPEI-9 sample served as confirmation of the successful modification of the polymer.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec27\" class=\"Section2\"\u003e \u003ch2\u003eMeasuring buffering capacity of SPEI-9 nanocarrier\u003c/h2\u003e \u003cp\u003eThe buffer capacity of PEI and SPEI-9 was also evaluated in this study. In this regard, compared to the negative control (deionized water), both SPEI-9 and PEI showed significant buffer capacity \u003cb\u003e(Fig.\u0026nbsp;4C)\u003c/b\u003e. The pH of the solutions remained relatively stable even with the addition of high amounts of acid, indicating their resilience to pH changes. However, since the degree of 9% succinylation was used, SPEI-9 showed relatively lower buffering capacity compared to PEI at concentrations above 80 \u0026micro;l of HCl \u003cb\u003e(Fig.\u0026nbsp;4C)\u003c/b\u003e. Therefore, the modification of PEI with 9% succinic anhydride largely preserved the suitable buffering properties of the basic nanocarrier, which can be useful for various applications such as drug delivery and gene therapy, where maintaining a specific pH range is very important.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec28\" class=\"Section2\"\u003e \u003ch2\u003eMeasuring the gel retardation by SPEI-9 nanocarrier\u003c/h2\u003e \u003cp\u003eThe DNA loading capacity of both PEI and SPEI-9 was assessed through a gel retardation assay, utilizing various C/P ratios ranging from 0.25 to 8. The results of the gel retardation assay revealed that at lower C/P ratios, specifically 0.25 and 1, SPEI-9 polyplexes exhibited limited DNA loading, as evidenced by their increased mobility during gel electrophoresis \u003cb\u003e(Additional file 1. Figure S2C)\u003c/b\u003e. In contrast, at C/P ratios of 4 and 8, SPEI-9 nanocarriers demonstrated complete plasmid encapsulation, signifying an optimal loading capacity conducive to efficient plasmid delivery \u003cb\u003e(Fig.\u0026nbsp;4D)\u003c/b\u003e. Conversely, the PEI-based nanocarrier displayed full DNA loading at three distinct C/P ratios: 1, 4, and 8 \u003cb\u003e(Fig.\u0026nbsp;4D)\u003c/b\u003e. Consequently, the findings from agarose gel electrophoresis underscored the suitability of SPEI-9 nanocarriers at a C/P ratio of 4 and PEI at a C/P ratio of 1 as optimal ratio for gene delivery applications.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec29\" class=\"Section2\"\u003e \u003ch2\u003eDNase protection analysis of SPEI-9\u003c/h2\u003e \u003cp\u003eThe experiment involved treating SPEI-9 polyplexes at C/P ratios of 0.25, 4, and 8, along with a control gene construct group, with and without DNase. This simulated the presence of nucleases that could potentially break down genetic material. The results revealed that polyplexes formed at a C/P ratio of 0.25, as well as the plasmid structure, were significantly degraded after DNase treatment, as evidenced by the absence of plasmid bands in agarose gel electrophoresis \u003cb\u003e(Fig.\u0026nbsp;4E) (Additional file 1. Figure S2D)\u003c/b\u003e. This indicated the vulnerability of genetic material when complexed with SPEI-9 at this specific C/P ratio. In contrast, polyplexes formed with SPEI-9 at C/P ratios of 4 and 8 displayed robust resistance against DNase degradation \u003cb\u003e(Fig.\u0026nbsp;4E)\u003c/b\u003e. The bands corresponding to the gene constructs remained well-defined and intact after DNase treatment, underscoring the effective protection provided by SPEI-9 against enzymatic digestion.\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eMeasuring the size and surface charge of SPEI-9 nanocarrier\u003c/h3\u003e\n\u003cp\u003eThe size and surface charge (zeta potential) of PEI and SPEI-9 nanocarriers were determined to evaluate their physicochemical properties, which can affect their stability and interaction with genetic materials. In this regard, the results showed that the polyplexes formed with SPEI-9 had an average size of 149.6 nm with an optimum PDI, which indicates that the polyplexes are relatively homogeneous in size and have good stability \u003cb\u003e(Fig.\u0026nbsp;4F)\u003c/b\u003e. In contrast, polyplexes formed with PEI had a larger average size of 205 nm, indicating a broader size distribution compared to SPEI-9 polyplexes \u003cb\u003e(Fig.\u0026nbsp;4F)\u003c/b\u003e. Zeta potential measurements also showed that SPEI-9 polyplexes have a positive surface charge, with an average surface charge of +\u0026thinsp;11.2 mV \u003cb\u003e(Fig.\u0026nbsp;4G)\u003c/b\u003e. This positive charge is attributed to the presence of succinyl and amine groups in the PEI column, which can interact with the negatively charged genetic material. Positive zeta potential indicates good electrostatic stability and effective complexation potential with nucleic acids. In contrast, unmodified PEI polyplexes showed positive zeta potential with an average value of +\u0026thinsp;17.7 mV \u003cb\u003e(Fig.\u0026nbsp;4G)\u003c/b\u003e. This higher positive charge is due to the lack of coverage of amine groups by succinyl. With this positive zeta potential, PEI polyplexes showed good stability and the ability to form complexes with genetic materials.\u003c/p\u003e \u003cdiv id=\"Sec31\" class=\"Section2\"\u003e \u003ch2\u003eMeasuring the effect of SPEI-9 nanocarrier on hemolysis rate\u003c/h2\u003e \u003cp\u003eThe hemolytic activity of PEI and SPEI-9 polyplexes was evaluated to assess their potential cytotoxic effects on RBCs. The hemolysis assay included the incubation of polyplexes with RBCs and the measurement of hemoglobin release, which acts as an indicator of cell membrane damage and hemolysis. The results showed that the rate of hemolysis increases with increasing C/P ratio for SPEI-9 polyplexes \u003cb\u003e(Fig.\u0026nbsp;4H)\u003c/b\u003e. At the C/P ratio of 0.25, the amount of hemolysis was relatively low. However, with the increase of C/P ratio to 1, 4, and 8, the degree of hemolysis also increased gradually \u003cb\u003e(Fig.\u0026nbsp;4H)\u003c/b\u003e. This shows that higher concentrations of SPEI-9 polyplexes may have more potential to induce hemolysis. In comparison, PEI polyplexes at a C/P ratio of 1 had slightly similar hemolysis rates to SPEI-9 polyplexes at a C/P ratio of 4. This suggests that PEI polyplexes may also have some hemolytic activity. Although to a lesser extent compared to the SPEI-9 polyplex, the C/P ratio was higher than 8 \u003cb\u003e(Fig.\u0026nbsp;4H)\u003c/b\u003e. These results highlight the importance of carefully selecting the C/P ratio and optimizing the formulation of polyplexes to minimize potential cytotoxic effects, especially in the context of functional \u003cem\u003ein vivo\u003c/em\u003e gene delivery purposes.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec32\" class=\"Section2\"\u003e \u003ch2\u003eInteraction assay of SPEI-9 nanocarrier with BSA protein\u003c/h2\u003e \u003cp\u003eThe interaction of PEI and SPEI-9 polyplexes with BSA was evaluated to assess their protein interaction capabilities. The BSA interaction test included the incubation of polyplexes with BSA and measuring the removal or retention of protein in the supernatant of the interaction reaction using spectrometry. In this regard, the results showed that the SPEI-9 polyplex with a C/P ratio of 4, which was selected based on previous tests for downstream studies, had a lower interaction (with an average of 0.48) with BSA compared to PEI polyplexes of C/P ratio 1 with an average of 0.61 (p\u0026thinsp;=\u0026thinsp;0.017) \u003cb\u003e(Fig.\u0026nbsp;4I)\u003c/b\u003e. The reduction of protein interaction observed with SPEI-9 polyplex indicates that modification of succinylation of PEI may change its surface characteristics and reduce its ability to interact with serum proteins such as BSA. This can be useful in gene delivery applications, as reduced protein interactions can improve stability in circulation to help transfer with higher efficiency.\u003c/p\u003e \u003cdiv id=\"Sec33\" class=\"Section3\"\u003e \u003ch2\u003eCytotoxicity assay of SPEI-9 nanocarrier\u003c/h2\u003e \u003cp\u003eCytotoxicity assessment of PEI and SPEI-9 was performed in two cell lines, HCT-116 and Vero. In this regard, PEI in C/P ratio 1 showed the highest cytotoxicity in both cell lines, which indicates its destructive effect on cell viability (p\u0026thinsp;=\u0026thinsp;0\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) \u003cb\u003e(Fig.\u0026nbsp;4J, 4K)\u003c/b\u003e. This can be attributed to the high cationic charge density of PEI, which leads to electrostatic interactions with negatively charged cell membranes. These interactions can eventually cause irreparable damage to the cell membrane and lead to cell lysis or necrosis. In contrast, the cytotoxicity of SPEI-9 in both cell lines at different C/P ratios was relatively lower compared to PEI 1 (p\u0026thinsp;=\u0026thinsp;0.0102, 0.0004, 0\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) \u003cb\u003e(Fig.\u0026nbsp;4J, 4K)\u003c/b\u003e. Reducing the charge density of succinylated polymers may help reduce the deleterious effects on cell viability. HCT-116 cells had the lowest toxicity in the presence of SPEI-9 at all C/P ratios, which indicates higher resistance compared to Vero cells. Furthermore, the cytotoxicity of SPEI-9 increased with increasing C/P ratio, indicating a concentration-dependent effect. Even at the highest C/P ratio (8:1), the cytotoxicity of SPEI-9 was almost equal compared to PEI at a C/P ratio of 1:1 \u003cb\u003e(Fig.\u0026nbsp;4J)\u003c/b\u003e. Cytotoxicity was observed in Vero cells treated with PEI and SPEI-9 more severely. In this context, it was observed that the cytotoxicity of Vero cells was notably lower when treated with SPEI-9 at a C/P ratio of 0.25:1 in comparison to other ratios. However, as the C/P ratio increased, there was a significant elevation in cytotoxicity among Vero cells (p\u0026thinsp;=\u0026thinsp;0.017, p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) \u003cb\u003e(Fig.\u0026nbsp;4K)\u003c/b\u003e. These findings underscore the significance of polymer modification, such as succinylation, in mitigating the cytotoxic effects associated with PEI. The reduced cytotoxicity observed with SPEI-9 implies its potential as a safer alternative for gene transfer applications, particularly in the context of cancer cells like HCT-116.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec34\" class=\"Section3\"\u003e \u003ch2\u003eTransfection efficiency assay by SPEI-9 nanocarrier\u003c/h2\u003e \u003cp\u003eAnalysis of the images acquired via fluorescence microscopy revealed that both SPEI-9 (C/P 4) and PEI (C/P 1) nanocarriers exhibited remarkable efficacy in delivering the pEGFP-N1 plasmid construct, which contains the EGFP protein as a transfection marker. The results indicated that the optimal transfection time for plasmid treatment was 72 h, a widely accepted standard in plasmid transfection protocols. Notably, the transfection rate achieved by the SPEI-9 nanocarrier surpassed that of PEI in both the cancer cell lines HCT-116 \u003cb\u003e(Fig.\u0026nbsp;5A, 5B, 5E, p\u0026thinsp;=\u0026thinsp;0.0229)\u003c/b\u003e and the normal Vero cell line \u003cb\u003e(Fig.\u0026nbsp;5C, 5D, 5E, p\u0026thinsp;=\u0026thinsp;0.0373)\u003c/b\u003e. Consequently, the SPEI-9 nanocarrier, administered for 72 h, was selected for subsequent assessments in cell culture studies.\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e\n\u003ch3\u003eCell culture study design\u003c/h3\u003e\n\u003cp\u003eAfter conducting different studies involving PEI and SPEI-9 nanocarriers at varying C/P ratios, we have determined that SPEI-9, due to its significantly lower toxicity and superior transfection efficiency during the 72 h treatment, is the optimal choice for subsequent cell culture studies. Furthermore, considering its effective loading at a C/P ratio of 4, along with its reduced toxicity compared to a C/P ratio of 8, we have selected this C/P ratio for the treatment groups in conjunction with various constructs, including pCMV-GUCA2A loaded SPEI-9, HRE-pMUC1-GUCA2A loaded SPEI-9, pEGFP-N1 loaded SPEI-9, and a control group.\u003c/p\u003e\n\u003ch3\u003eEvaluation of gene expression changes\u003c/h3\u003e\n\u003cp\u003eAt first, the \u003cem\u003eGUCA2A\u003c/em\u003e expression level in 10 CRC tissues and 10 adjacent healthy tissues was investigated using RT-qPCR. The results of this study showed a notable decreased and differential expression of \u003cem\u003eGUCA2A\u003c/em\u003e in tumor tissue compared to the adjacent healthy tissue among different patients \u003cb\u003e(Fig.\u0026nbsp;5F)\u003c/b\u003e. Additionally, RT-qPCR for \u003cem\u003eGUCA2A\u003c/em\u003e, p21, β-catenin, \u003cem\u003eBAX\u003c/em\u003e, \u003cem\u003eBCL-2\u003c/em\u003e, Cadherin-2, Vimentin, and \u003cem\u003eGAPDH\u003c/em\u003e (as reference gene) was performed to evaluate the mRNA expression changes upon treatment with different gene therapeutics. In both cell lines, SPEI-9 loaded with pCMV-GUCA2A showed remarkable over-expression of guanylin hormone (\u0026asymp;\u0026thinsp;15-fold increase in logFC, p\u0026thinsp;=\u0026thinsp;0\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) \u003cb\u003e(Fig.\u0026nbsp;5G)\u003c/b\u003e. While, SPEI-9 nanocarrier loaded with pMUC1-GUCA2A, shown a lower level of increased expression than pCMV-GUCA2A in HCT-116 (\u0026asymp;\u0026thinsp;5-fold increase in logFC, p\u0026thinsp;=\u0026thinsp;0\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) and much lower level of increased expression in Vero cells (not significant), indicating moderate but specific expression of guanylin in cancer cells lines \u003cb\u003e(Fig.\u0026nbsp;5G)\u003c/b\u003e. This result is consistent with the tumor-specific nature of the MUC1 gene promoter, which directs the expression of guanylin specifically in tumor cells and minimizes its expression in normal cells.\u003c/p\u003e \u003cp\u003eIn addition to measuring expression changes by the gene constructs, the effects of inducing gene expression by HRE cassette were also evaluated. We chose the treatment time with and without the effects of hypoxia for 16 h, which showed a significant increase in this period compared to the untreated group (\u0026asymp;\u0026thinsp;3.5-fold increase in fold change, p\u0026thinsp;=\u0026thinsp;0.0004) \u003cb\u003e(Fig.\u0026nbsp;5H)\u003c/b\u003e.\u003c/p\u003e \u003cp\u003eIn this regard, the pCMV-GUCA2A group showed a significant decrease of \u0026asymp;\u0026thinsp;6-fold (p\u0026thinsp;=\u0026thinsp;0.0005) and \u0026asymp;\u0026thinsp;1.5-fold (p\u0026thinsp;=\u0026thinsp;0.0023) decrease in β-catenin mRNA levels in HCT-116 and Vero cells, respectively \u003cb\u003e(Fig.\u0026nbsp;5I)\u003c/b\u003e. Regarding the pMUC1-GUCA2A construct, it showed a significant decrease of \u0026asymp;\u0026thinsp;2-fold (p\u0026thinsp;=\u0026thinsp;0.002) and \u0026asymp;\u0026thinsp;1-fold (p\u0026thinsp;=\u0026thinsp;0.113) in both HCT-116 and Vero cell lines, but with less intensity \u003cb\u003e(Fig.\u0026nbsp;5I)\u003c/b\u003e. Concerning p21, a significant increase in the expression of the pCMV-GUCA2A gene construct (p\u0026thinsp;=\u0026thinsp;0.001) compared to pMUC1-GUCA2A (p\u0026thinsp;=\u0026thinsp;0.0019) was observed for the HCT-116 cell line \u003cb\u003e(Fig.\u0026nbsp;5J)\u003c/b\u003e. However, in Vero cell line, both gene constructs showed\u0026thinsp;\u0026asymp;\u0026thinsp;a 1-fold decrease in p21 mRNA level, that this result can be based on the fact that in this cell line the expression of p21 is naturally reduced [\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e] \u003cb\u003e(Fig.\u0026nbsp;5K)\u003c/b\u003e.\u003c/p\u003e \u003cp\u003eThe effect of guanylin over expression on the levels of two key mediators of apoptosis, BAX and BCL-2 as promoter and inhibitor of apoptosis were also investigated, respectively. In this regard, both gene constructs of pCMV-GUCA2A and pMUC1-GUCA2A showed a significant increase in the expression of the apoptosis-promoting gene, BAX, for the HCT-116 cell line (p\u0026thinsp;=\u0026thinsp;0.0040 and p\u0026thinsp;=\u0026thinsp;0.0173) \u003cb\u003e(Fig.\u0026nbsp;5K)\u003c/b\u003e. These changes in the pCMV-GUCA2A group were more intense (\u0026asymp;\u0026thinsp;2-fold), which is caused by the significant difference in guanylin expression. On the other hand, in the Vero cell line, this difference in expression was observed with less severity for both pCMV-GUCA2A (p\u0026thinsp;=\u0026thinsp;0.0199) and pMUC1-GUCA2A (p\u0026thinsp;=\u0026thinsp;0.0493) treatment groups \u003cb\u003e(Fig.\u0026nbsp;5K)\u003c/b\u003e. Moreover, BCL-2 levels have shown a significant decrease in both gene constructs in HCT-116 (p\u0026thinsp;=\u0026thinsp;0\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) and Vero (p\u0026thinsp;=\u0026thinsp;0\u0026thinsp;\u0026lt;\u0026thinsp;0.001) cell lines \u003cb\u003e(Fig.\u0026nbsp;5L)\u003c/b\u003e. However, these changes were more intense for pCMV-GUCA2A compared to pMUC1-GUCA2A, with tumor-specific promoters \u003cb\u003e(Fig.\u0026nbsp;5L)\u003c/b\u003e.\u003c/p\u003e \u003cp\u003eThese differential results were also repeated in the expression of two key genes involved in the epithelial-mesenchymal transition (EMT) pathway, including Vimentin and N-cadherin, due to the strong but non-specific CMV promoter and the moderate but tumor-specific promoter \u003cem\u003eMUC1\u003c/em\u003e. Regarding Vimentin, the results showed a significant decrease in expression in the HCT-116 cell line for both treatments (p\u0026thinsp;=\u0026thinsp;0\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) \u003cb\u003e(Fig.\u0026nbsp;5M)\u003c/b\u003e. For the Vero cell line, the pCMV-GUCA2A group showed a lower expression decrease (p\u0026thinsp;=\u0026thinsp;0.0156) \u003cb\u003e(Fig.\u0026nbsp;5M)\u003c/b\u003e. On the other hand, in the case of pMUC1-GUCA2A treatment, this gene showed a very small increase (p\u0026thinsp;=\u0026thinsp;0.0142). Additionally, for N-cadherin in both HCT-116 and Vero cell lines, both treatment groups showed a significant decrease in expression (p\u0026thinsp;=\u0026thinsp;0\u0026thinsp;\u0026lt;\u0026thinsp;0.001), while for the Vero cell line, the changes in the mRNA level were less intense than HCT-116 cancer cell line \u003cb\u003e(Fig.\u0026nbsp;5N)\u003c/b\u003e. Finally, heat maps were also generated based on the expression of \u003cem\u003eGUCA2A\u003c/em\u003e and its 6 downstream genes for both cancer and normal cell lines to better show the expression distribution between these two cell lines \u003cb\u003e(Fig.\u0026nbsp;5O, 5P)\u003c/b\u003e.\u003c/p\u003e \u003cdiv id=\"Sec37\" class=\"Section2\"\u003e \u003ch2\u003e\u003cb\u003eEvaluation of apoptosis induction upon guanylin expressing nano-system\u003c/b\u003e\u003c/h2\u003e \u003cp\u003eTo assess the anti-tumor effects of the gene therapeutics, we measured the percentage of induced apoptosis using the Annexin-PI kit and analyzed the results in three categories: necrosis, apoptosis, and total cell death. In this context, we observed minimal necrosis in HCT-116 cancer cells as a result of the genetic constructs \u003cb\u003e(Fig.\u0026nbsp;6A, 6B)\u003c/b\u003e. However, in normal Vero cells, necrosis reached levels of up to 25% \u003cb\u003e(Fig.\u0026nbsp;6A, 6B)\u003c/b\u003e. This relatively higher necrosis percentage in Vero cells can be attributed to their strong adhesion to the culture plate. Additionally, mechanical scraping with a cell scraper contributed to the induction of necrosis. Furthermore, both gene constructs exhibited significant induction of apoptosis in HCT-116 cancer cells (p\u0026thinsp;=\u0026thinsp;0.0001), with approximately 35% for pCMV-GUCA2A and approximately 30% for pMUC1-GUCA2A \u003cb\u003e(Fig.\u0026nbsp;6A, 6C)\u003c/b\u003e. In Vero cells, the induction of apoptosis was relatively lower, approximately 25% for pCMV-GUCA2A (p\u0026thinsp;=\u0026thinsp;0.0001), and even less in the pMUC1-GUCA2A group, approximately 11% (p\u0026thinsp;=\u0026thinsp;0.0120) \u003cb\u003e(Fig.\u0026nbsp;6A, 6C)\u003c/b\u003e. Finally, the overall assessment of cell death, which included both early and late apoptosis as well as necrosis, revealed similar patterns to apoptosis and necrosis \u003cb\u003e(Fig.\u0026nbsp;6D)\u003c/b\u003e.\u003c/p\u003e \u003cdiv id=\"Sec38\" class=\"Section3\"\u003e \u003ch2\u003eEvaluation of cytotoxicity upon guanylin gain of function\u003c/h2\u003e \u003cp\u003eFollowing the evaluation of guanylin expression through RT-qPCR, we proceeded to assess the impact of different gene constructs delivered via SPEI-9 on cell viability and potential cytotoxicity. In the case of HCT-116 cells, it was evident that cell viability significantly decreased in both the pCMV-GUCA2A (p\u0026thinsp;=\u0026thinsp;0.0001) and pMUC1-GUCA2A (p\u0026thinsp;=\u0026thinsp;0.0030) groups when compared to the control and SPEI-9 groups \u003cb\u003e(Fig.\u0026nbsp;6E)\u003c/b\u003e. Conversely, the cytotoxicity induced by the gene therapeutics markedly increased in both groups when applied to HCT-116 cell lines. In normal Vero cells, the cytotoxicity induced by pCMV-GUCA2A was higher in comparison to pMUC1-GUCA2A (p\u0026thinsp;=\u0026thinsp;0.0001) \u003cb\u003e(Fig.\u0026nbsp;6F)\u003c/b\u003e. The subsequent increase in cytotoxicity observed with pMUC1-GUCA2A was relatively lower than that associated with pCMV-GUCA2A (p\u0026thinsp;=\u0026thinsp;0.0019), aligning with expectations \u003cb\u003e(Fig.\u0026nbsp;6F)\u003c/b\u003e.\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec39\" class=\"Section2\"\u003e \u003ch2\u003eEvaluation of cell migration ability\u003c/h2\u003e \u003cp\u003eTo investigate the inhibitory effect of gene constructs on cell migration, a scratch or wound-healing assay was performed. The results of this test showed that pCMV-GUCA2A had stronger anti-migration effects compared to the pMUC1-GUCA2A vector. In this regard, after 24 and 48 h after treatment in HCT-116 cancer cells, the scratch assay created in the group treated with guanylin expression constructs, cell migration at a much lower speed than the nanocarrier group containing gene constructs control and group without treatment were performed \u003cb\u003e(Fig.\u0026nbsp;7A, 7C)\u003c/b\u003e. Interestingly, these effects in Vero cells were accompanied by a significant decrease in the inhibition of cell migration by treatment with the pMUC1-GUCA2A gene construct, which results from the low expression of guanylin \u003cb\u003e(Fig.\u0026nbsp;7B, 7D)\u003c/b\u003e. It is noteworthy to mention that in part A, 24 h and 48 h are separately seeded, treated, and colored, and the control group shown corresponds to the 24 h group.\u003c/p\u003e \u003cdiv id=\"Sec40\" class=\"Section3\"\u003e \u003ch2\u003eEvaluation of the guanylin expressing nano-system on colony formation\u003c/h2\u003e \u003cp\u003eIn this test, the effect of different treatments through genetic constructs on the process of colony formation from a seeded cell to a colony of cells (about 50 cells) was evaluated. The obtained results, like the previous results, indicated stronger inhibitory effects of pCMV-GUCA2A treatment compared to the structure containing the specific promoter in the HCT-116 cancer cell line. In this regard, both gene constructs in the HCT-116 cell line showed a significant decrease in the number of colonies (p\u0026thinsp;=\u0026thinsp;0\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) \u003cb\u003e(Fig.\u0026nbsp;7E, 7G)\u003c/b\u003e. Also, in the group of normal Vero cells, far less inhibitory effects of the structure containing the MUC1 promoter (p\u0026thinsp;=\u0026thinsp;0.0001) than CMV (p\u0026thinsp;=\u0026thinsp;0\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) were observed, which is consistent with the previous findings \u003cb\u003e(Fig.\u0026nbsp;7F, 7G)\u003c/b\u003e.\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eThe application of gene therapy as a potential treatment for cancer has urged the development of various polymeric nanocarriers. The aim is to enhance non-viral vectors as safe and efficient agents for gene transfer. Among these, the PEI nanocarrier, recognized as a benchmark for polymeric vectors, demonstrates notable gene transfer efficiency in serum-free and \u003cem\u003ein vitro\u003c/em\u003e conditions. Nevertheless, challenges arise under serum-supplemented conditions that mimic the \u003cem\u003ein vivo\u003c/em\u003e environment. Specifically, PEI/DNA polyplexes tend to aggregate with serum proteins, leading to a reduction in overall transfection efficiency [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe approaches employed to enhance transfection efficiency and improve the physicochemical characteristics of PEI nanocarriers encompass the conjugation of PEI with diverse polymers, the incorporation of distinct chemical moieties, and the integration of targeting components. For instance, the coupling of polyethylene glycol (PEG) or a stealth polymer, along with more complex chemical groups, establishes a charge protection layer within PEI/DNA polyplexes. This layer serves to mitigate the excess positive charge of the polycation, preventing nonspecific binding to other proteins [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e]. Nevertheless, while these chemical modifications can alleviate polymer toxicity and mitigate interactions with nonspecific proteins, they may concurrently diminish the efficacy of DNA transfer into the cell by reducing its buffering capacity. Hence, the modifications contribute to enhanced gene transfer efficiency, reduced cytotoxicity, improved stability, and tunable properties were explored to make modified PEI a promising candidate for advancing gene therapy applications [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e, \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eOne approach involves attaching anionic components to PEI to reduce the cationic charge density of polyplexes, thereby mitigating cytotoxicity. The utilization of succinic anhydride as a surface modification agent for this polymer can alter its surface characteristics. Following the surface modification of PEI with succinic anhydride, carboxylic groups are introduced to the polymer surface. These carboxylic groups induce various alterations, encompassing changes in contact angle, hydrophobic properties, dispersibility, and the capacity to modify and enhance the electrical charge of the polymer [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. The modification degree of Succinylated PEI (SPEI) can be adjusted by varying the quantity of succinic anhydride employed during the modification process, which ranges from 9 to 55% of modified amines. This variability can result in distinct levels of modification, impacting the properties of the resulting SPEI polymer. Notably, SPEI-9, denoting SPEI with a low degree of succinylation (approximately 9% by polymer weight), usually yields lower charge density. Despite a relatively modest reduction in toxicity, it demonstrates higher gene transfer efficiency compared to unmodified PEI. Due to its efficient DNA condensation and protective attributes against degradation, SPEI-9 emerges as a promising and optimal gene delivery vector [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e]. In this regard, in a study conducted by Warriner et al., it was demonstrated that modifying the PEI polymer with varying degrees of succinyl groups diminishes the strength of electrostatic interactions between the plasmid and the polymer. Conversely, as the degree of succinylation increases, nonspecific interactions between the polymer and serum proteins decrease, allowing more polymer to be utilized for efficient DNA loading [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eAdditionally, the resultant SPEI-9 polyplex exhibited a size of approximately 150 nm, falling within the optimum range for endocytosis without receptor mediation [\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]. It has been observed that the increase in the size of SPEI-based nanocarriers, corresponding to an escalation in the degree of succinylation (ranging from 9, the lowest, to 55, the highest), is primarily attributed to the reduction of electrostatic interactions produced by the polyplex with lower density, resulting in a larger nanocarrier. Moreover, the ζ potential of the polyplexes remained positive, albeit experiencing a slight decrease attributable to succinylation [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eHowever, the significance of size in polymer design for gene delivery is often underestimated. Studies reveal that PEI-pDNA polyplexes exceeding 100 nm demonstrate enhanced transfection efficiency compared to smaller counterparts [\u003cspan additionalcitationids=\"CR41\" citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e]. Several explanations have been suggested to rationalize this observation. Firstly, smaller particles indeed exhibit greater solution stability compared to larger ones, which may lead to higher interactions as they sediment onto cell surfaces. Similarly, centrifuging smaller particles onto cells can achieve a similar effect. Another explanation lies in the role of size in endocytic cycle. For polymers reliant on buffering the endosome and escaping via the proton-sponge phenomenon, larger complexes resulting from higher polymer weight possess increased buffering capacity. This is evident from the limited benefits observed in transfections with lysosomotropic agents for large complexes, while significant efficiency increases are noted for smaller ones. Additionally, vector size can influence the route of internalization [\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e, \u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e]. Clathrin-coated vesicles measure approximately 200 nm in diameter, necessitating adherence to this constraint for particles entering via this route. Larger particles, on the other hand, opt for clathrin-independent pathways, thereby avoiding harsh acidification and trafficking to lysosomes. Cationic polyplexes have a tendency to aggregate with circulatory components like serum proteins and erythrocytes, resulting in clearance or toxicity [\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e]. However, smaller and more neutrally charged polyplexes evade this issue by minimizing electrostatic and non-specific binding interactions. Conversely, large polyplexes face reduced cytosolic mobility and rely on active transportation by microtubular and microfibril networks. thus, achieving an optimal polyplex size entails balancing favorable endocytic trafficking and cellular interactions while optimizing cytotoxicity and cytosolic mobility [\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIt is also possible that the end groups of carboxyl succinate may induce a hydration layer, protecting the nanocarrier against serum proteins. However, similar to PEG derivatives, an elevation in the degree of succinylation (45 or 55 degrees) may lead to diminished interactions, stemming either from electrostatic repulsion or physical shielding through hydrated branches. This, in turn, could enhance the polymer's potential to cause damage to the cell membrane, ultimately associated with a decrease in effective gene transfer [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e, \u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e]. Therefore, considering that SPEI with lower degrees of succinylation offers both lower cytotoxicity and more effective gene transfer, and, in contrast, higher degrees of succinylation lead to increased interactions with serum proteins, the current study opted for the minimum degree of succinylation, 9%, on branched PEI. This choice was made to reduce cytotoxic effects and enhance the efficiency of gene transfer.\u003c/p\u003e \u003cp\u003eGiven that prior investigations on PEI succinylation primarily employed 2 kDa linear PEI, this study stands out by conducting comprehensive structural and functional analyses on the SPEI-9 nanocarrier based on 25 kDa nanocarrier, yielding novel and promising outcomes. The results obtained from structural confirmation, utilizing FT-IR and H-NMR for the SPEI-9 nanocarrier, align with the findings presented in studies conducted by Zaaeri et al. [\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e] and Warriner et al.[\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eFurthermore, concerning the efficient loading of genetic material and the protective capability of the SPEI-9 nanocarrier against degradation by the DNase enzyme, the findings align with the broader outcomes of the study conducted by Nouri et al. Specifically, their study focused on a succinic anhydride group-conjugated nanocarrier (PEI-SUC-PEI) with determined structural and functional characteristics. Nouri et al. demonstrated that this nanocarrier exhibited superior buffering resistance compared to both PEI-SUC and the base PEI. Interestingly, the loading efficiency and resistance to genetic structure degradation by DNase were nearly identical between PEI-SUC-PEI and PEI-SUC. Notably, the study's results indicated that the PEI-SUC-PEI nanocarrier, benefiting from the presence of two PEI groups, facilitated more effective gene transfer at higher C/P ratios compared to other groups [\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn addition, Zintchenko et al. conducted a foundational study in 2008 where the PEI nanocarrier underwent modification with various functional groups, including ethyl acrylate (PEI-EA), acetyl (PEI-AC), succinyl (PEI-SUC), and propionic acid (PEI-PROP). These modifications were applied with varying degrees to assess siRNA transfer efficiency and cytotoxicity in HuH-7 hepatoma cells. The results regarding cell viability demonstrated a proportional increase in cytotoxicity with the escalation of modification degree for all four PEI groups. Notably, the cytotoxicity of PEI-SUC and PEI-PROP nanocarriers was significantly lower than the others. Furthermore, to evaluate the efficacy of siRNA transfer, polymers from each group were examined at different C/P ratios (ranging from 0.5 to 8). Interestingly, among all the polymers tested, PEI-PROP-18 (C/P ratio 8), PEI-EA-31 (C/P ratios 6 and 8), and PEI-SUC-9 (C/P ratios 4, 6, and 8) exhibited the most potent silencing effects of siRNA. Among these, PEI-SUC-9 demonstrated the highest efficiency, highlighting its remarkable capability for effective gene transfer. Considering the cumulative evidence, the nanocarrier based on succinylated PEI with the lowest modification degree, 9%, emerges as the optimal choice for gene transfer due to its minimal cytotoxicity and maximal gene transfer efficiency [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eGuanylyl cyclase C (GC-C) is a transmembrane receptor prominently expressed apically in intestinal crypts and villus cells [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. The GC-C signaling pathway has emerged as a promising therapeutic target for widespread gastrointestinal disorders, including irritable bowel syndrome with constipation, chronic idiopathic constipation, and inflammatory bowel disease [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e]. Specifically, GC-C activation is facilitated by intracellular hormonal ligands, uroguanylin and guanylin predominantly expressed in the small intestine and large intestine, respectively. These hormones activate GC-C, setting off a cascade of downstream signaling pathways. These pathways play a pivotal role in regulating fluid and electrolyte homeostasis, maintaining the integrity of the intestinal epithelium, and influencing tumorigenesis [\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eInactivating mutations in \u003cem\u003eAPC\u003c/em\u003e are linked to 80% of CRC tumors [\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e] and are also prevalent in other gastrointestinal cancers like gastric cancer [\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e]. In this subtype of CRCs, the loss of function in both \u003cem\u003eAPC\u003c/em\u003e alleles is a crucial step in tumor initiation. The inability of APC to regulate the stability of β-catenin protein results in uncontrolled β-catenin nuclear signaling, leading to the activation of oncogenic genes [\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e]. Although the APC/β-catenin signaling pathway is an appealing target for gastrointestinal cancers, achieving therapeutic effects with drug interventions targeting these molecules proves to be challenging [\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eRemarkably, the connection between the GC-C signaling pathway and CRC was initially revealed through population studies, highlighting an inverse relationship between CRC prevalence and enterotoxigenic Escherichia coli (ETEC) infections [\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e]. ETEC infections involve heat-stable enterotoxins that produce STs, ultimately activating the GC-C signaling pathway and causing diarrhea [\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e]. Additionally, the GC-C signaling pathway is implicated in CRC through the depletion of intracellular ligands, guanylin and uroguanylin. In a study encompassing around 300 tumors and their corresponding adjacent normal tissues, guanylin mRNA exhibited a loss of expression in over 85% of tumors compared to the corresponding normal epithelium [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Notably, recent observations in mice suggest that the loss of guanylin is a direct downstream consequence of mutant APC/β-catenin signaling [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. Furthermore, the loss of APC heterozygosity (loss of two alleles) is pivotal for the loss of guanylin hormone expression [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. Consequently, these findings highlight that the \u003cem\u003eGUCY2C\u003c/em\u003e signaling pathway, mediated by guanylin and uroguanylin hormones, may be directly associated with APC/β-catenin mutant signaling in CRC tumorigenesis. Thus, investigating the gain of function of these two hormones holds promise for advancing CRC treatment, representing the primary objective of this study.\u003c/p\u003e \u003cp\u003eFurthermore, based on our prior study involving an integrative transcriptome analysis, we identified the peptide hormone guanylin as the primary therapeutic target for the gain of function studies [\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e]. Subsequently, guanylin was amplified and cloned into gene constructs containing CMV and \u003cem\u003eMUC1\u003c/em\u003e promoters. Conversely, considering the synthesis and characterization of the SPEI-9 nanocarrier as an efficient and safe gene delivery agent for gene constructs, diverse cell culture studies were conducted to assess the anti-tumor effects of this therapeutic system.\u003c/p\u003e \u003cp\u003eInitially, to validate the transfection efficiency, the SPEI-9 nanocarrier, with a C/P ratio of 4 and loaded with pCMV-GUCA2A and pMUC1-GUCA2A gene constructs, was applied to HCT-116 cancer cells and normal Vero cells. The optimal transfection period of 72 h was chosen to induce maximal peptide hormone expression within the cells. The results of the transfection process, as indicated by \u003cem\u003eGUCA2A\u003c/em\u003e mRNA expression levels, revealed that the pCMV-GUCA2A gene construct exhibited significantly higher expression with lower specificity compared to the construct containing the MUC1-specific promoter. It can be inferred that the efficacy of the MUC1 promoter is contingent on its tissue-specific expression in the relevant cancer. For instance, in a study by Farokhimanesh et al., the PEI nanocarrier loaded with a gene construct containing the MUC1 promoter and encoding the pro-apoptotic gene truncated \u003cem\u003eBID\u003c/em\u003e (tBid) demonstrated specific and elevated expression in breast cancer in contrast to the construct with the CMV promoter. Their findings suggested that this heightened and specific expression could potentially induce apoptosis in breast cancer cells (MCF7, T47D, and SKBR3) with minimal impact on normal AGO skin fibroblast cells. Moreover, the induction of expression through the specific MUC1 promoter in the CRC cell line HT-29 exhibited a notable increase, albeit less obvious than in breast cancer cell lines. Considering that the expression of \u003cem\u003eMUC1\u003c/em\u003e in this cell line differs from HCT-116, it holds more potential for inducing expression [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. However, according to diverse investigations, HCT-116 cells are identified as non-differentiated and highly aggressive, with a p53 mutation occurring in the advanced stages of cancer and this cell line exhibited a low expression profile for MUC1. In contrast, HT-29 cells are recognized as more differentiated and less aggressive cell lines with mutations in APC observed in the early stages of cancer. Additionally, HT-29 cells can differentiate into enterocytes and MUC1-expressing cells [\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e, \u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e]. Conversely, given the markedly reduced or absent expression of the guanylin hormone in the progression of CRC and the proved enhanced therapeutic effects in advanced disease stages, the HCT-116 cell line was selected as a tumor model. As a counterpart, the Vero cell line, characterized by very low \u003cem\u003eMUC1\u003c/em\u003e expression, was chosen as a normal model [\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn addition to assessing the specific induction effects of the \u003cem\u003eMUC1\u003c/em\u003e promoter, we explored the impact of this stimulus using the HRE upstream of the promoter. Recognizing that prolonged exposure to hypoxia can inhibit apoptosis through therapeutic interventions, a treatment duration of 16 h was chosen based on literature findings. This short period yielded favorable results in terms of expression, as evaluated by RT-qPCR. However, it's important to note that this aspect remained focused on the measurement of expression levels, with the primary emphasis of the study directed towards investigating the therapeutic effects of the promoters, \u003cem\u003eGUCA2A\u003c/em\u003e gene, and the SPEI-9 nanocarrier [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e, \u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e, \u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn alignment with the signaling pathways associated with the guanylin hormone, this study focused on the expression of β-catenin and p21 genes as direct components engaged in the downstream pathway. In this regard, in the study by Rajabi et al., they explored the inhibitory effect of the doxorubicin-loaded zymosan nanoparticles on the Wnt/β-catenin pathway. The research revealed that zymosan nanoparticles were effective in suppressing the expression of key genes associated with the Wnt/β-catenin pathway and the treatment groups upregulated caspase-8 expression while modulating the Bax/Bcl-2 ratio, promoting apoptosis [\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e]. Gonzalez-Valdivieso et al. and Fatemi et al. investigated not only the PI3K/Akt pathway but also delved into the Wnt/β-catenin signaling pathway to examine their respective inhibitory effects on CRC cell lines [\u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e, \u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e]. Additionally, to explore the impact on apoptosis induction and the inhibition of cell migration pathways, measurements were conducted on \u003cem\u003eBAX/BCL-2\u003c/em\u003e, Cadherin 2, and Vimentin genes. The results demonstrated that elevating guanylin expression, facilitated by both gene constructs, led to suppressed apoptosis induction and diminished expression of genes associated with cell migration pathways. In accordance with our results, Chen et al. conducted a study revealing that the long noncoding RNA SRRM2-AS exerts inhibitory effects on angiogenesis in nasopharyngeal carcinoma by activating the MYLK-mediated cGMP-PKG signaling pathway. Their research demonstrated that silencing SRRM2-AS led to increased levels of MYLK, cGMP, PKG, Bax, and Caspase 3, while decreasing levels of VEGF, PCNA, Ki-67, and Bcl-2. Consequently, SRRM2-AS silencing suppressed cell proliferation, colony formation, and angiogenesis, disrupted the cell cycle, and heightened cell apoptosis in nasopharyngeal carcinoma [\u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e]. Replication of these effects by activation of the cGMP-PKG signaling pathway has also been followed by several other studies in the field[\u003cspan additionalcitationids=\"CR65\" citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eNotably, in the group treated with the gene construct featuring the specific \u003cem\u003eMUC1\u003c/em\u003e promoter, there was a quantitative increase in tumor suppressor genes and a decrease in oncogene expression, as observed in the normal Vero cell group. These outcomes signify a specific expression pattern. In this context, Basu et al.'s study yielded interesting findings. In Gucy2c\u003csup\u003e+/+\u003c/sup\u003e model mice, where the guanylate cyclase C pathway was activated, treatment with bacterial heat-resistant enterotoxin (ST) led to potent antitumor effects. This activation positively regulated the expression of p21 and p38 MAPK genes, culminating in a significant reduction in formed colonies. Notably, these effects were absent in the Gucy2c\u003csup\u003e\u0026minus;/\u0026minus;\u003c/sup\u003e mouse model, underscoring the critical role of the combined GC-C/cGMP signaling pathway in colorectal carcinogenesis [\u003cspan citationid=\"CR67\" class=\"CitationRef\"\u003e67\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eConsidering the dual regulation (up- and down-regulation) of genes involved in diverse carcinogenic pathways upon increased guanylin hormone function, its potential therapeutic effects were systematically assessed through various assays. Notably, tests focusing on cytotoxicity and apoptosis induction revealed a significant augmentation in both parameters in HCT-116 cancer cells in groups containing both CMV and \u003cem\u003eMUC1\u003c/em\u003e promoters, correlating with elevated guanylin hormone function. However, distinctive patterns were observed between the two promoters. The induction of guanylin hormone by the CMV promoter exhibited stronger inhibitory effects on cytotoxicity and apoptosis induction, indicating robust but less specific impacts. Conversely, the induction by the \u003cem\u003eMUC1\u003c/em\u003e promoter demonstrated slightly weaker effects but showcased greater specificity. In the Vero cell line, induction of the hormone from the CMV promoter displayed obvious inhibitory effects, an aspect that remains relatively unexplored in the current body of research.\u003c/p\u003e \u003cp\u003eExisting studies in this domain have predominantly centered on activating the GC-C pathway through bacterial ST. For instance, Li et al.'s 2017 study elucidated the effects of GC-C paracrine pathway activation via oral administration of bacterial ST in a mouse model of radiation-induced gastrointestinal syndrome and different cancer cells. The outcomes highlighted the significant induction of apoptosis in CRC cells (HCT-116) upon GC-C activation by ST. Interestingly, these antitumor effects were contingent on the p53 pathway, as evidenced by their absence in the HCT-116 cell line with an altered phenotype of p53\u003csup\u003eint\u0026minus;/\u0026minus;\u003c/sup\u003e (with biallelic loss of p53). Moreover, in mouse models of gastrointestinal syndrome, oral administration of bacterial ST manifested substantial reductions in disease symptoms and mortality rates, underscoring its potential therapeutic efficacy [\u003cspan citationid=\"CR68\" class=\"CitationRef\"\u003e68\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eBased on the findings of this study, the modified SPEI nanocarrier demonstrates superior gene transfer efficacy and safety compared to the conventional PEI carrier. This characteristic holds immense significance, particularly in animal research. However, certain challenges hindered our ability to conduct practical tests. Notably, the considerable difference between human and mouse guanylin hormone sequences (approximately 68% similarity) posed a significant hurdle. In this case, the use of nude mice models for experimentation was not applicable due to the lack of experimental and well-established facility for this purpose. Moreover, the PEI-based nanocarriers exhibits a remarkable ability to target cancerous tissues \u003cem\u003ein vivo\u003c/em\u003e, primarily leveraging the Enhanced Permeability and Retention (EPR) effect. Future investigations are poised to enhance the carrier's efficacy by incorporating targeting moieties into the PEI structure. This approach holds promise for maximizing therapeutic outcomes, either individually or synergistically, particularly when combined with genetic vectors containing tumor-specific promoters. These prospective studies are primed to boost advancements in targeted gene therapy and cancer treatment [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e].\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eIn our thorough examination of pan-cancer, we discovered exciting insights into the expression patterns of the guanylin hormone across various parts of the colon and rectum. Our findings suggest that guanylin may exert a significant influence on the development of colorectal cancer, participating in intricate pathways of interaction. Moreover, the hormone experiences numerous mutations and widespread depletion in cancer cases, leading to a marked decline in patient survival rates. This aberration also correlates with dysfunctional interactions with the immune system, heightened cell proliferation, inhibition of apoptosis, etc. The comprehensive findings highlight the pivotal role of the GC-C signaling pathway in leading the digestive system, encompassing both the small and large intestines. Disruption of this pathway, whether through alterations in the receptor itself or via exogenous ligands like guanylin and uroguanylin, can precipitate lethal effects on healthy digestive system. It's noteworthy that the bulk of existing research has predominantly focused on activating this pathway using chemical stimuli such as bacterial ST and analogous pharmaceutical agents. In contrast, the present study introduces a novel approach, evaluating the potential antitumor effects arising from the targeted induction of the guanylin hormone via safe and efficient transfection of pMUC1-GUCA2A vector with SPEI-9 as a potent nanocarrier. Both specifically and universally expression of guanylin hormone, the outcomes of this study can be characterized as promising.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eFunding Declaration\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work is supported by a grant from Hamadan University of Medical Sciences, Hamadan, Iran (No. 9907295351).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of supporting data\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll the data employed in this study are comprehensively presented within the article, and availability upon reasonable request from the corresponding author is ensured. The relevant datasets can also be accessed through direct web links: TCGA - https://www.cancer.gov/; GTEx - https://commonfund.nih.gov/GTEx/; GDC-https://gdc.cancer.gov/; cBioPortal-https://www.cbioportal.org/; DAVID-https://david.ncifcrf.gov/; TIMER2.0- http://timer.cistrome.org/; Smartapp-www.bioinfo-zs.com/smartapp/; TISDB- http://cis.hku.hk/TISIDB/index.php. Further inquiries are available from the corresponding author upon reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthical Approval and Consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll procedures were performed in accordance with the Declaration of Helsinki and approved by the ethics committee of the Hamadan university of medical sciences (IR.UMSHA.REC.1399.562). Informed consent was obtained from all subjects and or their legal guardians. Patient samples were collected from the Poursina Hakim Research Institute (Esfahan, Iran).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that there are no conflicts of interest.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026apos; information\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAffiliations\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResearch Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ePS, AJ \u0026amp; RN\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDepartment of Pharmaceutical Biotechnology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMS \u0026amp; FN\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDepartment of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eFR\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStudent Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAJ\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026apos; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ePS designed the research, performed the experiments, analyzed the bioinformatics data, and prepared the original draft and revised the manuscript during rounds of revision. MS, FN, and RN supervised the synthesis of the nanocarrier, edited and revised the manuscript, and evaluated the final data. FR prepared the HRE-pMUC1 plasmid and edited and revised the manuscript. AJ conceptualized the project, revised the manuscript, and provided final suggestions. All authors read and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e*\u003c/sup\u003e \u003cstrong\u003eCorrespondence\u003c/strong\u003e:\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eCorrespondence to Akram Jalali, Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. Email: [email protected]\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eDebela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, Kitui SK, Manyazewal T: \u003cstrong\u003eNew approaches and procedures for cancer treatment: Current perspectives.\u003c/strong\u003e \u003cem\u003eSAGE open medicine \u003c/em\u003e2021, \u003cstrong\u003e9:\u003c/strong\u003e20503121211034366.\u003c/li\u003e\n\u003cli\u003eKatsila T, Spyroulias GA, Patrinos GP, Matsoukas M-T: \u003cstrong\u003eComputational approaches in target identification and drug discovery.\u003c/strong\u003e \u003cem\u003eComputational and structural biotechnology journal \u003c/em\u003e2016, \u003cstrong\u003e14:\u003c/strong\u003e177-184.\u003c/li\u003e\n\u003cli\u003eWang Y, Wang Z, Xu J, Li J, Li S, Zhang M, Yang D: \u003cstrong\u003eSystematic identification of non-coding pharmacogenomic landscape in cancer.\u003c/strong\u003e \u003cem\u003eNature communications \u003c/em\u003e2018, \u003cstrong\u003e9:\u003c/strong\u003e3192.\u003c/li\u003e\n\u003cli\u003eZhang Y, Chen F, Chandrashekar DS, Varambally S, Creighton CJ: \u003cstrong\u003eProteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways.\u003c/strong\u003e \u003cem\u003eNature Communications \u003c/em\u003e2022, \u003cstrong\u003e13:\u003c/strong\u003e2669.\u003c/li\u003e\n\u003cli\u003eChen F, Chandrashekar DS, Varambally S, Creighton CJ: \u003cstrong\u003ePan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers.\u003c/strong\u003e \u003cem\u003eNature communications \u003c/em\u003e2019, \u003cstrong\u003e10:\u003c/strong\u003e5679.\u003c/li\u003e\n\u003cli\u003eVande Voorde J, Steven RT, Najumudeen AK, Ford CA, Dexter A, Gonzalez-Fernandez A, Nikula CJ, Xiang Y, Ford L, Maneta Stavrakaki S: \u003cstrong\u003eMetabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target.\u003c/strong\u003e \u003cem\u003eNature Metabolism \u003c/em\u003e2023\u003cstrong\u003e:\u003c/strong\u003e1-16.\u003c/li\u003e\n\u003cli\u003ePattison AM, Barton JR, Entezari AA, Zalewski A, Rappaport JA, Snook AE, Waldman SA: \u003cstrong\u003eSilencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity.\u003c/strong\u003e \u003cem\u003eCancer Biol Ther \u003c/em\u003e2020, \u003cstrong\u003e21:\u003c/strong\u003e799-805.\u003c/li\u003e\n\u003cli\u003eWaldman SA, Camilleri M: \u003cstrong\u003eGuanylate cyclase-C as a therapeutic target in gastrointestinal disorders.\u003c/strong\u003e \u003cem\u003eGut \u003c/em\u003e2018, \u003cstrong\u003e67:\u003c/strong\u003e1543-1552.\u003c/li\u003e\n\u003cli\u003eKuhn M: \u003cstrong\u003eMolecular physiology of membrane guanylyl cyclase receptors.\u003c/strong\u003e \u003cem\u003ePhysiol Rev \u003c/em\u003e2016, \u003cstrong\u003e96:\u003c/strong\u003e751-804.\u003c/li\u003e\n\u003cli\u003ePitari GM, Di Guglielmo M, Park J, Schulz S, Waldman SA: \u003cstrong\u003eGuanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells.\u003c/strong\u003e \u003cem\u003eProceedings of the National Academy of Sciences \u003c/em\u003e2001, \u003cstrong\u003e98:\u003c/strong\u003e7846-7851.\u003c/li\u003e\n\u003cli\u003eLin JE, Li P, Snook AE, Schulz S, Dasgupta A, Hyslop TM, Gibbons AV, Marszlowicz G, Pitari GM, Waldman SA: \u003cstrong\u003eThe hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling.\u003c/strong\u003e \u003cem\u003eGastroenterology \u003c/em\u003e2010, \u003cstrong\u003e138:\u003c/strong\u003e241-254.\u003c/li\u003e\n\u003cli\u003eWang R, Kwon I-K, Thangaraju M, Singh N, Liu K, Jay P, Hofmann F, Ganapathy V, Browning DD: \u003cstrong\u003eType 2 cGMP-dependent protein kinase regulates proliferation and differentiation in the colonic mucosa.\u003c/strong\u003e \u003cem\u003eAmerican Journal of Physiology-Gastrointestinal and Liver Physiology \u003c/em\u003e2012, \u003cstrong\u003e303:\u003c/strong\u003eG209-G219.\u003c/li\u003e\n\u003cli\u003ePiroozkhah M, Aghajani A, Jalali P, Shahmoradi A, Piroozkhah M, Tadlili Y, Salehi Z: \u003cstrong\u003eGuanylate cyclase-C Signaling Axis as a theragnostic target in colorectal cancer: a systematic review of literature.\u003c/strong\u003e \u003cem\u003eFront Oncol \u003c/em\u003e2023, \u003cstrong\u003e13\u003c/strong\u003e.\u003c/li\u003e\n\u003cli\u003eBashir B, Merlino DJ, Rappaport JA, Gnass E, Palazzo JP, Feng Y, Fearon ER, Snook AE, Waldman SA: \u003cstrong\u003eSilencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia.\u003c/strong\u003e \u003cem\u003eHum Pathol \u003c/em\u003e2019, \u003cstrong\u003e87:\u003c/strong\u003e103-114.\u003c/li\u003e\n\u003cli\u003eBlomain ES, Rappaport JA, Pattison AM, Bashir B, Caparosa E, Stem J, Snook AE, Waldman SA: \u003cstrong\u003eAPC-\u0026beta;-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis.\u003c/strong\u003e \u003cem\u003eCancer Biol Ther \u003c/em\u003e2020, \u003cstrong\u003e21:\u003c/strong\u003e441-451.\u003c/li\u003e\n\u003cli\u003eWilson C, Lin JE, Li P, Snook AE, Gong J, Sato T, Liu C, Girondo MA, Rui H, Hyslop T: \u003cstrong\u003eThe paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer.\u003c/strong\u003e \u003cem\u003eCancer Epidemiol Biomarkers Prev \u003c/em\u003e2014, \u003cstrong\u003e23:\u003c/strong\u003e2328-2337.\u003c/li\u003e\n\u003cli\u003eRappaport JA, Waldman SA: \u003cstrong\u003eThe guanylate cyclase C\u0026mdash;cGMP signaling axis opposes intestinal epithelial injury and neoplasia.\u003c/strong\u003e \u003cem\u003eFront Oncol \u003c/em\u003e2018, \u003cstrong\u003e8:\u003c/strong\u003e299.\u003c/li\u003e\n\u003cli\u003eKumar A, Das SK, Emdad L, Fisher PB: \u003cstrong\u003eApplications of tissue-specific and cancer-selective gene promoters for cancer diagnosis and therapy.\u003c/strong\u003e \u003cem\u003eAdv Cancer Res \u003c/em\u003e2023, \u003cstrong\u003e160:\u003c/strong\u003e253-315.\u003c/li\u003e\n\u003cli\u003eMonta\u0026ntilde;o-Samaniego M, Bravo-Estupi\u0026ntilde;an DM, M\u0026eacute;ndez-Guerrero O, Alarc\u0026oacute;n-Hern\u0026aacute;ndez E, Ib\u0026aacute;\u0026ntilde;ez-Hern\u0026aacute;ndez M: \u003cstrong\u003eStrategies for targeting gene therapy in cancer cells with tumor-specific promoters.\u003c/strong\u003e \u003cem\u003eFront Oncol \u003c/em\u003e2020, \u003cstrong\u003e10:\u003c/strong\u003e605380.\u003c/li\u003e\n\u003cli\u003ePourjafar M, Samadi P, Saidijam M: \u003cstrong\u003eMUC1 antibody-based therapeutics: The promise of cancer immunotherapy.\u003c/strong\u003e \u003cem\u003eImmunotherapy \u003c/em\u003e2020, \u003cstrong\u003e12:\u003c/strong\u003e1269-1286.\u003c/li\u003e\n\u003cli\u003eGuo M, You C, Dou J: \u003cstrong\u003eRole of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates.\u003c/strong\u003e \u003cem\u003eBiomed Pharmacother \u003c/em\u003e2018, \u003cstrong\u003e107:\u003c/strong\u003e1318-1325.\u003c/li\u003e\n\u003cli\u003eFarokhimanesh S, Rahbarizadeh F, Rasaee MJ, Kamali A, Mashkani B: \u003cstrong\u003eHybrid promoters directed tBid gene expression to breast cancer cells by transcriptional targeting.\u003c/strong\u003e \u003cem\u003eBiotechnol Prog \u003c/em\u003e2010, \u003cstrong\u003e26:\u003c/strong\u003e505-511.\u003c/li\u003e\n\u003cli\u003eCasper J, Schenk SH, Parhizkar E, Detampel P, Dehshahri A, Huwyler J: \u003cstrong\u003ePolyethylenimine (PEI) in gene therapy: Current status and clinical applications.\u003c/strong\u003e \u003cem\u003eJournal of Controlled Release \u003c/em\u003e2023, \u003cstrong\u003e362:\u003c/strong\u003e667-691.\u003c/li\u003e\n\u003cli\u003eLinsha Mali A, Priya S, Rekha M: \u003cstrong\u003eHydrophobic and hydrophilic modifications of polyethylenimine towards gene delivery applications.\u003c/strong\u003e \u003cem\u003eJ Appl Polym Sci \u003c/em\u003e2021, \u003cstrong\u003e138:\u003c/strong\u003e51323.\u003c/li\u003e\n\u003cli\u003eKobayashi Y, Nirasawa K, Negishi Y, Asayama S: \u003cstrong\u003eNoncorrelative relation between in vitro and in vivo for plasmid DNA transfection by succinylated polyethylenimine muscular injection.\u003c/strong\u003e \u003cem\u003eJ Biomater Sci Polym Ed \u003c/em\u003e2021, \u003cstrong\u003e32:\u003c/strong\u003e405-416.\u003c/li\u003e\n\u003cli\u003eZintchenko A, Philipp A, Dehshahri A, Wagner E: \u003cstrong\u003eSimple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity.\u003c/strong\u003e \u003cem\u003eBioconjugate chemistry \u003c/em\u003e2008, \u003cstrong\u003e19:\u003c/strong\u003e1448-1455.\u003c/li\u003e\n\u003cli\u003eHe S, Liu S: \u003cstrong\u003eZwitterionic materials for nucleic acid delivery and therapeutic applications.\u003c/strong\u003e \u003cem\u003eJournal of Controlled Release \u003c/em\u003e2024, \u003cstrong\u003e365:\u003c/strong\u003e919-935.\u003c/li\u003e\n\u003cli\u003eRitchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK: \u003cstrong\u003elimma powers differential expression analyses for RNA-sequencing and microarray studies.\u003c/strong\u003e \u003cem\u003eNucleic Acids Res \u003c/em\u003e2015, \u003cstrong\u003e43:\u003c/strong\u003ee47-e47.\u003c/li\u003e\n\u003cli\u003eRobinson MD, McCarthy DJ, Smyth GK: \u003cstrong\u003eedgeR: a Bioconductor package for differential expression analysis of digital gene expression data.\u003c/strong\u003e \u003cem\u003eBioinformatics \u003c/em\u003e2010, \u003cstrong\u003e26:\u003c/strong\u003e139-140.\u003c/li\u003e\n\u003cli\u003eKassambara A, Kosinski M, Biecek P, Fabian S: \u003cstrong\u003ePackage \u0026lsquo;survminer\u0026rsquo;.\u003c/strong\u003e \u003cem\u003eDrawing Survival Curves using \u0026lsquo;ggplot2\u0026rsquo;(R package version 03 1) \u003c/em\u003e2017, \u003cstrong\u003e3\u003c/strong\u003e.\u003c/li\u003e\n\u003cli\u003eTherneau TM, Lumley T: \u003cstrong\u003ePackage \u0026lsquo;survival\u0026rsquo;.\u003c/strong\u003e \u003cem\u003eR Top Doc \u003c/em\u003e2015, \u003cstrong\u003e128:\u003c/strong\u003e28-33.\u003c/li\u003e\n\u003cli\u003eWickham H, Chang W, Wickham MH: \u003cstrong\u003ePackage \u0026lsquo;ggplot2\u0026rsquo;.\u003c/strong\u003e \u003cem\u003eCreate elegant data visualisations using the grammar of graphics Version \u003c/em\u003e2016, \u003cstrong\u003e2:\u003c/strong\u003e1-189.\u003c/li\u003e\n\u003cli\u003eH\u0026auml;nzelmann S, Castelo R, Guinney J: \u003cstrong\u003eGSVA: gene set variation analysis for microarray and RNA-seq data.\u003c/strong\u003e \u003cem\u003eBMC Bioinformatics \u003c/em\u003e2013, \u003cstrong\u003e14:\u003c/strong\u003e1-15.\u003c/li\u003e\n\u003cli\u003eYang L, Wang C, Shu J, Feng H, He Y, Chen J, Shu J: \u003cstrong\u003ePorcine epidemic diarrhea virus induces vero cell apoptosis via the p53-PUMA signaling pathway.\u003c/strong\u003e \u003cem\u003eViruses \u003c/em\u003e2021, \u003cstrong\u003e13:\u003c/strong\u003e1218.\u003c/li\u003e\n\u003cli\u003eWarriner LW, Duke III JR, Pack DW, DeRouchey JE: \u003cstrong\u003eSuccinylated polyethylenimine derivatives greatly enhance polyplex serum stability and gene delivery in vitro.\u003c/strong\u003e \u003cem\u003eBiomacromolecules \u003c/em\u003e2018, \u003cstrong\u003e19:\u003c/strong\u003e4348-4357.\u003c/li\u003e\n\u003cli\u003eYang S, Wang Z, Ping Y, Miao Y, Xiao Y, Qu L, Zhang L, Hu Y, Wang J: \u003cstrong\u003ePEG/PEI-functionalized single-walled carbon nanotubes as delivery carriers for doxorubicin: synthesis, characterization, and in vitro evaluation.\u003c/strong\u003e \u003cem\u003eBeilstein Journal of Nanotechnology \u003c/em\u003e2020, \u003cstrong\u003e11:\u003c/strong\u003e1728-1741.\u003c/li\u003e\n\u003cli\u003eHan X-M, Zheng K-W, Wang R-L, Yue S-F, Chen J, Zhao Z-W, Song F, Su Y, Ma Q: \u003cstrong\u003eFunctionalization and optimization-strategy of graphene oxide-based nanomaterials for gene and drug delivery.\u003c/strong\u003e \u003cem\u003eAmerican Journal of Translational Research \u003c/em\u003e2020, \u003cstrong\u003e12:\u003c/strong\u003e1515.\u003c/li\u003e\n\u003cli\u003eLiu L, Yang Z, Liu C, Wang M, Chen X: \u003cstrong\u003ePreparation of PEI‐modified nanoparticles by dopamine self‐polymerization for efficient DNA delivery.\u003c/strong\u003e \u003cem\u003eBiotechnology and Applied Biochemistry \u003c/em\u003e2023, \u003cstrong\u003e70:\u003c/strong\u003e824-834.\u003c/li\u003e\n\u003cli\u003eSheikhsaran F, Sadeghpour H, Khalvati B, Entezar-Almahdi E, Dehshahri A: \u003cstrong\u003eTetraiodothyroacetic acid-conjugated polyethylenimine for integrin receptor mediated delivery of the plasmid encoding IL-12 gene.\u003c/strong\u003e \u003cem\u003eColloids Surf B Biointerfaces \u003c/em\u003e2017, \u003cstrong\u003e150:\u003c/strong\u003e426-436.\u003c/li\u003e\n\u003cli\u003eCao M, Gao Y, Qiu N, Shen Y, Shen P: \u003cstrong\u003eFolic acid directly modified low molecular weight of polyethyleneimine for targeted pDNA delivery.\u003c/strong\u003e \u003cem\u003eJ Drug Deliv Sci Technol \u003c/em\u003e2020, \u003cstrong\u003e56:\u003c/strong\u003e101522.\u003c/li\u003e\n\u003cli\u003eNouri F, Sadeghpour H, Heidari R, Dehshahri A: \u003cstrong\u003ePreparation, characterization, and transfection efficiency of low molecular weight polyethylenimine-based nanoparticles for delivery of the plasmid encoding CD200 gene.\u003c/strong\u003e \u003cem\u003eInternational journal of nanomedicine \u003c/em\u003e2017\u003cstrong\u003e:\u003c/strong\u003e5557-5569.\u003c/li\u003e\n\u003cli\u003eCheraghi R, Alipour M, Nazari M, Hosseinkhani S: \u003cstrong\u003eOptimization of conditions for gene delivery system based on PEI.\u003c/strong\u003e \u003cem\u003eNanomedicine Journal \u003c/em\u003e2017, \u003cstrong\u003e4\u003c/strong\u003e.\u003c/li\u003e\n\u003cli\u003eVon Gersdorff K, Sanders NN, Vandenbroucke R, De Smedt SC, Wagner E, Ogris M: \u003cstrong\u003eThe internalization route resulting in successful gene expression depends on both cell line and polyethylenimine polyplex type.\u003c/strong\u003e \u003cem\u003eMol Ther \u003c/em\u003e2006, \u003cstrong\u003e14:\u003c/strong\u003e745-753.\u003c/li\u003e\n\u003cli\u003eOgris M, Steinlein P, Kursa M, Mechtler K, Kircheis R, Wagner E: \u003cstrong\u003eThe size of DNA/transferrin-PEI complexes is an important factor for gene expression in cultured cells.\u003c/strong\u003e \u003cem\u003eGene Ther \u003c/em\u003e1998, \u003cstrong\u003e5:\u003c/strong\u003e1425-1433.\u003c/li\u003e\n\u003cli\u003eRajendran AP, Morales LC, Meenakshi Sundaram DN, Kucharski C, Uludağ H: \u003cstrong\u003eTuning the Potency of Farnesol-Modified Polyethylenimine with Polyanionic Trans-Booster to Enhance DNA Delivery.\u003c/strong\u003e \u003cem\u003eACS Biomaterials Science \u0026amp; Engineering \u003c/em\u003e2024.\u003c/li\u003e\n\u003cli\u003eWinkeljann B, Keul DC, Merkel OM: \u003cstrong\u003eEngineering poly-and micelleplexes for nucleic acid delivery\u0026ndash;A reflection on their endosomal escape.\u003c/strong\u003e \u003cem\u003eJournal of Controlled Release \u003c/em\u003e2023, \u003cstrong\u003e353:\u003c/strong\u003e518-534.\u003c/li\u003e\n\u003cli\u003eStefani S, Sharma SK, Haag R, Servin P: \u003cstrong\u003eCore-shell nanocarriers based on PEGylated hydrophobic hyperbranched polyesters.\u003c/strong\u003e \u003cem\u003eEuropean Polymer Journal \u003c/em\u003e2016, \u003cstrong\u003e80:\u003c/strong\u003e158-168.\u003c/li\u003e\n\u003cli\u003eZaaeri F, Khoobi M, Rouini M, Akbari Javar H: \u003cstrong\u003epH-responsive polymer in a core\u0026ndash;shell magnetic structure as an efficient carrier for delivery of doxorubicin to tumor cells.\u003c/strong\u003e \u003cem\u003eInternational Journal of Polymeric Materials and Polymeric Biomaterials \u003c/em\u003e2018, \u003cstrong\u003e67:\u003c/strong\u003e967-977.\u003c/li\u003e\n\u003cli\u003eShailubhai K, Palejwala V, Arjunan KP, Saykhedkar S, Nefsky B, Foss JA, Comiskey S, Jacob GS, Plevy SE: \u003cstrong\u003ePlecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.\u003c/strong\u003e \u003cem\u003eWorld J Gastrointest Pharmacol Ther \u003c/em\u003e2015, \u003cstrong\u003e6:\u003c/strong\u003e213.\u003c/li\u003e\n\u003cli\u003eEntezari AA, Snook AE, Waldman SA: \u003cstrong\u003eGuanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.\u003c/strong\u003e \u003cem\u003eExpert Opin Ther Targets \u003c/em\u003e2021, \u003cstrong\u003e25:\u003c/strong\u003e335-346.\u003c/li\u003e\n\u003cli\u003eZhang L, Shay JW: \u003cstrong\u003eMultiple roles of APC and its therapeutic implications in colorectal cancer.\u003c/strong\u003e \u003cem\u003eJNCI: Journal of the National Cancer Institute \u003c/em\u003e2017, \u003cstrong\u003e109:\u003c/strong\u003edjw332.\u003c/li\u003e\n\u003cli\u003eCl\u0026eacute;ment G, Bosman FT, Fontolliet C, Benhattar J: \u003cstrong\u003eMonoallelic methylation of the APC promoter is altered in normal gastric mucosa associated with neoplastic lesions.\u003c/strong\u003e \u003cem\u003eCancer Res \u003c/em\u003e2004, \u003cstrong\u003e64:\u003c/strong\u003e6867-6873.\u003c/li\u003e\n\u003cli\u003ePitari G, Zingman L, Hodgson D, Alekseev A, Kazerounian S, Bienengraeber M, Hajnoczky G, Terzic A, Waldman S: \u003cstrong\u003eBacterial enterotoxins are associated with resistance to colon cancer.\u003c/strong\u003e \u003cem\u003eProceedings of the National Academy of Sciences \u003c/em\u003e2003, \u003cstrong\u003e100:\u003c/strong\u003e2695-2699.\u003c/li\u003e\n\u003cli\u003eSamadi P, Soleimani M, Nouri F, Rahbarizadeh F, Najafi R, Jalali A: \u003cstrong\u003eAn integrative transcriptome analysis reveals potential predictive, prognostic biomarkers and therapeutic targets in colorectal cancer.\u003c/strong\u003e \u003cem\u003eBMC Cancer \u003c/em\u003e2022, \u003cstrong\u003e22:\u003c/strong\u003e1-22.\u003c/li\u003e\n\u003cli\u003eSzaryńska M, Olejniczak A, Kobiela J, Łaski D, Śledziński Z, Kmieć Z: \u003cstrong\u003eCancer stem cells as targets for DC-based immunotherapy of colorectal cancer.\u003c/strong\u003e \u003cem\u003eSci Rep \u003c/em\u003e2018, \u003cstrong\u003e8:\u003c/strong\u003e12042.\u003c/li\u003e\n\u003cli\u003eYeung TM, Gandhi SC, Wilding JL, Muschel R, Bodmer WF: \u003cstrong\u003eCancer stem cells from colorectal cancer-derived cell lines.\u003c/strong\u003e \u003cem\u003eProceedings of the National Academy of Sciences \u003c/em\u003e2010, \u003cstrong\u003e107:\u003c/strong\u003e3722-3727.\u003c/li\u003e\n\u003cli\u003eZhang Y, Guo S, Huang H, Mao G, Ji X, He Z: \u003cstrong\u003eSilicon nanodot-based aptasensor for fluorescence turn-on detection of mucin 1 and targeted cancer cell imaging.\u003c/strong\u003e \u003cem\u003eAnal Chim Acta \u003c/em\u003e2018, \u003cstrong\u003e1035:\u003c/strong\u003e154-160.\u003c/li\u003e\n\u003cli\u003eMinassian LM, Cotechini T, Huitema E, Graham CH: \u003cstrong\u003eHypoxia-induced resistance to chemotherapy in cancer.\u003c/strong\u003e \u003cem\u003eHypoxia and Cancer Metastasis \u003c/em\u003e2019\u003cstrong\u003e:\u003c/strong\u003e123-139.\u003c/li\u003e\n\u003cli\u003ePeters MC, Maas RG, van Adrichem I, Doevendans PA, Mercola M, \u0026Scaron;arić T, Buikema JW, van Mil A, Chamuleau SA, Sluijter JP: \u003cstrong\u003eMetabolic maturation increases susceptibility to hypoxia-induced damage in human iPSC-derived cardiomyocytes.\u003c/strong\u003e \u003cem\u003eStem Cells Translational Medicine \u003c/em\u003e2022, \u003cstrong\u003e11:\u003c/strong\u003e1040-1051.\u003c/li\u003e\n\u003cli\u003eRajabi A, Nejati M, Homayoonfal M, Arj A, Razavi ZS, Ostadian A, Mohammadzadeh B, Vosough M, Karimi M, Rahimian N: \u003cstrong\u003eDoxorubicin-loaded zymosan nanoparticles: Synergistic cytotoxicity and modulation of apoptosis and Wnt/\u0026beta;-catenin signaling pathway in C26 colorectal cancer cells.\u003c/strong\u003e \u003cem\u003eInt J Biol Macromol \u003c/em\u003e2024, \u003cstrong\u003e260:\u003c/strong\u003e128949.\u003c/li\u003e\n\u003cli\u003eFatemi M, Meshkini A, Matin MM: \u003cstrong\u003eA dual catalytic functionalized hollow mesoporous silica-based nanocarrier coated with bacteria-derived exopolysaccharides for targeted delivery of irinotecan to colorectal cancer cells.\u003c/strong\u003e \u003cem\u003eInt J Biol Macromol \u003c/em\u003e2024\u003cstrong\u003e:\u003c/strong\u003e129179.\u003c/li\u003e\n\u003cli\u003eGonzalez-Valdivieso J, Vallejo R, Rodriguez-Rojo S, Santos M, Schneider J, Arias FJ, Girotti A: \u003cstrong\u003eCD44-targeted nanoparticles for co-delivery of docetaxel and an Akt inhibitor against colorectal cancer.\u003c/strong\u003e \u003cem\u003eBiomaterials Advances \u003c/em\u003e2023, \u003cstrong\u003e154:\u003c/strong\u003e213595.\u003c/li\u003e\n\u003cli\u003eChen S, Lv L, Zhan Z, Wang X, You Z, Luo X, You H: \u003cstrong\u003eSilencing of long noncoding RNA SRRM2‐AS exerts suppressive effects on angiogenesis in nasopharyngeal carcinoma via activating MYLK‐mediated cGMP‐PKG signaling pathway.\u003c/strong\u003e \u003cem\u003eJ Cell Physiol \u003c/em\u003e2020, \u003cstrong\u003e235:\u003c/strong\u003e7757-7768.\u003c/li\u003e\n\u003cli\u003eZhao C-B, Chen W-B, Wang W-Z, Gong F-X, Fan C-Q, Li Y, Lan T, Wang W-J, Yuan M-Z: \u003cstrong\u003eNitro-oleic acid ameliorates erectile dysfunction in a streptozotocin-induced rat model of diabetes by inhibiting oxidative stress and apoptosis and activating the NO/cGMP pathway.\u003c/strong\u003e \u003cem\u003eAsian Journal of Andrology \u003c/em\u003e2024, \u003cstrong\u003e26:\u003c/strong\u003e57-66.\u003c/li\u003e\n\u003cli\u003eXu D, Liu A, Liu Q, Zhang H, Tian M, Bian Y, Zhang X, Ying M, Shen H: \u003cstrong\u003eCucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis.\u003c/strong\u003e \u003cem\u003eBiochem Pharmacol \u003c/em\u003e2023, \u003cstrong\u003e217:\u003c/strong\u003e115810.\u003c/li\u003e\n\u003cli\u003eDeng X, Wu Q, Li D, Liu Y: \u003cstrong\u003eErianin Exerts Antineoplastic Effects on Esophageal Squamous Cell Carcinoma Cells by Activating the cGMP-PKG Signaling Pathway.\u003c/strong\u003e \u003cem\u003eNutrition and Cancer \u003c/em\u003e2023\u003cstrong\u003e:\u003c/strong\u003e1-12.\u003c/li\u003e\n\u003cli\u003eBasu N, Saha S, Khan I, Ramachandra SG, Visweswariah SS: \u003cstrong\u003eIntestinal cell proliferation and senescence are regulated by receptor guanylyl cyclase C and p21.\u003c/strong\u003e \u003cem\u003eJ Biol Chem \u003c/em\u003e2014, \u003cstrong\u003e289:\u003c/strong\u003e581-593.\u003c/li\u003e\n\u003cli\u003eLi P, Wuthrick E, Rappaport JA, Kraft C, Lin JE, Marszalowicz G, Snook AE, Zhan T, Hyslop TM, Waldman SA: \u003cstrong\u003eGUCY2C signaling opposes the acute radiation-induced GI syndrome.\u003c/strong\u003e \u003cem\u003eCancer Res \u003c/em\u003e2017, \u003cstrong\u003e77:\u003c/strong\u003e5095-5106.\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Table","content":"\u003cp\u003e\u003cstrong\u003eTable 1. Characteristics of primers and oligomers used in amplification and RT-qPCR.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cimg src=\"data:image/png;base64,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\" width=\"1131\" height=\"339\"\u003e\u003cbr\u003e\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"colorectal cancer, guanylin, guanylyl cyclase c, gene therapy, gene delivery","lastPublishedDoi":"10.21203/rs.3.rs-4508842/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4508842/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground:\u003c/strong\u003e Addressing colorectal cancer (CRC) poses a significant challenge, demanding the precise delivery of therapeutic agents to eliminate cancer cells while minimizing the impact on healthy cells. The strategic selection of therapeutic targets, the utilization of nanocarriers with optimal efficacy and low toxicity, and the development of gene constructs with targeted expression in cancer cells are crucial aspects of this pursuit.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMaterials and Methods:\u003c/strong\u003e This study employed a systems biology approach to comprehensively investigate the guanylin hormone-encoding gene (\u003cem\u003eGUCA2A\u003c/em\u003e). Exploration encompassed expression patterns across tissues and single cells, clinical endpoints, methylation profiles, mutations, and immune and functional analyses. Subsequently, \u003cem\u003eGUCA2A\u003c/em\u003ewas identified as a potential target for gain of function studies, leading to its amplification and cloning into gene constructs featuring both a robust CMV promoter and a cancer-specific \u003cem\u003eMUC1\u003c/em\u003e promoter. The succinylated PEI-9, characterized by low toxicity and high gene transfer efficiency, was then fabricated and characterized on HCT-116 cancer cells and normal Vero cell lines.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults:\u003c/strong\u003e systems biology studies revealed guanylin\u003cem\u003e’s\u003c/em\u003eaberrant expression patterns, methylation variations, and mutational changes as well as its remarkable association with immune engagement and poor survival outcomes in CRC. Moreover, SPEI-9 was introduced as a highly efficient and safe nanocarrier for gene delivery purposes. Additionally, \u003cem\u003ein vitro\u003c/em\u003e studies revealed that both guanylin-expressing gene constructs exhibited the potential to inhibit cell growth and proliferation, inducing apoptosis, suppressing cell migration, and curtailing colony formation. Notably, these effects were more robust but non-specific in cancer cells treated with constructs containing the CMV general promoter, while, induction via the \u003cem\u003eMUC1\u003c/em\u003e promoter was more specific.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion:\u003c/strong\u003e A genetic construct featuring the strong universal CMV and specific \u003cem\u003eMUC1\u003c/em\u003e promoter, expressing the guanylin peptide hormone, demonstrated highly effective and specific anticancer effects when transfected with nanocarriers characterized by high efficiency and low cytotoxicity. This nano-system holds promising implications for targeted CRC therapy.\u003c/p\u003e","manuscriptTitle":"Targeted Gene-Hormone Therapy of Colorectal Cancer with Guanylin Expressing Nano-system: In Silico and In Vitro Study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-07-04 11:35:49","doi":"10.21203/rs.3.rs-4508842/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"ece2543a-e36e-40fe-b1f8-40d660f24e54","owner":[],"postedDate":"July 4th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2024-07-23T11:12:15+00:00","versionOfRecord":[],"versionCreatedAt":"2024-07-04 11:35:49","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4508842","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4508842","identity":"rs-4508842","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}